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Antiviral cellular immunity 
In immunocompetent individuals, viral infections are controlled by virus-specific antibodies 
and by virus-specific T cells. Virus-specific antibodies are produced by plasma cells and 
capture circulating viral particles, thereby preventing viral infection of cells. In the absence 
of sufficient humoral antiviral protection, cellular infection can be followed by intracellular 
viral replication to produce new viral particles, which may eventually result in viral disease. 
Virally infected cells are efficiently lysed by virus-specific T cells. These T cells express T cell 
receptors (TCRs) that recognize specific peptides derived from viral proteins, which are 
presented in major histocompatibility complex (MHC) molecules on the surface of infected 
cells. Generally, the TCR of an individual T cell is specific for a particular combination of an 
antigenic peptide and MHC molecule. Within the T cell compartment, CD8+ and CD4+ T 
cells can be distinguished that recognize peptides in the context of MHC class I or MHC 
class II molecules, respectively. During a primary viral infection, naive virus-specific T cells 
are activated and develop into functional effector T cells, which can proliferate and control 
the initial viral infection. Subsequently, apoptosis of effector T cells results in contraction of 
the virus-specific T cell response, during which part of the effector T cells differentiate into 
antigen-experienced memory T cells. The virus-specific memory T cells persist in low 
frequencies to provide long-term protection against subsequent infections with the same 
virus [1,2]. Based on the expression of cell surface markers, different naive and memory T 
cell subsets have been characterized [2,3]. Naive T cells express CD45RA, CC-chemokine 
receptor 7 (CCR7), lymph-node homing receptor CD62 ligand (CD62L), and the co-
stimulatory receptors CD27 and CD28. After primary infection, differentiated virus-specific 
memory T cells express CD45RO at the cell surface. During subsequent infections, the 
expression of phenotypic markers CCR7, CD62L, CD27, and CD28 may be progressively 
lost, reflecting the differentiation state of the virus-specific memory T cells [2,3]. Upon 
recognition of viral antigen, virus-specific memory T cells mount an immune response by 
vigorous proliferation, the secretion of inflammatory cytokines like interferon-gamma 
(IFNγ), tumor-necrosis factor alpha (TNFα) and interleukin-2 (IL-2), and direct cytotoxicity 
towards the target cell by degranulation with granzyme B and perforin [2,4]. CD8+ T cells 
predominantly have the capacity to kill infected target cells. CD4+ T cells have a more 
pronounced helper function in the immune response and support the production of specific 
antibodies and the development of CD8+ T cells by production of inflammatory cytokines, 














Not all viruses are completely cleared from the host after acute infection. Through 
evolutionary interaction of viral pathogenesis with the host cellular immune response, some 
viruses have acquired properties to establish persistent infections. Persistence can result in 
chronic infections, with active virus continuously replicating in host cells for a prolonged 
period of time. Alternatively, the viral genome may persist in a latent form in host cells 
without active replication. From this state of latency, the virus can reactivate to start lytic 
replication again. 
The function of antiviral cellular immunity can be hampered by genetic immunodeficiency 
disorders. Furthermore, antiviral cellular immunity can be suppressed by 
immunosuppressive agents, which may be required for prevention of graft rejection in 
recipients of solid organ transplantation or allogeneic stem cell transplantation, or for 
treatment of auto-immune disease. In immunocompromised patients, the lack of functional 
antiviral cellular immunity may allow primary viral infections and reactivation of latent 
viral infections to cause serious morbidity and mortality.  
 
Allogeneic stem cell transplantation 
Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment modality 
for a variety of hematologic malignancies and inherited hematopoietic disorders [7,8]. In 
patients with hematologic malignancies, chemotherapy is first used to reduce the tumor 
load. Prior to transplantation, conditioning regimens which may include high-dose 
chemotherapy, irradiation, and immune suppression aim to further eradicate malignant 
cells, and to reduce and suppress the hematopoietic system of the patient to allow 
engraftment of a donor-derived hematopoietic system. Traditionally, myeloablative 
conditioning regimens have been used that induce considerable toxicity, limiting the 
procedure to younger patients. To provide the curative potential of alloSCT to patients of 
higher age or with concomitant disease, reduced intensity conditioning regimens have been 
developed [9]. Subsequently, donor hematopoietic stem cells are transferred, which have the 
ability to proliferate and differentiate into mature blood cells and reconstitute the patient 
hematopoietic system with donor-derived blood cells. Hematopoietic stem cells for alloSCT 
may be directly harvested from donor bone marrow, but are usually acquired from donor 
peripheral blood after mobilization from the bone marrow by administration of granulocyte 
colony stimulating factor (G-CSF) [10,11]. 
In patients receiving alloSCT, the transfer of donor T cells in the stem cell graft can result in 
beneficial as well as detrimental clinical effects. Transferred virus-specific donor T cells may 
provide immediate protection from viral disease. Although patient and donor are 













against patient cells. Genetically polymorphic proteins can differ between donor and patient 
and may contain immunogenic polymorphic epitopes, which have been defined as minor 
histocompatibility antigens. Immunogenic polymorphic peptides derived from patient 
proteins can be presented in MHC class I or II molecules and can be recognized by donor T 
cells. Donor-derived immunity directed against residual malignant cells of the patient is 
referred to as the graft-versus-leukemia effect, and can result in durable eradication of 
hematopoietic malignancies. Donor-derived T cell responses directed against the recipient’s 
healthy tissue can lead to potentially lethal graft-versus-host disease (GvHD), characterized 
by lesions of the skin, gut, and liver. To decrease the incidence and severity of GvHD, 
depletion of T cells from the stem cell graft before transplantation or in vivo after 
transplantation may be performed [12-14]. However, the concomitant absence of virus-
specific donor T cells will increase the risk of viral complications, and the decrease in graft-
versus-leukemia activity will increase the risk of persistence of residual malignant cells [15-
18]. After engraftment of the donor hematopoietic system, the administration of donor T 
cells may therefore be considered to prevent or treat viral infections or malignant relapses. 
 
Reconstitution of cellular immunity after alloSCT 
Following engraftment, the allogeneic stem cells give rise to a new hematopoietic system of 
donor origin, although small numbers of patient-derived hematopoietic cells may survive 
the intensive conditioning regimens. Multiple factors influence the rate and diversity of 
reconstitution of the immune repertoire, such as patient age, stem cell source, conditioning 
therapy, and T cell depletion of the graft [19]. Recovery of innate immunity by appearance 
of NK cells, monocytes, and granulocytes occurs rapidly in the first year after 
transplantation. However, reconstitution of adaptive immunity by T cells and B cells can be 
considerably delayed when performing depletion of the graft, and is often incomplete [19-
21]. Both patient-derived mature T cells that have survived the conditioning regimen and 
donor-derived mature T cells that have been transferred with the stem cell graft can be a 
source for T cell reconstitution due to homeostatic expansion. The mature T cells from 
patient or donor origin may also comprise virus-specific memory T cells, which can readily 
provide protection from viral disease after alloSCT. Subsequently, de novo generation of 
naive T cells derived from the transplanted donor stem cells and produced in the recipient 
thymus can start to be a new source of T cell reconstitution [19-21]. In the absence of 
residual patient-derived or transferred donor-derived virus-specific memory T cells, 















Viral infections after alloSCT 
As explained above, the delayed reconstitution of virus-specific T cells is associated with a 
high incidence of viral infections after alloSCT. The major viral pathogens causing serious 
morbidity and mortality after alloSCT are the common viruses cytomegalovirus, Epstein-
Barr virus, and human adenovirus. Furthermore, varicella-zoster virus can reactivate in 
alloSCT recipients to produce herpes zoster, which presents with localized cutaneous 
eruptions that can be accompanied by neuralgic pain [22-24]. Other herpesviruses and the 
human polyomaviruses may also reactivate from latency, leading to overt disease [25-29]. 
We will focus on cytomegalovirus, Epstein-Barr virus, and human adenovirus, due to their 
significant impact on mortality after alloSCT. 
Cytomegalovirus (CMV) is a beta-herpesvirus, and the largest known human herpesvirus 
with a genome of about 230 kb. The virus has double-stranded linear DNA enveloped by a 
tegument matrix, which is surrounded by a lipid bilayer that contains viral glycoproteins 
[30]. After initial infection, CMV establishes lifelong latency in endothelial cells and cells of 
the myeloid lineage. Depending on the region, 40-90% of the human population is 
seropositive for CMV [31,32]. Replication of CMV is restrained by CMV-specific T cells, 
comprising on average 10% of both CD8+ and CD4+ memory T cells in peripheral blood of 
healthy CMV seropositive adults [32]. Extensive characterization of CMV-specific T cell 
responses has demonstrated that peptides derived from many different CMV proteins were 
recognized. A large number of immunogenic CMV peptides derived from the 
immunodominant tegument protein pp65 and immediate-early protein IE1 has been defined 
[5,33-35]. In alloSCT recipients, the disrupted control of CMV can result in viral reactivation 
presenting with pneumonitis and gastrointestinal disease, and less frequently hepatitis, 
retinitis, and encephalitis [31,36]. In the absence of adequate numbers of CMV-specific T 
cells, CMV reactivation can progress to serious CMV disease, which is associated with a 
high rate of mortality [31,37]. The availability of the antiviral agents ganciclovir, foscarnet, 
and cidofovir has contributed to a significant reduction of CMV-related morbidity and 
mortality following alloSCT. However, administration of these drugs is limited by 
hematological and renal toxicity, and subsequent viral reactivations and refractory disease 
are commonly observed [37,38]. Reconstitution of the CMV-specific T cell repertoire directed 
against immunodominant CMV proteins has been demonstrated to confer sustained 
protection from CMV disease after alloSCT [39-41]. 
Epstein-Barr virus (EBV) is a human gamma-herpesvirus, composed of double-stranded 
DNA of approximately 172 kb, enveloped by a nucleocapsid and protein tegument, 
surrounded by glycoproteins [42]. EBV has established lifelong latent persistence in B cells 













adequately controlled by EBV-specific T cells in healthy individuals, although symptomatic 
EBV mononucleosis may occur upon primary infection [42]. EBV-specific T cells have been 
shown to recognize epitopes derived from a number of proteins expressed during latency, 
as well as proteins expressed during lytic infection [43-45]. A unique set of genes provides 
EBV with the potential to deregulate replication of infected cells, which may eventually lead 
to cancer formation [46-48]. Due to lack of viral control in immunocompromised patients 
after alloSCT, reactivation of EBV may result in the malignant transformation of infected B 
cells, which can progress to post-transplant lymphoproliferative disease (PTLD). In the 
absence of sufficient EBV-specific T cells, EBV-associated malignancies can cause serious 
disease and mortality [49,50]. The risk of EBV-PTLD is particularly increased when the 
balance between circulating B cells and T cells is disturbed. Therefore, the incidence of EBV-
PTLD is dependent on the regimen of conditioning and graft manipulation, and differs 
greatly between treatment schedules. Treatment of EBV-PTLD with monoclonal antibodies 
directed against CD20 expressed on mature B cells is not always effective. Furthermore, 
drawbacks of this treatment are long-term depletion of all B cells, and the risk of emergence 
of CD20-negative malignant cells [51]. 
Human adenovirus (HAdV) is a double-stranded DNA virus composed of a protein capsid, 
containing 240 hexon and 12 penton components, and a nucleoprotein core that contains the 
DNA viral genome and internal proteins [52]. There are currently 51 HAdV serotypes 
described, which are grouped into six subgroups (A-F) [53]. DNA homology within 
subgroups ranges from 48% for group A to 99% for group C, but DNA homology between 
subgroups is less than 20% [54]. Symptomatic HAdV infections are most common in 
children, with a peak incidence between the ages of 6 months and 5 years, which mainly 
affect the respiratory, ocular, skin, and gastrointestinal systems [52]. Following initial HAdV 
infection, HAdV DNA has been detected in peripheral blood monocytes, lung, and upper 
airways, and may also reside in cells of the gastrointestinal tract [55-57]. However, 
reactivation of latent HAdV has not been described, and HAdV disease may result from de 
novo infections as well. Low frequencies of HAdV-specific T cells have been detected in 
healthy individuals, which were predominantly CD4+ T cells directed against the abundant 
hexon protein [58-60]. Only recently, a number of CD8+ and CD4+ epitopes derived from the 
HAdV hexon protein have been identified [59-64]. Since these epitopes are largely 
conserved, specific T cells were cross-reactive towards HAdV serotypes from different 
HAdV subgroups, and may therefore provide protection against a wide range of HAdV 
serotypes [62-64]. In absence of immune control in particular in pediatric recipients of 
alloSCT, HAdV infections can progress to disseminated HAdV disease, which is associated 














for treatment of HAdV infection has not been proven in clinical trials yet. It has been 
demonstrated that reconstitution of HAdV-specific T cells is essential to control HAdV 
infection after alloSCT [66-68]. However, epitope specificity of these responses has not been 
characterized. Furthermore, mainly CD4+ T cells and no CD8+ T cells specific for HAdV 
were detected. Since HAdV-specific CD4+ T cells are capable to directly lyse HAdV infected 
target cells, the relative contribution of HAdV-specific CD4+ and CD8+ T cells in protection 
from HAdV disease after alloSCT remains to be elucidated [6,69]. 
  
Generation of virus-specific T cell lines 
Since the reconstitution of T cells specific for CMV, EBV, and HAdV after alloSCT has been 
shown to be associated with sustained protection from viral disease, the adoptive transfer of 
donor-derived virus-specific T cells is an attractive strategy for prophylaxis or treatment of 
viral disease in alloSCT recipients. Infusion of unselected donor T cells may be an effective 
method to provide virus-specific T cell reconstitution. However, this approach is limited by 
the risk of simultaneous infusion of alloreactive T cells, which may result in the 
development of GvHD. Therefore, much effort has been put in the development of strategies 
to select virus-specific T cells from donor peripheral blood, to provide effective 
reconstitution of virus-specific T cells after alloSCT with a minimal risk of development of 
GvHD. 
Peripheral blood can be stimulated with viral antigens in vitro, resulting in enrichment for 
virus-specific T cells due to preferential expansion of the activated cells during subsequent 
culture. This approach is feasible, and has been described in many studies for the 
enrichment of T cells specific for CMV, EBV, or HAdV antigens [70-74]. However, repetitive 
antigenic stimulations and long culture periods with IL-2 are required to generate T cell 
lines containing high frequencies of virus-specific T cells. In mice, in vitro restimulation and 
culture of virus-specific T cells negatively affected their efficacy after adoptive transfer [75]. 
Likewise, some human studies demonstrated that in vitro expanded CMV-specific, but also 
HIV-specific and melanoma-specific T cells did not persist long-term in vivo [76-78]. In vivo 
efficacy and survival is likely to be hampered by abrupt withdrawal from IL-2, or 
exhaustion, and functional changes developing during prolonged culture [79]. Furthermore, 
culture periods of several weeks may preclude treatment of patients with rapidly 
progressive viral disease. 
Several strategies have been developed for the direct isolation of virus-specific T cells from 
peripheral blood for the generation of highly specific T cell lines without the need for long-
term culture in vitro. Isolated virus-specific T cells can be cultured for a short period to 













MHC class I multimers with high affinity for a specific TCR can be used for isolation of 
epitope-specific CD8+ T cell populations (Figure 1, method 1) [80,81]. However, to provide T 
cell therapy for every patient at risk of developing viral disease and to generate T cell lines 
against multiple epitopes, this method requires knowledge of defined epitopes restricted by 
prevalent MHC class I molecules, and production of a large number of peptide-MHC 
multimers. Furthermore, virus-specific CD4+ T cells can not be isolated using this method 
due to the lack of functional peptide-MHC class II multimers. 
 
Figure 1. Selection of virus-specific T cells for adoptive immunotherapy. Virus-specific T cells can be labeled with 
magnetic beads using several methods. 1) Multimeric complexes composed of MHC molecules containing a specific 
viral peptide can bind to the TCR of virus-specific T cells. 2) After stimulation of virus-specific T cells, the secreted 
cytokine IFNγ can be captured at the cell membrane by bispecific IFNγ/CD45-antibodies, after which a secondary 
IFNγ-antibody attached to a magnetic bead can bind. 3) After stimulation of virus-specific T cells the CD137 molecule 
is expressed at the cell surface, after which a CD137-antibody attached to a magnetic bead can bind. Subsequently, the 
virus-specific T cells labeled with magnetic beads can be isolated by rinsing all the cells over a magnetic column. 
 
Alternatively, peripheral blood can be stimulated with viral antigen, after which the 
activated virus-specific T cells can be isolated based on an activation-induced effect, such as 
the secretion of a cytokine, or the expression of an activation marker at the cell surface. 
IFNγ-producing T cells can be isolated using the IFNγ capture assay. The secreted IFNγ is 
captured by an antibody at the cell membrane, after which a secondary IFNγ-specific 
antibody attached to a magnetic bead can be used to isolate the labeled cells by magnetic 
separation (Figure 1, method 2) [82]. Since most virus-specific T cells produce IFNγ upon 
activation, the IFNγ capture assay has been successfully applied for isolation of T cells 














studies, the IFNγ-secreting cells were isolated after overnight incubation with viral antigen. 
However, the kinetics of the IFNγ response by human virus-specific T cells upon activation 
has not been studied in detail. It is unknown whether T cell populations specific for different 
viruses show similar kinetics of IFNγ production upon activation, which would allow 
simultaneous IFNγ-based isolation of T cells specific for multiple viruses. Although the 
protocols used resulted in virus-specific T cell lines after culture, which might be due to 
both enrichment and preferential expansion, the efficiency of isolation was not addressed 
and may have been suboptimal. Significant retention of specific T cells in the unselected cell 
fraction can limit the potential of this isolation method. Furthermore, the IFNγ-based 
isolation procedure is technically demanding, which may have hampered a wider clinical 
application. Therefore, a variety of molecules that are expressed at the surface of virus-
specific T cells upon antigen-specific activation has been evaluated for use as isolation 
marker. 
The co-stimulatory molecule CD40L (CD154) has been shown to be specifically expressed by 
virus-specific CD4+ T cells and by part of virus-specific CD8+ T cells upon activation. Since 
CD40L is only transiently expressed at the cell surface and is rapidly internalized after 
interaction with CD40 on the antigen-presenting cell (APC), labeling of antigen-specific T 
cells with a CD40L-antibody can be performed during stimulation, or by blocking the 
interaction with CD40 [86,87]. Another isolation marker may be the co-stimulatory molecule 
CD137, which has shown to be specifically upregulated following activation of CD8+ T cells 
specific for CMV and EBV [88-90]. The surface expression of CD137 allowed a simple 
procedure of labeling with a CD137-specific antibody and magnetic beads for isolation of 
the activated T cells, as is shown in Figure 1 (method 3). The expression of CD137 by 
activated CD8+ T cells was demonstrated to peak 24 hours after stimulation [88,90,91]. Slow 
and prolonged expression of CD137 may provide a wide timeframe for efficient isolation, 
which can contribute to the robustness of the isolation method. However, the kinetics of 
CD137 expression was analyzed on cultured T cells, while the expression of CD137 by 
uncultured virus-specific T cells in donor peripheral blood is unknown. Furthermore, 
conflicting results have been reported on the activation-induced expression of CD137 by 
virus-specific CD4+ T cells [88,89]. 
These different techniques for isolation of virus-specific T cells have been routinely used for 
research purposes. The reagents for IFNγ-based and peptide-MHC-based labeling of cells 
with magnetic beads and the closed system of magnetic separation have become available 
for clinical application, while reagents for CD137-based isolation have not been produced 















Since many immunodominant epitopes derived from CMV, EBV, or HAdV proteins have 
been characterized, T cells recognizing these defined epitopes can be isolated using peptide-
MHC multimers, or using IFNγ-based or CD137-based isolation after stimulation with the 
corresponding minimal synthetic peptides. However, in healthy individuals, polyclonal 
virus-specific CD8+ and CD4+ T cell responses are directed against a broad repertoire of 
epitopes from multiple viral proteins [32,33,43-45,59,64]. Furthermore, restoration of 
antiviral protection in immunodeficient individuals has been shown to be associated with 
an enlarged repertoire of virus-specific T cells [92]. Therefore, the adoptive transfer of a 
coordinated CD8+ and CD4+ T cell response against multiple viral epitopes may be most 
effective for prophylaxis or treatment of viral disease in alloSCT recipients. 
The use of full-length viral proteins for stimulation of virus-specific T cells in donor 
peripheral blood circumvents the need of knowing the exact epitopes, and can provide 
coordinated CD8+ and CD4+ T cell lines specific for multiple viral epitopes, irrespective of 
the HLA type of the patient. However, the simultaneous activation of both CD8+ and CD4+ 
virus-specific T cells in peripheral blood has been shown to be difficult. Viral antigen 
endogenously synthesized by transduction of specific cDNA into antigen-presenting cells 
was predominantly presented in MHC class I, while exogenously added viral proteins or 
lysates resulted in selected presentation of viral peptides in MHC class II [93-97]. 
Interestingly, pools of 15-mer peptides overlapping with 11 amino acids have been 
described to simultaneously induce activation of both CD8+ and CD4+ T cells specific for 
viral epitopes, and may be used for the generation of combined CD8+ and CD4+ T cell lines 
[73,98,99]. Synthetic protein-spanning peptide pools can be produced under good 
manufacturing practice (GMP) conditions more easily than recombinant proteins or vectors 
for genetic modification, and may therefore allow feasible and cost-effective production of 
virus-specific T cell lines for adoptive immunotherapy. 
The processing of exogenous antigen followed by presentation in MHC class II has been 
extensively described, and the exogenously added long peptides may also directly bind in 
MHC class II molecules at the cell surface [100]. However, the mechanisms that result in 
presentation of exogenously added long peptides in MHC class I molecules, which usually 
present peptides of 8-11 amino acids in length, are not clear. Various models have been 
proposed for the presentation of exogenous long peptides in MHC class I, which may 
explain the activation of specific CD8+ T cells following stimulation of peripheral blood with 
long peptides. Elution of endogenously synthesized and processed peptides from surface 
MHC I molecules has demonstrated the presentation of different length variants of minimal 














variants can directly bind in MHC class I [101-105]. Long peptides that bind in MHC I 
molecules have been shown to adapt a centrally bulged conformation, or to protrude from 
one side of the peptide binding groove [106-110]. Furthermore, exogenous processing of 
long peptides by serum peptidases or membrane-bound peptidases may allow extracellular 
binding of trimmed peptides to cell surface MHC I molecules [111-114]. Alternatively, 
following uptake of exogenous long peptides, transport over endosomal membranes to the 
cytosol may result in the classical route of presentation which is dependent on proteasomal 
degradation and the transporter associated with antigen processing (TAP) [115]. 
Internalized peptides may also enter endosomal compartments which have fused with the 
endoplasmic reticulum (ER), and therefore contain the machinery for peptide loading of 
MHC I molecules [116]. Finally, entrance of MHC class I molecules in the recycling 
endocytic MHC II pathway has been demonstrated to allow exchange with exogenous 
peptides, which can be edited by endosomal peptidases [117-120]. Although the 
mechanisms that result in MHC presentation following stimulation of peripheral blood with 
exogenously added long peptides remain to be elucidated, the use of synthetic protein-
spanning peptide pools may be a very effective strategy for simultaneous activation and 
isolation of virus-specific CD8+ and CD4+ T cells for adoptive immunotherapy. 
 
Clinical results of antiviral adoptive immunotherapy 
The first cases of alloSCT recipients with life-threatening EBV-PTLD and HAdV disease that 
were successfully treated by the adoptive transfer of donor-derived T cells were described in 
1994 [121,122]. In these patients, sustained viral clearance was observed within weeks after 
administration of approximately 1x106 unselected donor T cells per kilogram body weight. 
Although these and subsequent reports showed that the adoptive transfer of unselected 
donor T cells can be very effective for treatment of viral disease after alloSCT, the infusion of 
donor T cells that can cause potentially lethal GvHD is a major limitation of this approach. 
Acute or chronic GvHD has been shown to develop in 50-60% of alloSCT recipients after 
infusion of 5x106 unselected donor T cells per kilogram body weight, and can even result in 
mortality in 10% of patients [123,124]. Therefore, virus-specific T cell lines have been 
generated to provide effective antiviral immune reconstitution with a minimal risk of 
GvHD. These virus-specific T cell products have been used for prophylaxis or treatment of 
viral disease in a number of small clinical trials. 
In several clinical studies, CMV-specific T cells were infused for prophylaxis of CMV 
disease approximately 1 month after alloSCT [78,95,97,125-127]. Transient increases in 
frequencies of CMV-specific T cells were demonstrated within weeks after administration. 













development of CMV-specific CD8+ T cells in vivo [95]. Although CMV-related morbidity 
and mortality appeared to be reduced compared to historical controls, these non-
randomized trials can not provide evidence on protection from CMV disease. In other 
studies, CMV-specific T cells were infused pre-emptively after detection of a CMV DNA 
plasma load [94,128,129]. Reconstitution of CMV-specific T cells was detected in vivo, even 
after administration of low numbers of CMV-specific T cells with a median of 9x103 T cells 
per kilogram body weight [129]. It was likely that the CMV-specific T cells expanding in 
vivo were derived from the T cell infusions, since the TCR CDR3 sequence of the CMV-
specific T cells was shown to be identical. After adoptive transfer of the CMV-specific T 
cells, the CMV DNA load was cleared in all patients. In one clinical trial, CMV-specific T 
cells were administered to patients without detectable CMV-specific T cells and 
experiencing CMV reactivation that was refractory to standard pharmacotherapy [93]. 
Despite cessation of antiviral pharmacotherapy, the CMV load dropped significantly after 
administration of CMV-specific T cells, and sustained clearance of CMV occurred in 5 of 7 
patients. Importantly, no adverse events related to infusion of CMV-specific T cells were 
reported in these clinical trials.  
In the first clinical study on adoptive transfer of donor-derived EBV-specific T cells after 
alloSCT for prophylaxis of EBV-PTLD, the EBV-specific T cells were labeled with a marker 
gene [130,131]. Using this marker gene, persistence of the transferred T cells was 
demonstrated up to 9 years after infusion [132,133]. Furthermore, the marked EBV-specific T 
cells were shown to expand in vivo during EBV reactivation [130,133]. In another study, pre-
emptive administration of EBV-specific T cells was shown to decrease the EBV DNA load in 
8 of 9 patients, although no sustained viral clearance was observed and 1 of the patients 
progressed to fatal EBV-positive lymphoma [134]. Treatment of early stage EBV-PTLD by 
infusion of EBV-specific T cells was shown to result in complete and stable remissions, while 
treatment of late stage EBV-PTLD was not successful [133,135]. To provide EBV-specific T 
cells for treatment of EBV-PTLD in solid organ transplant recipients, banked EBV-specific T 
cell lines were used to select the best HLA-matched product [136]. The response rate of 52% 
appeared promising, since these patients had failed conventional therapy. Despite the 
partial HLA-mismatch, the infused EBV-specific T cells persisted up to 194 days in vivo, and 
antibodies against a mismatched HLA antigen were only detected in 1 patient. Even in the 
partially mismatched setting, no adverse events related to the EBV-specific T cell infusions 
were described. 
Only a very limited number of alloSCT recipients has been treated with HAdV-specific T 
cells yet. In one published study, donor peripheral blood was stimulated with HAdV lysate, 














the HAdV-specific T cells were administered to 9 pediatric patients after alloSCT with a 
detectable HAdV DNA load which did not respond to pharmacotherapy. In 5 of 6 evaluable 
patients, increased frequencies of HAdV-specific T cells were detected after infusion, which 
was accompanied by a decrease in HAdV load. In 1 of the patients, pre-existing GvHD of 
the skin increased 10 days after administration of HAdV-specific T cells. Furthermore, 
HAdV-specific T cell lines are being generated by culture of donor PBMC with 5 conserved 
HAdV hexon 30-mer peptides at the department of Pediatrics of the Leiden University 
Medical Center [62]. Administration of these HAdV-specific T cell lines to pediatric alloSCT 
recipients for treatment of HAdV disease is under investigation. 
 Recently, the generation of T cell lines specific for antigens derived from different viruses 
has been proposed to provide prophylaxis or treatment for multiple viruses after alloSCT. In 
two studies, combined T cell lines specific for CMV, EBV, and HAdV were administered to 
alloSCT recipients for prophylaxis of viral reactivation and disease [96,138]. Increased 
frequencies of virus-specific T cells were demonstrated after adoptive transfer, which may 
have prevented the development of viral disease. 
From these clinical trials it can be concluded that the adoptive transfer of donor-derived 
virus-specific T cells appeared to be safe and did not result in GvHD. Even high numbers of 
virus-specific T cells, up to 1x109 T cells per square meter of body surface area, were well 
tolerated [125]. Furthermore, the T cell infusions resulted in increased frequencies of 
circulating virus-specific T cells, which were demonstrated to be able to expand and persist 
long-term in vivo. Since the trials were non-randomized, no conclusions can be drawn on 
efficacy of treatment. However, in most studies the adoptive transfer of virus-specific T cells 
was associated with a decrease in viral DNA plasma load or with sustained viral clearance, 
indicating that adoptive immunotherapy may be effective. The methods used to generate 
virus-specific T cell products were very variable with regard to viral antigens used, isolation 
steps, culture period, and cell numbers infused. Furthermore, the patient populations were 
very variable in conditioning, transplantation regimens, viral infections, and the time of 
adoptive transfer. Therefore, the optimal strategy for adoptive transfer of donor-derived 
virus-specific T cells and its clinical benefit remain to be elucidated. 
 
Quality assurance and regulatory aspects of adoptive immunotherapy 
Before adoptive transfer of virus-specific T cells can be implemented in clinical studies, the 
quality of the final cellular product has to be assured. Analogous to the production of 
conventional medicinal products, the starting material and reagents should be released for 
clinical use, and the production process and environment should be strictly defined. Donor 













for blood donation and processing. Clinical grade culture media and devices can be 
obtained, and appropriate cleanroom facilities are available in a number of hospitals across 
Europe. Clinical grade viral antigens and isolation reagents are currently being developed. 
The small scale production of viral lysate or recombinant proteins can not easily be 
performed under GMP conditions, and poses the risk of introducing intact viral particles 
and animal-derived components. The production of synthetic peptides for use as viral 
antigen in vitro can be more easily performed under GMP conditions. The reagents for 
IFNγ-based and peptide-MHC-based labeling of cells with magnetic beads and the closed 
system of magnetic separation are available for clinical application. The CD137-specific 
monoclonal antibodies have not been produced for clinical purposes yet. 
The release criteria of the final T cell product should be designed for each product for 
clinical use to ensure maximal safety, efficacy, and feasibility. The absence of 
microbiological contamination should be analyzed in cultured samples of the starting 
material and of the final T cell product. Furthermore, the correct donor origin of the starting 
peripheral blood cells can be confirmed by DNA profiling. The composition of the final 
product can be analyzed by flow cytometry, and should confirm the presence of mainly 
viable T cells. When using a well defined viral antigen, the total frequency of virus-specific T 
cells in the cellular product can be properly analyzed by antigen-specific restimulation 
followed by functional analysis. In addition, the frequency of T cell populations specific for 
defined viral epitopes can be analyzed using peptide-MHC multimeric complexes. 
Confirmation of high frequencies of virus-specific T cells that can be achieved by isolation 
methods (>50% of cells) will indicate that the production process has been adequately 
performed, and is crucial to justify release. The concomitant low absolute numbers of T cells 
with unknown specificity will assure a minimal risk of the development of GvHD. In 
addition to these criteria for the composition and specificity of the cellular product, the 
functional response of the virus-specific T cells can be confirmed towards patient and donor 
cells loaded with viral antigen, and should be absent towards unloaded control patient and 
donor cells. Possible functional read-out systems include the measurement of cytokine 
production or the analysis of cytotoxic activity. The absence of residual alloreactive potential 
can be further confirmed by the analysis of functional responses during co-culture of the 
virus-specific T cell product with a panel of peripheral blood cells from allogeneic third 
party donors and from the patient. When all standard operation procedures for the process 
of production as well as for the analysis of the cellular product have been properly followed 















In parallel to the developments in detection, isolation and culture of virus-specific T cells for 
clinical application, the regulatory framework for cellular therapies has also evolved. With 
the adoption of the European Directive 2003/63/EC, somatic cellular products were for the 
first time defined as medicinal products when their biological characteristics have been 
substantially altered as a result of their manipulation to obtain a therapeutic, diagnostic or 
preventive effect. By the end of 2008, with the adoption of the Advanced Therapy Medicinal 
Product (ATMP) regulation, this definition was further specified to products that are 
substantial manipulated and/or not intended to be used for the same essential functions in 
the recipient as in the donor. According to the ATMP regulation, isolation and expansion of 
virus-specific T cells should be seen as substantial manipulation. This means that the 
production and application of these cells should comply with all the relevant regulations for 
investigational medicinal products for human use, including GMP and good clinical practice 
(GCP) guidelines. Although the ATMP regulation is primarily adopted to aid the marketing 
authorization of these advanced products, it will also influence the early development of 
AMTP from an academic perspective. The ATMP regulation states that “advanced therapy 
medicinal products which are prepared on a non-routine basis according to specific quality 
standards, and used within the same Member State in a hospital under the exclusive 
professional responsibility of a medical practitioner, in order to comply with an individual 
medical prescription for a custom-made product for an individual patient, should be 
excluded from the scope of this regulation, whilst at the same time ensuring that relevant 
community rules related to quality and safety are not undermined”. Hopefully, the 
adoption of the ATMP regulation will not hamper the early development of cellular 
therapies from an academic perspective, but aid to reach high quality standards for maximal 














Aim of the thesis 
Extended knowledge of antiviral T cell responses in vivo and the advanced methods for 
isolation, culture, and analysis of virus-specific T cells in vitro may contribute to improved 
strategies for adoptive immunotherapy with virus-specific T cells. In this thesis, we 
investigated how the immunological techniques that are currently available can be exploited 
to detect and select virus-specific T cells in peripheral blood. To support the rationale for 
antiviral T cell therapy, the role of virus-specific T cells in protection from viral disease after 
alloSCT was studied. Furthermore, strategies were developed for the efficient isolation of 
virus-specific T cells from peripheral blood for adoptive transfer. The studies aimed to 
develop methods for the rapid generation of clinical grade T cell lines with high specificity 
against multiple viral antigens, which may be used to establish the clinical benefit of 
adoptive immunotherapy for viral infections after alloSCT. 
In chapter 2, we performed a detailed analysis of the kinetics of IFNγ production by CMV 
pp65-specific CD8+ T cells upon stimulation to determine the optimal time point for IFNγ-
based isolation. The effect of the strength of antigenic stimulation on TCR downregulation, 
the kinetics of IFNγ production, and expansion was investigated. Based on these findings, 
we defined optimal conditions for IFNγ-based isolation of CMV pp65 peptide-specific CD8+ 
T cells for clinical application. 
In chapter 3, we aimed to isolate coordinated CD8+ and CD4+ T cells specific for a broad 
repertoire of CMV pp65 and IE1 epitopes from peripheral blood, since these cells may be 
more effective for adoptive immunotherapy as compared to CD8+ T cells specific for a single 
CMV epitope. The efficiency of activation and kinetics of IFNγ production by CD8+ and 
CD4+ CMV-specific T cells was analyzed after stimulation of peripheral blood with different 
CMV antigens. The results were translated into a procedure for the simultaneous isolation of 
CD8+ and CD4+ T cells specific for multiple CMV pp65 and IE1 epitopes. Subsequently, the 
specificity, phenotype and functionality of the combined CD8+ and CD4+ CMV-specific T 
cell lines were analyzed. 
Since the relative contribution of HAdV-specific CD8+ and CD4+ in protection from HAdV 
disease after alloSCT is not clear, and the epitope specificity of HAdV-specific T cell 
responses after alloSCT has not been characterized, we studied the development of T cell 
responses against HAdV hexon epitopes in pediatric and adult alloSCT recipients in 
chapter 4. Subsequently, a clinical grade method was developed for rapid generation of 
CD8+ and CD4+ T cell lines with high and defined specificity for HAdV hexon epitopes for 














specific T cell lines was investigated to identify novel HAdV hexon epitopes, and 
recognition of HAdV-infected target cells was analyzed. 
In chapter 5, we aimed to define a single and feasible method for isolation of CD8+ and 
CD4+ T cells recognizing epitopes derived from different viral proteins from peripheral 
blood. To ensure that the method was applicable to a wide variety of virus-specific T cells 
that may differ in phenotypic and functional properties, we focused on T cells specific for 
the persistent viruses CMV and EBV, as well as T cells specific for HAdV and influenza 
(FLU), which are not repetitively activated in vivo after initial viral clearance The kinetics of 
IFNγ production and CD137 expression were analyzed, to allow simultaneous IFNγ-based 
or CD137-based isolation of CD8+ and CD4+ T cells specific for multiple viruses. Based on 
these findings, an efficient and widely applicable strategy for generation of multivirus-
specific T cell lines was developed. 
To activate virus-specific CD8+ and CD4+ T cells for the purpose of detection or isolation, 
synthetic pools of overlapping long peptides spanning viral proteins are routinely used. 
Furthermore, synthetic long peptides have been used for vaccination to induce or boost 
antigen-specific CD8+ T cells in vivo. However, the mechanisms that result in presentation 
of exogenously added long peptides in MHC class I molecules, resulting in activation of 
peptide-specific CD8+ T cells, are not clear. In chapter 6, the efficiency of CD8+ T cell 
activation by several extended variants of minimal MHC class I binding peptides was 
analyzed. Subsequently, we investigated whether the CD8+ T cell activation resulted from 
direct binding of long peptides in MHC class I or from peptide processing followed by 
MHC I binding of the minimal peptides. 
In chapter 7, clinical results are presented of a phase I/II study for treatment of refractory 
CMV reactivation after alloSCT by the adoptive transfer of donor- or patient-derived CMV 
pp65-specific CD8+ T cells. Refractory CMV reactivation was defined as high CMV DNA 
load in peripheral blood for more than 2 weeks under antiviral pharmacotherapy or early 
relapse after antiviral pharmacotherapy. CMV pp65-specific CD8+ T cell lines were 
generated from peripheral blood by IFNγ-based isolation following CMV pp65 peptide 
stimulation. Patient follow-up and immune monitoring provided information on the 
relation between adoptive transfer of CMV-specific CD8+ T cells and the occurrence of 
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Detailed analysis of IFNγ response upon
activation permits efficient isolation  























Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific T cells may provide 
long-lived protection from CMV disease after allogeneic stem cell transplantation. Isolation 
of IFNγ-secreting cells following CMV peptide stimulation can be performed by IFNγ 
capture assay to generate highly specific T cell lines without the need for extensive culture, 
which may hamper their in vivo efficacy. To exploit the full potential of this approach, we 
analyzed the IFNγ response of CMV-specific CD8+ T cells in detail. Kinetic studies showed 
that TCR downregulation coincided with the induction of IFNγ production upon activation, 
which rapidly declined thereafter despite the continued presence of specific peptide. By 
varying the strength of stimulation we observed that overstimulation can result in profound 
TCR downregulation, more rapid decline of IFNγ production and reduced expansion. Based 
on these findings, we defined optimal conditions for IFNγ-based isolation of CMV-specific 
CD8+ T cells with maximal potential for clinical application. These data stress the 
importance of analyses of the kinetics of cytokine production for isolation of T cells specific 
for other infectious or malignant antigens to exploit the full potential of cytokine capture 














Reactivation of cytomegalovirus (CMV) can cause serious morbidity and mortality during 
the prolonged period of immune deficiency following allogeneic stem cell transplantation 
(alloSCT). Viral replication can occur in the absence of adequate numbers of CMV-specific T 
cells, which are eradicated or impaired by the conditioning regimen and immune 
suppression [1,2]. Reconstitution of the CMV-specific T cell repertoire directed against 
immunodominant proteins pp65 and IE-1 in the first year after transplantation has been 
demonstrated to confer sustained protection from CMV disease [3-8]. This is also illustrated 
by increased CMV-related morbidity in patients receiving a T cell depleted graft or a graft 
from a CMV-seronegative donor [6-10]. Treatment of CMV reactivation by pharmacological 
agents is limited by toxicity and not sufficient for long-term anti-viral protection in the 
absence of CMV-specific T cells [11-13]. Several clinical trials have shown that adoptive 
transfer of donor-derived CMV-specific T cells can be a safe and effective strategy to control 
CMV reactivation [14-23]. However, the generation of CMV-specific T cell lines has to be 
markedly improved with regard to specificity, reproducibility, and culture conditions, 
before the clinical benefit of this treatment can be confirmed, resulting in broad application. 
In most studies CMV-specific T cell lines were generated by preferential expansion, 
including repetitive antigenic stimulations and long culture with high dose IL-2. In mice, in 
vitro restimulation and culture of CMV-specific T cells negatively affected their efficacy 
following adoptive transfer [24]. Likewise, some human studies demonstrated that in vitro 
expanded CMV-specific, but also HIV- and melanoma-specific CD8+ T cells did not persist 
long-term in vivo [14,22,25,26]. In vivo efficacy and survival is likely to be hampered by 
abrupt withdrawal from IL-2, or exhaustion, and functional changes developing during 
prolonged culture [27]. Moreover, the high concentrations of antigen which are used for 
activation and restimulation may not be physiological, and may reduce T cell functionality 
[28-31]. Alternatively, the lack of in vivo survival may be due to selection of effector 
memory T cells, while only T cells derived from CD62L-positive central memory T cells 
have been reported to establish persistent CMV-specific T cell memory in macaques [32]. 
Direct isolation of antigen-specific T cells allows the generation of highly specific T cell lines 
without the need for extensive culture. Since the presence of CMV-specific memory T cells 
that produce IFNγ upon activation has been found to be associated with protection from 
CMV reactivation after alloSCT, isolation of this population may be a good strategy for 
generating effective CMV-specific T cell lines [4,5,7,8]. It has been demonstrated that 
adoptive transfer of IFNγ-producing memory T cells can provide long-lived functional 














capture assay is the only isolation method currently available which can be performed 
under GMP regulations. Only antigen-specific T cells that secrete IFNγ during the isolation 
procedure can be isolated using the IFNγ capture assay. Murine virus-specific T cells have 
shown to constantly produce IFNγ between 1 and 24 hours after activation in the continued 
presence of antigen [34-36]. Production of IFNγ by human virus-specific T cells is commonly 
detected by cumulative techniques like intracellular staining and ELISA after 4 to 24 hours 
of stimulation. However, the real-time kinetics of the IFNγ response of human virus-specific 
T cells have not been studied in detail. To date, virus-specific T cells were isolated from 
peripheral blood mononuclear cells by the IFNγ capture assay after overnight stimulation 
with high concentrations of viral antigen [21,37-40]. Although these protocols resulted in 
specific T cell lines after culture, which can be due to both enrichment and preferential 
expansion, the efficiency of isolation was not addressed and may have been suboptimal. 
Significant retention of specific T cells in the unselected cell fraction can limit the potential of 
this isolation method. 
Another strategy for adoptive transfer of antigen-specific T cells is T cell receptor (TCR) 
gene transfer, which has shown promising results in the first clinical study [41]. Isolation of 
virus-specific T cells offers the possibility to redirect their specificity to malignant cells by 
TCR gene transfer. Activation of the endogenous TCR due to latent presence of viral antigen 
in vivo may result in enhanced survival of TCR-transferred T cells. Furthermore, 
introduction of a tumor-reactive TCR into restricted virus-specific T cell populations will 
minimize the risk of autoimmunity [42]. 
In this study, we performed detailed analysis of the IFNγ response by CMV-specific CD8+ T 
cells and defined optimal conditions for activation and isolation of CMV-specific CD8+ T 
cells based on IFNγ secretion. Kinetic studies showed that the rapid induction of IFNγ 
secretion by CMV-specific CD8+ T cells upon activation was followed by a strong decrease 
already after several hours. By varying the strength of antigenic stimulation we illustrated 
that overstimulation can result in extensive TCR downregulation, more rapid decline of 
IFNγ production and reduced expansion. In contrast, a more physiological strength of 
stimulation permitted efficient isolation of CMV-specific T cells while preserving maximal 
in vivo potential for clinical application. 
 
Materials and methods 
Donor cells and stimulation 
Peripheral blood was obtained from CMV-seropositive healthy individuals after informed 













separation. After thawing, cells were resuspended in culture medium, consisting of Iscove’s 
modified Dulbecco’s medium (IMDM, Lonza, Basel, Switzerland) supplemented with 10% 
pooled human serum, 100 U/ml penicillin/streptomycin (Lonza), and 3 mM L-glutamine 
(Lonza). Cells were cultured at 10x106 cells/ml at 37°C and 5% CO2, and stimulated with 10-4 
to 10-11 M CMV pp65-derived peptide YSEHPTFTSQY (YSE/HLA-A*0101), NLVPMVATV 
(NLV/HLA-A*0201), TPRVTGGGAM (TPR/HLA-B*0702), RPHERNGFTVL (RPH/HLA-
B*0702), or IPSINVHHY (IPS/HLA-B*3501).  
 
Flow cytometric analyses 
Cells were stained with FITC-labeled CD3, CD14, CD27 (BD Biosciences, San Jose, CA, 
USA), CD45RO (Caltag, Burlingame, CA, USA), CD62L (Bender MedSystems, Vienna, 
Austria), PE-labeled CD28, CD56 (BD), CD45RA (Beckman Coulter, Fullerton, CA, USA), 
CCR7 (R&D Systems, Minneapolis, MN, USA), PerCP-labeled CD3, CD8 (BD), APC-labeled 
CD4 (Beckman Coulter),  and CD19 (BD) monoclonal antibodies (mAbs). PE- and APC-
labeled CMV peptide-MHC tetramers were produced as described previously [43]. 
Fluorescence was analyzed using a FACSCalibur and Cellquest software (BD). 
 
Analysis of cytokine production 
For cumulative measurement of intracellular cytokines, 10 µg/ml brefeldin A (BFA, Sigma-
Aldrich, Zwijndrecht, The Netherlands) was added at the start of peptide stimulation. For 
real-time measurement of intracellular cytokines, 10 µg/ml BFA was added only during the 
last hour of peptide stimulation. After harvesting, cells were washed in phosphate-buffered 
saline (PBS) and stained with PE-labeled tetramers for 15 minutes at 37°C. Subsequently, 
mAbs for cell-surface staining were added and incubated for 30 minutes at 4°C. Cells were 
washed in PBS and fixed with 1% paraformaldehyde for 8 minutes at 4°C. For 
permeabilization, samples were washed in PBS with 0.1% saponin (Sigma-Aldrich) and 
incubated for 30 minutes at 4°C. Cells were stained with APC-labeled IFNγ mAb or PE-
labeled TNFα mAb (BD) for 30 minutes at 4°C, washed, and fluorescence was analyzed by 
flow cytometry. To analyze production of multiple cytokines by CMV-specific T cells, 
supernatant was harvested after peptide stimulation and analyzed by the human 
Th1/Th2/Th17 multi-analyte profiler ELISArrayTM kit (SA Biosciences, Frederick, MD, 
USA), performed according to the manufacturer’s instructions. 
 
Detection, isolation, and culture of IFNγ-secreting cells 
Cells were harvested, thoroughly washed in PBS, and IFNγ-secreting cells were stained by 














to the manufacturer’s instructions. Briefly, cells were labeled with IFNγ-catch reagent and 
cultured for 45 minutes at 37°C. Cells were counterstained with PE-labeled IFNγ mAb. For 
subsequent isolation, the IFNγ-PE-labeled cells were bound to anti-PE microbeads, and 
isolated using the midi-MACS system (Miltenyi Biotec). For analysis of IFNγ-secreting cells 
and composition of the isolated fractions, samples were stained with APC-labeled tetramers 
for 15 minutes at 4 °C. Subsequently, mAbs for cell-surface staining were added and 
incubated for 30 minutes at 4°C. Low dose propidium iodide (0.2 µg/ml) was added upon 
flow cytometric analysis of the isolated fractions to exclude dead cells. The isolated IFNγ-
enriched and IFNγ-depleted cell fractions were both cultured at 1x106 cells/ml in culture 
medium, containing 50 IU/ml IL-2 (Chiron, Amsterdam, The Netherlands) with 10x106 
cells/ml 30 Gy-irradiated feeder cells derived from the IFNγ-depleted fraction. Cultures were 
supplemented with fresh medium and 50 IU/ml IL-2 every 3-4 days. 
 
Proliferation assay 
PBMC were thoroughly washed with PBS, resuspended at 10x106 cells/ml, and labeled with 
3.5 µM carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Leiden, 
The Netherlands) for 10 minutes at 37 °C. The reaction was stopped by the addition of an 
equal volume of fetal calf serum (Lonza). After overnight incubation in culture medium at 
37 °C, the cells were washed and incubated in culture medium at 10x106 cells/ml with 10-4 to 
10-9 M CMV peptide and 50 IU/ml IL-2. After 6 days of incubation at 37°C, samples were 
washed in PBS and stained with APC-labeled tetramers for 15 minutes at 37°C. 
Subsequently, mAbs for cell-surface staining were added and incubated for 30 minutes at 
4°C. Cells were washed and fluorescence was analyzed by flow cytometry. 
 
Results 
Kinetics of IFNγ response by CMV-specific CD8+ T cells upon peptide stimulation 
The fraction of CD8+ T cells recognizing immunodominant CMV pp65 epitopes which 
produces IFNγ upon antigen-specific activation was determined in PBMC from healthy 
CMV-seropositive donors. To measure the induction of the IFNγ response at the single cell 
level, cumulative intracellular IFNγ staining was performed at several time points following 
stimulation with a saturating concentration (10-6 M) of CMV peptide. T cells recognizing this 
epitope were identified by peptide-MHC tetramer after stimulation to analyze both IFNγ 
production and TCR downregulation of the specific cells. As shown in Figure 1A, tetramer-
positive CD8+ T cells produced IFNγ upon peptide stimulation within 6 hours. The mean 













extensive TCR downregulation that showed similar kinetics to IFNγ production. Expression 
of CD8, CD3, and TCRab by IFNγ-producing T cells decreased to similar levels, indicating 




Figure 1. Kinetics of IFNγ response by CMV-specific CD8+ T cells upon stimulation with 10-6 M CMV pp65 TPR 
peptide. A) Cumulative intracellular IFNγ staining of PBMC after 0-6 hours of peptide stimulation in the presence of 
BFA. The MFI of tetramer, CD8, and CD3 staining of peptide-specific CD8+ T cells is depicted. B) Real-time 
intracellular IFNγ staining of PBMC after 0-24 hours of peptide stimulation with addition of BFA only during the last 
hour of incubation. The MFI of intracellular IFNγ staining of peptide-specific CD8+ T cells is depicted. C) IFNγ capture 
















To investigate the kinetics of the IFNγ response, real-time production of IFNγ was measured 
at several time points after stimulation by addition of BFA only during the last hour of 
peptide incubation. Figure 1B demonstrates that IFNγ production by peptide-specific T cells 
started already in the first hour after stimulation, and reached a maximum between 2 and 4 
hours when most tetramer-positive cells produced IFNγ. Thereafter, the production of IFNγ 
rapidly declined both in the percentage of tetramer-positive cells actively producing IFNγ 
and the amount of IFNγ produced per cell (decrease in IFNγ MFI). To confirm that kinetics 
of intracellular IFNγ production correlated with kinetics of IFNγ secretion, detection of IFNγ 
by capture assay was performed at the same time points after stimulation, reflecting IFNγ 
secretion in a fixed timeframe of 45 minutes. Figure 1C shows that the kinetics of IFNγ 
secretion were consistent with intracellular IFNγ production, with peak IFNγ secretion 
between 2 and 4 hours of stimulation, followed by a rapid decrease. Peptide-specific T cells 
could not be identified among IFNγ-labeled cells by staining with peptide-MHC tetramer 
due to downregulation upon activation. The IFNγ-labeled cells contained some CD14+, and 
few CD4+, CD19+, and CD56+ cells (data not shown), indicating non-specific labeling or 
indirect labeling with IFNγ secreted by peptide-specific CD8+ T cells, since intracellular 
staining had shown that only the peptide-specific T cells actively produced IFNγ (Figure 
1A). 
These experiments demonstrate that stimulation with this high peptide concentration 
resulted in rapid induction of IFNγ secretion by nearly all peptide-specific T cells, and rapid 
and vigorous TCR downregulation of at least 90%. Thereafter, the production of IFNγ 
strongly declined. 
 
Effect of epitope density on TCR downregulation and IFNγ production 
To study the relation between the strength of stimulation, TCR downregulation and IFNγ 
production, the epitope density was varied by stimulation with different peptide 
concentrations. 
As shown in Figure 2A, stimulation of donor PBMC with CMV peptide for 4 hours resulted 
in both a decrease of tetramer staining and increase of IFNγ production starting at a peptide 
concentration of 10-11 M, gradually progressing up to plateau levels at peptide 
concentrations above 10-7 M. The direct correlation between TCR downregulation and IFNγ 














Figure 2. Effect of epitope density on TCR downregulation and IFNγ production. Cumulative intracellular IFNγ 
staining of PBMC was performed after 4 hours of stimulation with 10-4 to 10-14 M CMV pp65 TPR peptide. A) IFNγ MFI 
of CMV pp65 TPR-specific cells (black squares) is plotted against the left Y-axis, and tetramer MFI (white triangles) is 
plotted against the right Y-axis. B) Tetramer MFI of CMV pp65 TPR-specific cells is plotted against IFNγ MFI. Samples 
were stained with pp65-TPR-B7 tetramer after stimulation. 
 
To study the effect of epitope density on the kinetics of IFNγ production, real-time 
measurement of IFNγ production was performed following stimulation with different 
peptide concentrations. Figure 3A and 3B show that after stimulation with 10-7 M HLA-B7 
restricted CMV TPR peptide a maximal percentage of IFNγ-producing cells was induced 
after 4 hours, which decreased thereafter. The kinetics of IFNγ production were similar for 
peptide concentrations below 10-7 M with maximal IFNγ production after 4 hours of 
stimulation, however, the percentage of cells producing IFNγ and the amount of IFNγ 
produced per cell (IFNγ MFI) was lower. Stimulation with peptide concentrations higher 
than 10-7 M induced a more rapid peak of IFNγ production, which also declined rapidly 
thereafter, resulting in only marginal IFNγ production after 8 hours with 10-5 M peptide 
stimulation (Figure 3B). Furthermore, as shown in Figure 3A, peptide concentrations higher 
than 10-7 M induced more extensive TCR downregulation (4 hr tetramer MFI 10-5 M=62 vs 
10-7 M=150). Stimulation with HLA-A1 or HLA-B35 restricted CMV YSE or IPS peptides, 
which are less immunodominant epitopes, showed a slightly slower induction of IFNγ 
production, and higher peptide concentrations of 10-5 M (YSE) to 10-6 M (IPS) were required 














Figure 3. Effect of epitope density on the kinetics of IFNγ production by CMV-specific CD8+ T cells. Real-time 
intracellular IFNγ staining of PBMC after 0-24 hours of stimulation with CMV peptide with addition of BFA only 
during the last hour of incubation. Samples were stained with peptide-MHC tetramer after stimulation. A) Dot plots 
are shown for stimulation with HLA-B7 restricted TPR peptide using concentrations of 10-5, 10-7 and 10-9 M. B) 
Percentage of IFNγ-producing cells after stimulation with 10-5 to 10-10 M HLA-B7 restricted TPR peptide over time. C) 
Percentage of IFNγ-producing cells after stimulation with 10-5 to 10-10 M HLA-B35 restricted IPS peptide over time. 
 
To investigate whether the different peptide concentrations required for maximal IFNγ 
production resulted from differences in peptide-MHC affinity between selected epitopes, we 
determined the efficiency of stabilizing peptide-MHC monomers by the different peptides 
by the addition of different concentrations of CMV peptide to a fixed concentration of heavy 
chain and beta-2-microglobulin. All selected CMV pp65 peptides were shown to stabilize 
monomers at low peptide concentrations (1:1 ratio of peptide:heavy chain), indicating high 
affinity for the relevant MHC complex. The highest yield of peptide-MHC monomers at low 
peptide concentrations was observed for IPS/HLA-B35, followed by NLV/HLA-A2, 
indicating that these peptides had highest peptide-MHC binding affinity. These data 
indicate that the differences in peptide concentration required for maximal IFNγ production 
were not due to differences in peptide-MHC binding affinity, but more likely resulted from 













These data show that the kinetics and amount of IFNγ produced by activated peptide-
specific cells were determined by the peptide concentration. A maximal IFNγ response was 
observed after stimulation with 10-7 to 10-5 M peptide, depending on the epitope. More 
vigorous triggering of TCRs by higher peptide concentrations resulted in increased TCR 
downregulation and a more brief IFNγ response. 
 
Effect of epitope density on CMV-specific CD8+ T cell expansion 
Overstimulation of CMV-specific T cells may not only cause a more rapid decline and 
reduced secretion of IFNγ, but also affect proliferation. To determine the effect of epitope 
density on CMV-specific CD8+ T cell expansion, CFSE-labeled PBMC were stimulated with 
different concentrations of CMV peptide and cultured with 50 IU/ml IL-2. As shown in 
Figure 4A, maximal 70-fold expansion of peptide-specific T cells was observed after 
stimulation for 6 days with 10-8 to 10-7 M HLA-B7 restricted TPR peptide. Increasing peptide 
concentrations above this optimum reduced expansion to only 12-fold after incubation with 
10-4 M peptide. Dilution of CFSE by tetramer-positive T cells indicated that limited 
expansion was not due to a lack of proliferation, but numbers of dividing cells were lower 
(data not shown). Stimulation with less immunodominant HLA-A1 or HLA-B35 restricted 
YSE or IPS peptides resulted in maximal expansion of peptide-specific T cells after 
stimulation with higher peptide concentrations of 10-5 M (YSE) and 10-7 to 10-6 M (IPS), but 
similarly reduced expansion was observed when increasing peptide concentrations above 
the optimum (Figure 4B). These data show that overstimulation of CMV-specific T cells by a 
non-physiological level of TCR triggering impairs expansion. 
 
Figure 4. Effect of epitope density on CMV-specific CD8+ T cell expansion. The fold increase in the absolute number of 
A) CMV pp65 TPR peptide-specific CD8+ T cells and B) CMV pp65 IPS-specific CD8+ T cells is depicted after 6 days of 
stimulation of CFSE-labeled PBMC without peptide or with peptide concentrations of 10-9 M to 10-4 M in the presence 















Enrichment by IFNγ capture assay and subsequent expansion of CMV-specific CD8+ T 
cells 
These findings were translated into a procedure for optimal activation, isolation, and 
expansion of peptide-specific CD8+ T cells, allowing efficient generation CMV-specific T cell 
lines. To define optimal activation conditions, IFNγ-based enrichment was performed after 
stimulation with 10-7, 10-6 and 10-5 M peptide for 4 hours or overnight. Since not all specific T 
cells produced IFNγ using lower peptide concentrations, these were not included. As 
depicted for a representative experiment in Figure 5A, IFNγ capture labeling at the peak of 
the IFNγ response after 4 hours resulted in a higher percentage and amount of IFNγ 
secretion by peptide-specific T cells compared to overnight stimulation. Tetramer-staining 
revealed modest TCR downregulation after 4 hours of stimulation, and confirmed that all 
peptide-specific cells were activated and secreted IFNγ. As shown in Table 1, the percentage 
of cells isolated from donor PBMC in the IFNγ-enriched fraction was higher after 4 hours of 
stimulation compared to overnight stimulation, and was highest using 10-7 M peptide. 
Directly after enrichment, the recovery of CMV peptide-specific T cells was assessed by CD8 
and IFNγ capture staining, because tetramer staining was not possible due to TCR 
downregulation. Due to indirect IFNγ labeling of other cells, the percentage of virus-specific 
CD8+IFNγ+ cells was approximately 2-fold lower after 4 hours of stimulation compared to 
overnight stimulation. Therefore, comparing the absolute numbers of isolated CD8+IFNγ+ 
cells with tetramer-positive T cells in donor PBMC indicated that the recovery of peptide-
specific CD8+ T cells from donor PBMC in the enriched fraction was only modestly higher 
after 4 hours of stimulation compared to overnight stimulation (Table 1). Preferential 
expansion of the specific cells resulted in IFNγ-enriched fractions with similar frequencies of 
73-79% tetramer-positive CD8+ T cells for the different conditions after 9-11 days culture. 
The yield of peptide-specific cells after culture was higher using 4 hours of stimulation, as 
shown in Figure 5B and Table 1 by the fold increase in absolute number of specific cells 
compared with donor PBMC. In line with the highest recovery of peptide-specific cells after 
enrichment, a mean 62-fold yield of peptide-specific cells was observed after culture using 4 
hour stimulation with 10-7 M peptide. In contrast to the IFNγ-depleted fractions after 4 hours 
of stimulation, the IFNγ-depleted fractions after overnight stimulation contained significant 
residual tetramer-positive cells (day 6-7: 0.3% vs 4.0%) and higher absolute numbers of 
tetramer-positive cells compared with IFNγ-enriched fractions, confirming the difference in 
isolation efficiency (Figure 5A and 5B). Although not statistically significant, amongst others 
due to variable frequencies of peptide-specific T cells in donor PBMC (0.14-1.14%), the trend 
of optimal isolation efficiency and expansion after 4 hours of 10-7 M peptide stimulation is 














Figure 5. Enrichment by IFNγ capture assay and subsequent expansion of CMV-specific CD8+ T cells. A) PBMC from 
donor PLC were stimulated for 4 hours (upper panel) or overnight (lower panel) with 10-7 M CMV pp65 TPR peptide. 
IFNγ staining by IFNγ capture assay before enrichment, and of the IFNγ-enriched fraction are shown. Subsequently, 
CMV pp65 TPR-specific CD8+ T cells were identified in both the IFNγ-enriched and IFNγ-depleted fractions after 7 
days of culture. B) PBMC from 5 donors were stimulated for 4 hours or overnight with 10-5, 10-6, or 10-7 M CMV pp65 
peptide, and both IFNγ-enriched (left panels) and IFNγ-depleted (right panels) fractions were cultured. The fold 















Table 1. Enrichment by IFNγ Capture Assay and Subsequent Expansion of CMV-specific CD8+ T Cells. 
 
 
To determine which peptide-specific memory T cell subsets were isolated, phenotypic cell 
surface markers were analyzed on specific T cells in donor PBMC and T cell lines generated 
with the different activation protocols. As shown for a representative experiment in 
Figure 6, CMV tetramer-positive CD8+ T cells in donor PBMC expressed either CD45RO (25-
63%) or CD45RA (22-70%), 5-61% expressed both CD27 and CD28, and 4-48% expressed 
both CCR7 and CD62L. Following activation and isolation, at day 7 all cultured CMV-
specific T cells expressed CD45RO, CD28, CCR7 and CD62L, and low levels of CD27. 
During further culture, peptide-specific cells remained CD45RO+, but lost some CD28 
expression and most expression of CD27, CCR7 and CD62L. No differences in phenotype of 
tetramer-positive T cells were observed after culture between the different isolation 
protocols. These data do not indicate that the different activation protocols select for 
different subsets of T cells, but show that the phenotype of the cells changed during in vitro 
activation and culture. 
We next determined whether CMV-specific T cells isolated on basis of IFNγ production were 
multifunctional, since this may correlate with anti-viral protection. Analysis by ELISA of 
supernatant obtained after stimulation with CMV peptide showed production of IFNγ and 
TNFα by isolated CMV-specific T cells, while no IL-2 could be detected. As shown by 
intracellular staining in Figure 7, single CMV-specific T cells in generated T cell lines 
produced both IFNγ and TNFα upon peptide stimulation. Furthermore, intracellular 
staining showed production of perforin and granzyme B (data not shown). These 
experiments demonstrated that the functional profile of isolated CMV-specific T cells was 
comparable to CMV-specific T cells in donor PBMC, which also produced IFNγ and TNFα, 














Figure 6. Phenotype of CMV pp65 TPR-specific CD8+ T cells in donor PBMC (left panels), in IFNγ-enriched cell lines 
after 7 days of culture (middle panels), and after 14 days of culture (right panels). Dot plots are gated on pp65-TPR-B7 
















Figure 7. Intracellular staining of IFNγ and TNFα of T cell lines derived from donor PLC (top) and donor UCE 
(bottom) containing CMV pp65 TPR- and RPH-specific T cells isolated on basis of IFNγ secretion without restimulation 
(left) and following CMV peptide restimulation (right). 
 
Discussion 
Based on the detailed analysis of the IFNγ response, we developed an optimal method for 
IFNγ-based isolation of CMV peptide-specific CD8+ T cells. Efficient isolation allows 
adoptive immunotherapy with the complete population of CMV peptide-specific CD8+ T 
cells, while suboptimal isolation may result in the absence of functional subpopulations. 
Since the presence of T cells with multiple effector functions has been described to correlate 
with anti-viral protection [44], isolated CMV-specific T cells were shown to produce both 
IFNγ and TNFα upon stimulation, which was comparable to CMV-specific T cells in donor 
PBMC. The isolated CMV-specific T cells may be directly infused or cultured for a short 
period, allowing the generation of highly specific cell lines containing on average 62-fold the 
number of CMV peptide-specific CD8+ T cells in donor PBMC. Large-scale isolation from 
1x109 PBMC with a frequency of 0.2% peptide-specific CD8+ T cells therefore permits the 
generation of 1.2x108 specific T cells after only 9-11 days. This approach allows infusion of 














The rapid production of IFNγ by CMV-specific CD8+ T cells in the first hours after activation 
was consistent with the common detection of IFNγ production by human virus-specific T 
cells by cumulative techniques after 4 to 24 hours of stimulation. However, the rapid decline 
thereafter was in sharp contrast with the prolonged IFNγ production in the presence of 
antigen reported for murine virus-specific T cells [34-36]. Although these observations may 
reflect a general difference in IFNγ response kinetics between human and murine virus-
specific T cells, the rapidity of the induction of IFNγ production by virus-specific T cells has 
been reported to be associated with immunodominance [45]. We therefore speculate that 
persistent and frequent presentation of human immunodominant CMV epitopes in vivo not 
only drives differentiation of specific T cells, but may also shape the kinetics of the IFNγ 
response to limit the extent of inflammation during minor reactivations. Likewise, the 
vigorous TCR downregulation, more rapid decline of IFNγ production and reduced 
expansion as observed following high epitope density stimulation may serve to dampen the 
immune response to highly abundant antigens [28-31]. 
Whereas minimal amounts of antigen have been reported to be required for cytolytic 
activity, robust IFNγ secretion needed stimulation with higher levels of antigen, 
accompanied by TCR downregulation of at least 20-50% [46,47]. Downregulation of surface 
TCR after activation of T cells by TCR triggering has been described to be predominantly 
caused by increased intracellular retention and degradation of the complete TCR complex 
after constitutive endocytosis, although increased internalization may contribute as well 
[48,49]. Our data confirm that triggering of TCRs resulting in downregulation is associated 
with IFNγ production. Moreover, a direct correlation between TCR downregulation and the 
amount of IFNγ production was observed, with maximal IFNγ production induced by 10-5 to 
10-7 M peptide stimulation. The differences in peptide concentration required for maximal 
IFNγ production or expansion were not due to differences in peptide-MHC affinity, since we 
did not observe a relation with peptide-MHC binding affinity of selected CMV pp65 
epitopes [unpublished data], but more likely result from differences in avidity between T 
cell populations. Stimulation with higher peptide concentrations resulted in increased TCR 
downregulation, a more brief IFNγ response and reduced expansion. Since proliferation by 
specific T cells was observed, the reduced expansion was likely to result from activation-
induced cell death (AICD), and not anergy. Death of peptide-specific T cells resulting from 
contact between specific T cells presenting CMV peptide themselves is unlikely to occur due 
to the low frequency of specific cells among total PBMC.  
Our data indicate that nearly all tetramer-positive cells produced IFNγ and could be isolated 
using the IFNγ capture assay following activation. This may be due to the selection of 














predominantly a late differentiation phenotype circulate in healthy donors, although in 
some donors we observed up to 50% of CMV-specific T cells showing an early 
differentiation phenotype. Phenotypic changes of CMV-specific T cells in vitro have been 
described before, among which functional upregulation of CCR7 upon antigenic 
stimulation, and the downregulation of CD28, CCR7 and CD62L during prolonged culture 
[32,50,51], which is consistent with our findings. Since central memory T cells were 
described to retain the capacity to reacquire their phenotypic and functional properties 
following adoptive transfer [32], these surface molecules may not be valid markers for 
memory T cell subsets during in vitro activation and culture. However, the upregulated 
expression of CD27, CD28, CCR7 and CD62L may result in increased survival and efficacy 
after adoptive transfer due to increased co-stimulatory interaction and homing to lymph 
nodes, which can be a reason to administer T cells within 9 days of culture. 
This study provides an isolation method enabling efficient and reproducible generation of 
high numbers of CMV-specific CD8+ T cells for adoptive transfer without the need for 
extensive culture. The applicability of this strategy may be further extended by the 
simultaneous isolation of antigen-specific CD8+ and CD4+ T cells without regard to patient 
HLA following activation with long synthetic peptides or recombinant protein. Since 
optimal peptide concentrations differed between epitopes and kinetics of IFNγ production 
may be variable, we suggest that similar analyses should be performed for isolation of T 
cells specific for other infectious or malignant antigens to exploit the full potential of 
cytokine capture isolation of antigen-specific T cells. 
 
Acknowledgements 




1. Gandhi MK, Wills MR, Sissons JG et al: Human cytomegalovirus-specific immunity following haemopoietic stem 
cell transplantation. Blood Rev 17: 259-264, 2003 
2. Gandhi MK, Khanna R: Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. 
Lancet Infect Dis 4: 725-738, 2004 
3. Cwynarski K, Ainsworth J, Cobbold M et al: Direct visualization of cytomegalovirus-specific T-cell reconstitution 
after allogeneic stem cell transplantation. Blood 97: 1232-1240, 2001 
4. Hebart H, Daginik S, Stevanovic S et al: Sensitive detection of human cytomegalovirus peptide-specific cytotoxic 
T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy 
individuals and in patients after allogeneic stem cell transplantation. Blood 99: 3830-3837, 2002 
5. Avetisyan G, Larsson K, Aschan J et al: Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell 













6. Gratama JW, van Esser JW, Lamers CH et al: Tetramer-based quantification of cytomegalovirus (CMV)-specific 
CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for 
progressive CMV infection. Blood 98: 1358-1364, 2001 
7. Lacey SF, Diamond DJ, Zaia JA: Assessment of cellular immunity to human cytomegalovirus in recipients of 
allogeneic stem cell transplants. Biol Blood Marrow Transplant 10: 433-447, 2004 
8. Ganepola S, Gentilini C, Hilbers U et al: Patients at high risk for CMV infection and disease show delayed CD8+ 
T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39: 293-299, 2007 
9. Chakrabarti S, Mackinnon S, Chopra R et al: High incidence of cytomegalovirus infection after nonmyeloablative 
stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99: 4357-4363, 
2002 
10. Brown JM: Exogenous administration of immunomodulatory therapies in hematopoietic cell transplantation: an 
infectious diseases perspective. Curr Opin Infect Dis 18: 352-358, 2005 
11. Landolfo S, Gariglio M, Gribaudo G et al: The human cytomegalovirus. Pharmacol Ther 98: 269-297, 2003 
12. Baldanti F, Lurain N, Gerna G: Clinical and biologic aspects of human cytomegalovirus resistance to antiviral 
drugs. Hum Immunol 65: 403-409, 2004 
13. Boeckh M, Leisenring W, Riddell SR et al: Late cytomegalovirus disease and mortality in recipients of allogeneic 
hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414, 2003 
14. Walter EA, Greenberg PD, Gilbert MJ et al: Reconstitution of cellular immunity against cytomegalovirus in 
recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044, 
1995 
15. Einsele H, Roosnek E, Rufer N et al: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV 
infection not responding to antiviral chemotherapy. Blood 99: 3916-3922, 2002 
16. Peggs KS, Verfuerth S, Pizzey A et al: Adoptive cellular therapy for early cytomegalovirus infection after 
allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377, 2003 
17. Cobbold M, Khan N, Pourgheysari B et al: Adoptive transfer of cytomegalovirus-specific CTL to stem cell 
transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386, 2005 
18. Perruccio K, Tosti A, Burchielli E et al: Transferring functional immune responses to pathogens after 
haploidentical hematopoietic transplantation. Blood 106: 4397-4406, 2005 
19. Leen AM, Myers GD, Sili U et al: Monoculture-derived T lymphocytes specific for multiple viruses expand and 
produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166, 2006 
20. Mackinnon S, Thomson K, Verfuerth S et al: Adoptive cellular therapy for cytomegalovirus infection following 
allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis , 2007 
21. Meij P, Zandvliet ML, Van der Heiden PLJ et al: Generation and administration of CMV pp65-specific donor T-
cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation. EBMT [Abstract] O-292 - 
33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France, 2007 
22. Micklethwaite K, Hansen A, Foster A et al: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-
specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood 
Marrow Transplant 13: 707-714, 2007 
23. Micklethwaite KP, Clancy L, Sandher U et al: Prophylactic infusion of cytomegalovirus specific cytotoxic T-
lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells following allogeneic haemopoietic stem 
cell transplantation. Blood , 2008 
24. Holtappels R, Bohm V, Podlech J et al: CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of 
concept" provided by the murine model. Med Microbiol Immunol 197: 125-134, 2008 
25. Tan R, Xu X, Ogg GS et al: Rapid death of adoptively transferred T cells in acquired immunodeficiency 
syndrome. Blood 93: 1506-1510, 1999 
26. Yee C, Thompson JA, Byrd D et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the 
treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of 
transferred T cells. Proc Natl Acad Sci U S A 99: 16168-16173, 2002 
27. Gattinoni L, Klebanoff CA, Palmer DC et al: Acquisition of full effector function in vitro paradoxically impairs 
the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626, 2005 
28. Oved K, Ziv O, Jacob-Hirsch J et al: A novel postpriming regulatory check point of effector/memory T cells 
dictated through antigen density threshold-dependent anergy. J Immunol 178: 2307-2317, 2007 
29. Anderton SM, Radu CG, Lowrey PA et al: Negative selection during the peripheral immune response to antigen. 














30. Alexander-Miller MA, Derby MA, Sarin A et al: Supraoptimal peptide-major histocompatibility complex causes a 
decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T 
lymphocytes. J Exp Med 188: 1391-1399, 1998 
31. Derby MA, Snyder JT, Tse R et al: An abrupt and concordant initiation of apoptosis: antigen-dependent death of 
CD8+ CTL. Eur J Immunol 31: 2951-2959, 2001 
32. Berger C, Jensen MC, Lansdorp PM et al: Adoptive transfer of effector CD8+ T cells derived from central memory 
cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305, 2008 
33. Lohning M, Hegazy AN, Pinschewer DD et al: Long-lived virus-reactive memory T cells generated from purified 
cytokine-secreting T helper type 1 and type 2 effectors. J Exp Med 205: 53-61, 2008 
34. Slifka MK, Rodriguez F, Whitton JL: Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. 
Nature 401: 76-79, 1999 
35. Slifka MK, Whitton JL: Antigen-specific regulation of T cell-mediated cytokine production. Immunity 12: 451-457, 
2000 
36. Badovinac VP, Corbin GA, Harty JT: Cutting edge: OFF cycling of TNF production by antigen-specific CD8+ T 
cells is antigen independent. J Immunol 165: 5387-5391, 2000 
37. Bissinger AL, Rauser G, Hebart H et al: Isolation and expansion of human cytomegalovirus- specific cytotoxic T 
lymphocytes using interferon-gamma secretion assay. Exp Hematol 30: 1178-1184, 2002 
38. Rauser G, Einsele H, Sinzger C et al: Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for 
adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103: 3565-3572, 2004 
39. Feuchtinger T, Matthes-Martin S, Richard C et al: Safe adoptive transfer of virus-specific T-cell immunity for the 
treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134: 64-76, 
2006 
40. Chatziandreou I, Gilmour KC, McNicol AM et al: Capture and generation of adenovirus specific T cells for 
adoptive immunotherapy. Br J Haematol 136: 117-126, 2007 
41. Morgan RA, Dudley ME, Wunderlich JR et al: Cancer regression in patients after transfer of genetically 
engineered lymphocytes. Science 314: 126-129, 2006 
42. Heemskerk MH, Hoogeboom M, Hagedoorn R et al: Reprogramming of virus-specific T cells into leukemia-
reactive T cells using T cell receptor gene transfer. J Exp Med 199: 885-894, 2004 
43. Altman JD, Moss PA, Goulder PJ et al: Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96, 
1996 
44. Seder RA, Darrah PA, Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat 
Rev Immunol 8: 247-258, 2008 
45. Liu F, Whitton JL, Slifka MK: The rapidity with which virus-specific CD8+ T cells initiate IFN-gamma synthesis 
increases markedly over the course of infection and correlates with immunodominance. J Immunol 173: 456-462, 
2004 
46. Valitutti S, Muller S, Dessing M et al: Different responses are elicited in cytotoxic T lymphocytes by different 
levels of T cell receptor occupancy. J Exp Med 183: 1917-1921, 1996 
47. Betts MR, Price DA, Brenchley JM et al: The functional profile of primary human antiviral CD8+ T cell effector 
activity is dictated by cognate peptide concentration. J Immunol 172: 6407-6417, 2004 
48. Liu H, Rhodes M, Wiest DL et al: On the dynamics of TCR:CD3 complex cell surface expression and 
downmodulation. Immunity 13: 665-675, 2000 
49. von Essen M, Bonefeld CM, Siersma V et al: Constitutive and ligand-induced TCR degradation. J Immunol 173: 
384-393, 2004 
50. Sallusto F, Kremmer E, Palermo B et al: Switch in chemokine receptor expression upon TCR stimulation reveals 
novel homing potential for recently activated T cells. Eur J Immunol 29: 2037-2045, 1999 
51. van Leeuwen EM, van Buul JD, Remmerswaal EB et al: Functional re-expression of CCR7 on CMV-specific CD8+ 









Coordinated isolation of CD8+ and  
CD4+ T cells recognizing a broad repertoire 
of cytomegalovirus pp65 and IE1 epitopes  









Cytotherapy 2010, 12: 933-944
Comment in:
















Adoptive transfer of CMV-specific memory T cells can be used for treatment of CMV 
reactivation after allogeneic stem cell transplantation. Since coordinated CD8+ and CD4+ T 
cells specific for a broad repertoire of CMV epitopes may be most effective for adoptive 
immunotherapy, the aim of this study was to isolate these cells from peripheral blood of 
CMV seropositive donors, irrespective of their HLA type. 
 
Methods  
Activation of CMV-specific CD8+ and CD4+ T cells was compared after stimulation of donor 
peripheral blood with minimal epitope peptides, pools of overlapping 15-mer peptides, or 
full-length protein. Furthermore, the kinetics of IFNγ production after stimulation was 
analyzed to determine the optimal time-point for IFNγ-based isolation of CMV-specific T 
cells. The specificity, phenotype and functionality of generated T cell lines were analyzed. 
 
Results  
CMV protein-spanning 15-mer peptide pools induced simultaneous activation of both CD8+ 
and CD4+ CMV-specific T cells, while full-length CMV protein only efficiently activated 
CD4+ CMV-specific T cells. Isolation of IFNγ-secreting cells at the peak of the IFNγ response 
after 4 hours stimulation with CMV pp65 and IE1 peptide pools resulted in efficient 
enrichment of CMV-specific T cells. The T cell lines contained high frequencies of CD8+ and 
CD4+ T cells recognizing multiple CMV pp65 and IE1 epitopes, and produced IFNγ and 
TNFα upon specific restimulation. 
 
Conclusion 
This study provides a feasible strategy for the rapid generation of clinical grade CD8+ and 
CD4+ T cell lines with high specificity for multiple CMV pp65 and IE1 epitopes, which may 














In healthy individuals, recurrent reactivations of cytomegalovirus (CMV) are controlled by 
CMV-specific CD8+ and CD4+ T cells [1]. However, CMV reactivation can cause serious 
disease in the absence of an adequate CMV-specific T cell response in immunocompromised 
recipients of allogeneic stem cell transplantation (alloSCT) [2,3]. Pharmacological treatment 
of CMV reactivation is limited by toxicity and not sufficient for long-term anti-viral 
protection [4-6]. It has been shown that reconstitution of CD8+ and CD4+ T cells recognizing 
epitopes derived from immunodominant CMV proteins pp65 and IE1 in the first year after 
transplantation was associated with sustained protection from CMV disease [7-11]. Several 
clinical studies have demonstrated that reconstitution of donor-derived CMV-specific T cells 
by adoptive transfer can be a safe and effective treatment for CMV reactivation after alloSCT 
[12-21]. 
Clinical trials have indicated that adoptively transferred CMV-specific CD4+ T cells may 
promote development of a CMV-specific CD8+ T cell response in vivo [18-21]. Furthermore, 
adoptively transferred CMV-specific CD8+ T cells showed better persistence in the presence 
of CMV-specific CD4+ T cells [12]. These observations indicate the requirement of a CMV-
specific CD4+ T cell response in the development of a sustained CMV-specific CD8+ T cell 
response and anti-viral protection, which has also been described after primary CMV 
infections in renal transplant recipients [22,23]. CMV-specific CD4+ T cells do not only 
support the development and function of CD8+ T cells, but can also exert direct cytolytic 
activity [24]. These data provide a rationale for the generation of CMV-specific T cell lines 
including both CD8+ and CD4+ T cells for adoptive immunotherapy. 
Polyclonal CMV-specific T cell responses in healthy individuals are directed against a broad 
repertoire of epitopes from multiple CMV proteins [1,25]. Furthermore, restoration of 
immune protection against CMV in immunodeficient individuals has been shown to be 
associated with an enlarged repertoire of CMV-specific T cells [26]. Adoptive transfer of a 
coordinated CD8+ and CD4+ T cell response against multiple CMV epitopes may therefore 
be most effective for treatment of CMV disease in alloSCT recipients. 
Several strategies have been developed to isolate virus-specific memory T cells from donor 
peripheral blood for the generation of virus-specific T cell lines without the need for long-
term in vitro culture. Clinical grade peptide-MHC class I multimers have become available, 
which can be used for isolation of epitope-specific CD8+ T cell populations due to the high 
affinity for a specific T cell receptor (TCR) [13,27,28]. However, to provide T cell therapy for 
every patient at risk of developing CMV disease and to generate T cell lines against multiple 














class I molecules, and production of numerous peptide-MHC multimers. Furthermore, 
antigen-specific CD4+ T cells can not be isolated using this method due to the lack of 
functional peptide-MHC class II multimers. Alternatively, virus-specific memory T cells can 
be isolated based on activation-induced IFNγ production. Stimulation with minimal 
peptides corresponding to defined MHC class I restricted epitopes followed by IFNγ-based 
isolation has been demonstrated to result in efficient isolation of CMV-specific CD8+ T cells, 
but requires epitope knowledge as well [16,29]. Although this method may be extended to 
the isolation of CMV-specific CD4+ T cells, only a limited number of minimal peptides 
corresponding to defined MHC class II restricted epitopes has been characterized. 
The use of full-length CMV proteins for stimulation circumvents the need of knowing the 
exact epitopes, and can provide CMV-specific T cell lines irrespective of the HLA type of the 
patient. However, the generation of a coordinated CD8+ and CD4+ CMV-specific T cell 
response from donor peripheral blood has been shown to be difficult. CMV antigen 
endogenously synthesized by transduction of specific cDNA into antigen-presenting cells 
was predominantly presented in MHC class I, while exogenously added CMV proteins or 
lysates resulted in selected presentation of CMV peptides in MHC class II [14,17-21,30]. 
Interestingly, 15-mer peptides have recently been described to simultaneously induce 
activation of both CD8+ and CD4+ T cells specific for CMV epitopes, and may be used for 
the generation of combined CD8+ and CD4+ T cell lines [31-33]. Synthetic protein-spanning 
pools of overlapping 15-mer peptides can be produced under good manufacturing practice 
(GMP) conditions more easily than recombinant proteins or vectors for genetic modification, 
and may therefore allow feasible and cost-effective production of CMV-specific T cells for 
adoptive immunotherapy. 
The aim of this study was to develop a method for the generation of clinical grade 
coordinated CD8+ and CD4+ T cell lines with high specificity for immunodominant CMV 
proteins pp65 and IE1, irrespective of the HLA type of the patient. Full-length protein-
spanning pools of overlapping 15-mer peptides induced simultaneous activation of both 
CMV-specific CD8+ and CD4+ T cells. To achieve high frequencies of CMV-specific T cells, 
activated T cells were isolated at the peak of the IFNγ response by the IFNγ capture assay. 
This strategy resulted in coordinated CD8+ and CD4+ T cell lines recognizing multiple CMV 
pp65 and IE1 epitopes, which can be generated irrespective of the patient HLA type, and 













Material and Methods 
Donor cells 
After informed consent, peripheral blood was obtained from CMV seropositive healthy 
individuals, and mononuclear cells (PBMC) were cryopreserved after Ficoll-Isopaque 
separation. Stable Epstein-Barr virus (EBV)-transformed B cell lines (EBV-LCL) were 
generated using standard procedures [34]. Monocytes were labeled with anti-CD14 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), and isolated from PBMC by 
immunomagnetic separation using the midi-MACS system (Miltenyi Biotec). 
 
CMV antigens 
Peptides used were derived from CMV pp65 protein (P06725, 561 amino acids) or CMV IE1 
protein (P13202, 491 amino acids). Minimal peptides corresponding to previously described 
MHC I or MHC II restricted pp65 epitopes, and MHC I restricted IE1 epitopes were 
synthesized using standard solid-phase strategies (Department of Immunohematology, 
Leiden University Medical Center, Leiden, The Netherlands). The minimal MHC I restricted 
pp65 peptides used were YSEHPTFTSQY (HLA-A*0101), NLVPMVATV (HLA-A*0201), 
QYDPVAALF (HLA-A*2402), TPRVTGGGAM (HLA-B*0702), RPHERNGFTVL (HLA-
B*0702), IPSINVHHY (HLA-B*3501), minimal MHC I restricted IE1 peptides were 
VLEETSVML (HLA-A*0201), ELRRKMMYM (HLA-B*0801), QIKVRVDMV (HLA-B*0801), 
and minimal MHC II restricted pp65 peptides were LLQTGIHVRVSQPSL, 
ALPLKMLNIPSINVH, IIKPGKISHIMLDVA, PQYSEHPTFTSQYRIQ, 
PPWQAGILARNLVPM, KYQEFFWDANDIYRI [24,35,36]. Full pp65 or IE1 protein-
spanning pools of 15-mer peptides overlapping with 11 amino acids (PeptivatorTM, 
Miltenyi Biotec, and PepMixTM, JPT Peptide Technologies, Berlin, Germany), and full-
length recombinant pp65 protein (Miltenyi Biotec) were used. 
 
Flow cytometric analyses 
Cells were stained with FITC-labeled CD3, CD4, CD14, IFNγ (BD Biosciences, San Jose, CA, 
USA), PE-labeled CD56, TNFα (BD), CD40L (Beckman Coulter, Fullerton, CA, USA), PerCP-
labeled CD3, CD8 (BD), APC-labeled CD4 (Beckman Coulter), CD19, IFNγ, and IL-2 (BD) 
monoclonal antibodies (mAbs). PE- and APC-labeled CMV peptide-MHC tetramers were 
produced as described previously [27]. Between 5x104 and 5x105 fluorescent events were 
analyzed for each sample using a FACSCalibur and Cellquest software (BD). The limit of 
detection was defined as a cluster of at least 10 specific events, after correction for 















Intracellular cytokine staining 
After thawing, PBMC were resuspended in culture medium, consisting of Iscove’s modified 
Dulbecco’s medium (IMDM, Lonza, Basel, Switzerland) supplemented with 10% pooled 
human serum, 100 U/ml penicillin/streptomycin (Lonza), and 3 mM L-glutamine (Lonza). 
For measurement of activated CMV-specific T cells in PBMC by cumulative intracellular 
cytokine staining, cells were stimulated in culture medium with 10-5 or 10-6 M CMV peptides 
or protein for 6 hours at 37°C and 5% CO2. During the last 5 hours of peptide stimulation, 
10 µg/ml brefeldin A (BFA, Sigma-Aldrich, Zwijndrecht, The Netherlands) was added. For 
real-time kinetic measurement of intracellular IFNγ, cells were stimulated for 2 to 48 hours, 
and 10 µg/ml BFA was added only during the last 2 hours of stimulation. To allow detection 
of CMV-specific T cells in the T cell lines, we used as stimulator cells autologous EBV-LCL 
or monocytes labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular 
Probes, Leiden, The Netherlands) for distinction in FACS analysis as described before [37]. 
Stimulator cells were incubated overnight in culture medium with 10-6 M CMV peptides, 
washed, and incubated in culture medium with the T cell line in an effector/stimulator ratio 
of 1/5 for 4 hours in the presence of 10 µg/ml BFA. After stimulation, cells were harvested 
and washed in phosphate-buffered saline (PBS) and stained with PE-labeled tetramers for 15 
minutes at 37°C. Subsequently, mAbs for cell-surface staining were added and incubated for 
30 minutes at 4°C. Cells were washed in PBS and fixed with 1% paraformaldehyde for 
8 minutes at 4°C. For permeabilization, samples were washed in PBS with 0.1% saponin 
(Sigma-Aldrich) and incubated for 30 minutes at 4°C. Cells were stained intracellularly with 
mAbs for 30 minutes at 4°C, washed, and fluorescent events were analyzed by flow 
cytometry. 
 
Isolation and culture of IFNγ-secreting cells 
For isolation of IFNγ-secreting cells, PBMC were stimulated in culture medium with 10-6 M 
CMV pp65 and IE1 protein-spanning peptide pools for 4 hours at 37°C and 5% CO2. After 
stimulation, cells were harvested and thoroughly washed in PBS, and IFNγ-secreting cells 
were stained by the IFNγ capture assay (Miltenyi Biotec) performed according to the 
manufacturer’s instructions. Briefly, cells were labeled with IFNγ-catch reagent and cultured 
for 45 minutes at 37°C. Cells were counterstained with PE-labeled IFNγ mAb. For 
subsequent isolation, the IFNγ-PE-labeled cells were bound to anti-PE microbeads, and 
isolated by immunomagnetic separation using the midi-MACS system (Miltenyi Biotec). The 
isolated IFNγ-enriched and IFNγ-depleted cell fractions were both cultured at 1x106 cells/ml 













10 ng/ml IL-15 (Peprotech, Rocky Hill, NJ, USA) and 10x106 cells/ml 30 Gy-irradiated feeder 
cells derived from the IFNγ-depleted fraction. Cultures were supplemented with fresh 
medium, 50 IU/ml IL-2, and 10 ng/ml IL-15 every 3-4 days. 
 
Results 
Activation efficiency of CMV pp65-specific T cells in PBMC 
To investigate whether a broad repertoire of CMV-specific T cells could be activated in 
PBMC from healthy CMV seropositive donors, irrespective of their HLA type, specific IFNγ 
production was determined following stimulation with different CMV pp65 antigens. 
Intracellular staining after stimulation with MHC class II binding immunodominant CMV 
pp65 peptides showed that CMV-specific CD4+ T cells produced IFNγ and concomitantly 
expressed CD40L, as shown for a representative example (Figure 1A). Stimulation with 
either full-length recombinant CMV pp65 protein or a CMV pp65 protein-spanning pool of 
overlapping 15-mer peptides induced IFNγ production by CMV-specific CD4+ T cells in 
PBMC from all 11 donors tested (Figure 1B). The HLA types of the donors were 
heterogeneous, containing 13 different HLA-DR and HLA-DQ alleles, indicating that CMV 
antigen was presented by various HLA alleles. Frequencies of activated CMV-specific CD4+ 
T cells were comparable using the protein or peptide pool, and ranged from 0.02% to 4.5% 
of CD4+ T cells. Addition of minimal peptides to the peptide pool and protein for 
stimulation did not further increase the frequency and magnitude of the CMV pp65-specific 
CD4+ T cell response. Since these paired measurements showed a similar pattern of 
frequencies of IFNγ-producing CD4+ T cells, it is likely that the CD4+ T cells activated with 
the 15-mer peptide pool were similar to the CD4+ T cells activated with the protein, and 
included the CD4+ T cells activated with the minimal peptides. 
To determine whether stimulation with CMV pp65 protein or 15-mer peptide pool could 
simultaneously induce activation of a broad repertoire of CMV-specific CD8+ T cells 
irrespective of the HLA type, specific IFNγ production by CD8+ T cells was determined in 
PBMC from the same CMV seropositive donors. Their heterogeneous HLA types comprised 
19 different HLA-A and HLA-B alleles. As expected, intracellular staining after stimulation 
with minimal MHC class I binding CMV pp65 peptides showed specific production of IFNγ 
by CMV-specific CD8+ T cells (Figure 1C). Stimulation with either the full-length 
recombinant CMV pp65 protein or the CMV pp65 protein-spanning pool of overlapping 15-
mer peptides also induced IFNγ production by CMV-specific CD8+ T cells. However, paired 
measurements showed that frequencies of activated CMV-specific CD8+ T cells were higher 














protein, indicating that part of the CMV pp65-specific CD8+ T cells were not activated using 
full-length protein. Stimulation with the combination of minimal peptides, peptide pool, 
and protein induced similar frequencies of IFNγ-producing CD8+ T cells compared to 
stimulation with peptide pool only. These data suggest that stimulation with the pp65 15-
mer peptide pool resulted in activation of CMV pp65-specific CD8+ T cells, including the 
CD8+ T cells activated with the minimal peptides or the protein. 
 
Figure 1. Activation of CMV pp65-specific T cells in PBMC. (A) Detection of CMV pp65-specific CD4+ T cells by 
intracellular IFNγ and CD40L staining upon stimulation of PBMC from donor 9 with MHC class II restricted 
immunodominant pp65 peptide PQY. (B) Frequencies of IFNγ-producing CD40L+ cells among CD4+ T cells or (C) 
frequencies of IFNγ-producing cells among CD8+ T cells in PBMC of 11 healthy CMV seropositive donors after 
stimulation with minimal MHC class II or I restricted pp65 peptides, pp65 protein, 15-mer pp65 peptide pool, or these 
antigens combined. Paired measurements from each donor are connected with lines. 
 
To analyze whether stimulation with the CMV pp65 peptide pool indeed induced activation 
of multiple individual CMV-specific CD8+ T cell populations, peripheral blood samples 
were selected from 10 donors containing high frequencies of CD8+ T cells specific for 5 
known CMV pp65 epitopes. The CMV-specific CD8+ T cells were efficiently activated after 
stimulation with the corresponding minimal MHC class I binding CMV peptides, as 
illustrated by representative examples of peptide-MHC tetramer staining combined with 
intracellular IFNγ staining (Figure 2). Production of IFNγ co-incided with a decrease in 
tetramer staining, indicating TCR downregulation. After stimulation with the CMV pp65 
peptide pool (10-6 M), CD8+ T cells specific for 4/5 CMV pp65 epitopes were efficiently 













CMV pp65-specific CD8+ T cells in the other donors. However, part of the CD8+ T cells 
specific for pp65-YSE/A1 did not produce IFNγ (range 20-83% IFNγ-producing tetramer+ T 
cells). Increasing the concentration of peptide pool to 10-5 M did not result in a higher 
frequency of pp65-YSE/A1-specific CD8+ T cells producing IFNγ. After stimulation with 
recombinant pp65 protein, only CD8+ T cells specific for pp65-NLV/A2 and pp65-TPR/B7 
produced IFNγ and showed modest TCR downregulation, while CD8+ T cells specific for 
pp65-YSE/A1, pp65-RPH/B7, and pp65-IPS/B35 did not show any IFNγ production or TCR 
downregulation (Figure 2). 
These results demonstrate that stimulation of donor PBMC with the CMV pp65 protein-
spanning 15-mer peptide pool efficiently induced activation of CD8+ and CD4+ T cells 
specific for multiple CMV pp65 epitopes, irrespective of the donor HLA type. In contrast, 
stimulation with the full-length CMV pp65 protein resulted in efficient activation of pp65-




Figure 2. Activation of individual CMV pp65-specific CD8+ T cell populations in PBMC. Dot plots show representative 
examples of intracellular IFNγ staining of PBMC from different donors, containing CD8+ T cell populations specific for 
5 immunodominant CMV pp65 epitopes, after stimulation with 10-6 M of the relevant minimal peptide, with 10-6 M 15-
mer CMV pp65 peptide pool, or with 10-6 M full-length recombinant CMV pp65 protein. Samples were stained with 
















Figure 3. Activation of CMV IE1-specific T cells in PBMC. (A) Frequencies of IFNγ-producing CD40L+ cells among 
CD4+ T cells or (B) frequencies of IFNγ-producing cells among CD8+ T cells in PBMC of 11 healthy CMV seropositive 
donors after stimulation with 15-mer CMV IE1 peptide pool. Filled symbols represent specific IFNγ-producing 
populations, and open symbols represent frequencies below the limit of detection. (C) Dot plots show representative 
examples of intracellular IFNγ staining of PBMC from different donors, containing CD8+ T cell populations specific for 
3 immunodominant CMV IE1 epitopes, after stimulation with 10-6 M of the relevant minimal peptide, or with 10-6 M 
15-mer CMV IE1 peptide pool. Samples were stained with peptide-MHC tetramers after stimulation, and dot plots 














Activation of CMV IE1-specific T cells in PBMC 
To further extend the repertoire of CMV-specific T cells that could be activated in peripheral 
blood from CMV seropositive donors for IFNγ-based isolation, we next investigated 
whether stimulation of PBMC with a CMV IE1 protein-spanning pool of overlapping 15-mer 
peptides induced IFNγ production by CD8+ and CD4+ T cells specific for CMV IE1 epitopes. 
After CMV IE1 peptide pool stimulation, specific IFNγ-production by CD4+ T cells was 
detected in PBMC from 5/11 donors tested, with frequencies between 0.03% and 0.28% of 
CD4+ T cells (Figure 3A). CMV IE1-specific CD8+ T cells producing IFNγ upon stimulation 
with the CMV IE1 peptide pool were also detected in PBMC from 5/11 donors tested, with 
frequencies of CD8+ T cells ranging from 0.06% to 1.5% (Figure 3B). The efficiency of CMV 
IE1-specific T cell activation using the CMV IE1 peptide pool could not be properly 
evaluated due to the limited number of known MHC class I and II restricted CMV IE1 
epitopes. 
To analyze whether stimulation with the CMV IE1 peptide pool induced activation of 
multiple individual CMV-specific CD8+ T cell populations as well, peripheral blood samples 
were selected from 6 donors containing high frequencies of CD8+ T cells specific for 3 
known CMV IE1 epitopes. As illustrated for representative examples, the CMV IE1-specific 
CD8+ T cells were efficiently activated after stimulation with the corresponding minimal 
MHC class I binding CMV IE1 peptides (Figure 3C). After stimulation with the CMV IE1 
peptide pool, CD8+ T cells specific for 2/3 CMV IE1 epitopes were efficiently activated as 
shown by IFNγ production, while part of the CD8+ T cells specific for IE1-QIK/B8 did not 
produce IFNγ. Similar results were obtained for the CMV IE1-specific CD8+ T cell 
populations in PBMC from the other donors.  
These results show that CMV IE1-specific T cells producing IFNγ after CMV IE1 peptide 
pool stimulation were observed in peripheral blood from 45% of healthy CMV seropositive 
donors. The efficiency of activation of CD8+ T cells specific for 3 CMV IE1 epitopes was 
consistent with the results obtained with the CMV pp65 peptide pool.  
 
Kinetics of IFNγ response by CMV-specific T cells upon activation 
To determine the optimal time-point for simultaneous isolation of a broad repertoire of 
CMV-specific CD8+ and CD4+ T cells by the IFNγ capture assay, the kinetics of IFNγ 
production following stimulation with CMV peptides was investigated. Real-time kinetic 
analysis after stimulation with the CMV pp65 or IE1 15-mer peptide pool showed a rapid 
and synchronized induction of IFNγ production by both CD8+ and CD4+ CMV-specific T 














representative examples (Figure 4A-B). These data indicate that peptides derived from the 
15-mer peptide pools were simultaneously presented in MHC class I and II following 
incubation. Similar kinetics of IFNγ production by CMV pp65-specific CD8+ T cells have 
previously been described after stimulation with minimal MHC I binding CMV pp65 
peptides [29], and were shown to be similar after stimulation with minimal MHC I binding 
CMV IE1 peptides or minimal MHC II binding CMV pp65 peptides as well. These 
measurements show that kinetics of IFNγ production was similar for CMV-specific CD8+ 
and CD4+ T cells, with maximal IFNγ production 4 hours after stimulation with CMV 
peptides. Therefore, simultaneous isolation of CMV-specific CD8+ and CD4+ T cells by the 
IFNγ capture assay is likely to be most efficient after 4 hours of stimulation with CMV 15-
mer peptide pools. 
 
Figure 4. Kinetics of IFNγ response by CMV-specific T cells upon activation. Real-time intracellular IFNγ staining, with 
addition of BFA only during the last 2 hours of incubation, after stimulation of PBMC for 0, 2, 4, 8, 24, and 48 hours (A) 














IFNγ-based enrichment and expansion of CMV pp65- and IE1-specific T cells 
A clinical grade protocol was developed for the generation of T cell lines comprising a broad 
repertoire of CD8+ and CD4+ T cells specific for both CMV pp65 and IE1 epitopes. Isolation 
of IFNγ-secreting cells from PBMC was performed by IFNγ capture assay during the peak of 
IFNγ production after 4 hours of stimulation with CMV 15-mer peptide pools. Since low 
frequencies of IE1-specific T cells in PBMC were observed and IE1-specific T cell lines have 
not been described in detail before, T cell lines specific for IE1 were first generated from 3 
CMV seropositive donors, resulting in high frequencies of CD8+ and CD4+ IE1-specific T 
cells after 14 days of culture (Table 1). Subsequently, T cell lines specific for both pp65 and 
IE1 were generated from 4 CMV seropositive donors, as shown for a representative example 
(Figure 5). Before enrichment, low frequencies of CD8+ T cells specific for CMV pp65 and 
IE1 epitopes and CD4+ T cells specific for CMV pp65 were detected in PBMC (Figure 5A). In 
the T cell line, high frequencies of CD8+ T cells specific for the same pp65 and IE1 epitopes 
were detected by peptide-MHC tetramer staining (Figure 5B). To determine the total 
frequency of CMV-specific T cells, the T cell lines was restimulated with autologous EBV-
LCL loaded with CMV pp65 or IE1 peptide pools, which induced IFNγ production by high 
frequencies of CD8+ T cells specific for CMV pp65 and IE1 and CD4+ T cells specific for 
CMV pp65 (Figure 5B). The IFNγ-depleted fractions contained only low frequencies of CMV 
tetramer-positive CD8+ T cells, and CD8+ and CD4+ T cells producing IFNγ upon CMV-
specific restimulation (Figure 5C). These data show efficient enrichment of CMV-specific T 
cells from PBMC, resulting in a T cell line containing CD8+ and CD4+ T cells specific for 
multiple pp65 and IE1 epitopes, with an overall specificity of 91% of T cells producing IFNγ 
upon CMV-specific restimulation.  
 
Table 1. Generation of 7 coordinated CD8+ and CD4+ T cell lines with high specificity for CMV pp65 and IE1 epitopes 

















Figure 5. IFNγ-based enrichment and cytokine production of CMV-specific T cells. (A) Peptide-MHC tetramer staining 
without stimulation and intracellular IFNγ staining upon stimulation of PBMC from donor 5 with 15-mer pp65 or IE1 
peptide pool. After stimulation with 15-mer pp65 and IE1 peptide pools, the IFNγ-enriched (B) and IFNγ-depleted (C) 
fraction were cultured for 15 days, and specificity was determined by peptide-MHC tetramer staining without 
stimulation and intracellular IFNγ staining upon restimulation with autologous EBV-LCL, which were unloaded, or 
loaded with 15-mer pp65 or IE1 peptide pool. (D) Intracellular staining of IFNγ, TNFα, and IL-2 upon stimulation of 
PBMC from donor 3 with MHC class II restricted pp65-IIK peptide (left), upon restimulation of the IL-2 and IL-15 
cultured CMV-specific T cell line generated from donor 3 (middle), and upon restimulation of the same CMV-specific 
T cell line after 14 days of culture with IL-15, in the absence of exogenous IL-2 (right), with autologous EBV-LCL 














Using this method, T cell lines with high specificity for a broad repertoire of CMV CD8+ and 
CD4+ epitopes were reproducibly generated from all donors, irrespective of the HLA type 
(Table 1). The alloreactive recognition of third party donor PBMC by the CMV-specific T cell 
lines was reduced to <10% compared with the donor PBMC which had been used as starting 
material in a 3H-incorporation assay. Furthermore, the T cell lines retained the capacity to 
proliferate upon antigen-specific restimulation, and showed efficient and specific lysis of 
CMV peptide-loaded target cells (data not shown). The composition of the T cell lines 
correlated with the frequencies of pp65- and IE1-specific CD8+ and CD4+ T cells in donor 
PBMC, illustrating that the repertoire of CMV-specific T cells in donor PBMC was 
represented in the T cell lines, irrespective of the HLA type of the donor. 
The phenotype and capacity to produce cytokines was compared between CMV-specific T 
cells in donor PBMC and in cultured T cell lines. CMV-specific T cells in donor PBMC 
predominantly showed a CD45RO+, CD27+ or CD27-, CD28+ or CD28-, CD62L-, and CCR7- 
effector memory T cell phenotype. After 6 days of culture following activation and isolation, 
the expression of CD27, CD28, CD62L, CCR7 transiently increased, as we have recently 
described [29]. However, after 14 days of culture, the phenotype of CMV-specific T cells was 
similar to their original phenotype in donor PBMC again. Intracellular staining showed that 
CMV-specific CD8+ and CD4+ T cells in donor PBMC produced both IFNγ and TNFα upon 
stimulation, and some CMV-specific T cell populations also produced IL-2, as shown for a 
representative CMV pp65-specific CD4+ T cell population (Figure 5D). Following 
restimulation of the cultured CMV-specific T cell lines with autologous EBV-LCL loaded 
with CMV peptide, CMV-specific T cells produced both IFNγ and TNFα, while no 
production of IL-2 was detected. To determine whether the capacity to produce IL-2 was 
downregulated by addition of exogenous IL-2 during culture, T cell lines were cultured for 
14 days with IL-15 in the absence of IL-2. Thereafter, restimulation of the cultured CMV-
specific T cell lines with autologous EBV-LCL loaded with CMV peptide suggested that IL-2 
production by CMV-specific T cells was partly restored (Figure 5D). 
These results demonstrate that coordinated CD8+ and CD4+ T cell lines with high specificity 
for multiple CMV pp65 and IE1 epitopes can be rapidly generated from all CMV 
seropositive donors using this method. The phenotype and function of CMV-specific T cells 
in generated T cell lines was comparable to CMV-specific T cells in donor PBMC. 
 
Discussion 
In this study, we developed a method for the simultaneous isolation of coordinated CD8+ 














protein from donor peripheral blood, which may be used for treatment of CMV disease in 
alloSCT recipients. While peptide-MHC multimers can only be used for isolation of CD8+ T 
cell populations specific for single and defined epitopes, IFNγ-based isolation can be used 
for the simultaneous isolation of a broad repertoire of CMV-specific CD8+ and CD4+ T cells. 
We here demonstrate that CMV protein-spanning pools of overlapping 15-mer peptides can 
be used to efficiently activate a broad repertoire of CMV-specific CD8+ and CD4+ T cells, 
irrespective of the donor HLA type, while the use of CMV lysate or transduced antigen-
presenting cells have not shown efficient simultaneous activation of both T cell subsets in 
previous studies. Subsequently, activated CMV-specific T cells were isolated at the peak of 
the IFNγ response by IFNγ capture assay. Using this method, highly specific T cell lines were 
generated from all CMV seropositive donors, and the composition of the T cell lines 
correlated with the frequencies of pp65- and IE1-specific CD8+ and CD4+ T cells in donor 
PBMC.  The phenotype and function of CMV-specific T cells after culture was comparable to 
CMV-specific T cells in donor PBMC, although the capacity to produce IL-2 upon activation 
appeared to be downregulated during culture with exogenous IL-2. However, the IL-2 
production capacity may be restored after adoptive transfer in vivo, since the negative 
feedback caused by addition of exogenous IL-2 during culture appeared to be reversible, 
which was consistent with previously described data [38]. 
The efficient activation of specific CD4+ T cells using 15-mer peptides or protein was 
anticipated, since processing of exogenous protein followed by presentation in MHC class II 
has been extensively described, and 15-mer peptides may also bind directly in MHC class II 
molecules at the cell surface [39]. The efficient activation of specific CD8+ T cells using 15-
mer peptides, but not protein, can not easily be explained. Activation of CMV-specific CD8+ 
T cells may not only result from the presence of contaminating shorter peptide fragments, 
since purified 15-mer peptides have also been shown to induce CD8+ T cell activation [40]. 
Although the mechanism of processing and MHC class I presentation of exogenously added 
long synthetic peptides is not known, several models have been proposed, including 
entrance of MHC class I in the recycling endocytic MHC class II pathway where peptidase-
trimmed exogenous antigens can exchange with peptides in the MHC class I molecules 
[41,42]. Alternatively, long peptides may reach the cytosol followed by the classical route of 
MHC class I loading [43]. 
Adoptive transfer of donor-derived CMV-specific T cell lines may be safe, since no adverse 
events associated with administration have been reported. However, total cell numbers 
infused were largely variable, and the frequency of CMV-specific T cells was often not 
determined or was limited. Identification of CMV CD8+ T cell epitopes and the availability 













reproducible generation of T cell lines containing more than 70% CMV-specific CD8+ T cells 
[13,15,16,29]. In contrast, high specificity for CMV antigens was not demonstrated for the 
CD4+ T cells administered in clinical trials [14,18-20]. The risk of graft-versus-host disease 
may be determined by the repertoire of T cells with unknown specificity, and therefore by 
the absolute number of T cells with unknown specificity isolated from donor PBMC. The 
very low numbers of T cells with unknown specificity isolated from donor PBMC using the 
strategy described in this study are assumed to result in a minimal risk of graft-versus-host 
disease. The high frequencies of CD8+ and CD4+ T cells specific for the defined CMV 
antigens in the generated T cell lines are not only desirable to increase the safety of clinical 
application, but may also allow a more detailed evaluation of in vivo persistence and the 
relation between efficacy and the number of specific T cells infused. 
This study provides a feasible strategy for the generation of coordinated CD8+ and CD4+ T 
cell lines specific for multiple CMV pp65 and IE1 epitopes, irrespective of the HLA type of 
the patient, which may be used for treatment of CMV infection after alloSCT. The 
applicability of this strategy may be extended by the isolation of T cells specific for other 
pathogens, provided that they produce IFNγ upon activation. 
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Background. Human adenovirus (HAdV) can cause morbidity and mortality in 
immunocompromised patients after allogeneic stem cell transplantation (alloSCT). 
Reconstitution of HAdV-specific CD4+ T cells has been reported to be associated with 
sustained protection from HAdV disease, but epitope specificity of these responses has not 
been characterized. Since mainly CD4+ T cells and no CD8+ T cells specific for HAdV have 
been detected after alloSCT, the relative contribution of HAdV-specific CD4+ and CD8+ T 
cells in protection from HAdV disease remains to be elucidated. 
 
Design and Methods. The presence of HAdV hexon-specific T cells was investigated in 
peripheral blood of pediatric and adult alloSCT recipients, who showed spontaneous 
resolution of disseminated HAdV infection. Subsequently, a clinical grade method was 
developed for rapid generation of HAdV-specific T cell lines for adoptive immunotherapy. 
 
Results. Clearance of HAdV viremia coincided with emergence of a coordinated CD8+ and 
CD4+ T cell response against HAdV hexon epitopes in patients after alloSCT. Activation of 
HAdV hexon-specific CD8+ and CD4+ T cells with a hexon protein-spanning peptide pool 
followed by IFNγ-based isolation allowed rapid expansion of highly specific T cell lines 
from healthy adults, including donors with very low frequencies of HAdV hexon-specific T 
cells. HAdV-specific T cell lines recognized multiple MHC class I and II restricted epitopes, 
including known and novel epitopes, and efficiently lysed HAdV-infected target cells. 
 
Conclusion. This study provides a rationale and strategy for the adoptive transfer of donor-
derived HAdV hexon-specific CD8+ and CD4+ T cells for treatment of disseminated HAdV 


















Human adenovirus (HAdV) can cause serious morbidity in immunocompromised patients, 
in particular in pediatric patients after allogeneic stem cell transplantation (alloSCT), and 
progression to disseminated HAdV disease is associated with high mortality [1-5]. Efficacy 
of antiviral agents such as ribavirin and cidofovir has not been proven in controlled trials 
yet, and administration is limited by toxicity. It has been demonstrated that reconstitution of 
HAdV-specific T cells is essential to control HAdV infection after alloSCT [5-9]. 
Manipulation of immune reconstitution by adoptive transfer of donor-derived HAdV-
specific T cells may therefore be an effective strategy to provide short- and long-term 
antiviral protection.  
In healthy individuals, low frequencies of T cells recognizing target cells infected with 
HAdV or loaded with HAdV lysate have been reported [10-12]. The majority of HAdV-
specific T cells was CD4+, although HAdV-specific CD8+ T cells could also be detected. 
Further characterization demonstrated that most HAdV-specific T cells recognized major 
capsid proteins, predominantly the abundant HAdV hexon protein [13-15]. Only recently, a 
number of immunodominant CD8+ and CD4+ epitopes of HAdV hexon have been defined 
[14-19]. Since these epitopes are largely conserved, specific T cells were shown to be cross-
reactive towards HAdV serotypes from different HAdV subgroups, and may therefore 
provide protection against a wide range of HAdV serotypes. HAdV hexon-specific T cells 
have been reported to be detectable in 72% of healthy donors, but may be present at very 
low frequencies in the remaining donors [20]. 
In alloSCT recipients, higher frequencies of HAdV-specific T cells have been detected after 
clearance of HAdV infection, but epitope specificity of these responses has not been further 
characterized [7-9]. Furthermore, mainly CD4+ T cells and no CD8+ T cells specific for 
HAdV were detected. Since HAdV-specific CD4+ T cells are capable to directly lyse HAdV 
infected target cells, the relative contribution of HAdV-specific CD4+ and CD8+ T cells in 
protection from HAdV disease after alloSCT remains to be elucidated [21,22]. 
For the generation of donor-derived HAdV-specific T cell lines for clinical application, 
peripheral blood has been stimulated with HAdV antigens or HAdV transduced antigen-
presenting cells, resulting in enrichment of either CD4+ or CD8+ T cells specific for HAdV 
[20,23-29]. Although alloreactivity was reduced using these strategies, the frequency of 
HAdV-specific T cells in the cell lines was not determined or was limited, even when IFNγ-
based isolation steps were included. 
In this study, we demonstrate that CD8+ and CD4+ T cell responses against HAdV hexon 














after alloSCT, providing a rationale for HAdV hexon-specific adoptive immunotherapy. For 
the generation of clinical grade combined CD8+ and CD4+ HAdV-specific T cell lines, 
efficient activation of both CD8+ and CD4+ HAdV-specific T cells by stimulation with an 
HAdV hexon protein-spanning peptide pool was followed by IFNγ-based isolation. 
Cultured T cell lines derived from all healthy donors tested contained high frequencies of 
CD8+ and CD4+ T cells specific for multiple HAdV hexon epitopes, and efficiently lysed 
HAdV-infected target cells. The adoptive transfer of these donor-derived HAdV hexon-
specific T cell lines may be used for treatment of disseminated HAdV disease after alloSCT. 
 
Design and Methods 
Donor and patient cells 
Donor and patient cells were obtained after informed consent, with approval from the local 
institutional review board. Peripheral blood mononuclear cells (PBMC) were obtained after 
Ficoll-Isopaque separation. Measurement of HAdV DNA in patient plasma was performed 
by RQ-PCR as previously described [30]. Fibroblasts were cultured from skin biopsies in 
DMEM with 10% fetal calf serum (Lonza, Basel, Switzerland). 
 
HAdV antigens 
Peptides were derived from the HAdV serotype 5 hexon protein (AP_000211). MHC I 
restricted peptides were TDLGQNLLY (HLA-A*0101), YVLFEVFDVV (HLA-A*0201), 
LLYANSAHAL (HLA-A*0201), TYFSLNNKF (HLA-A*2401), MPNRPNYIAF (HLA-
B*0702/HLA-B*3501), KPYSGTAYNAL (HLA-B*0702), and IPYLDGTFY (HLA-B*3501) 
[15,18,19]. The 30-mer peptides used corresponded to amino acids 571-600, 691-720, 796-825, 
856-885, and 901-930 [16,17]. Protein-spanning pools of 30-mer peptides overlapping with 15 
amino acids or 15-mer peptides overlapping with 11 amino acids (Miltenyi Biotec, Bergisch 
Gladbach, Germany) were used [17]. A titrated stock of HAdV serotype 5 was produced as 
previously described [8]. 
 
Flow cytometry 
Cells were stained with FITC-labeled CD3, CD4, CD27, CD28 (BD Biosciences, San Jose, CA, 
USA), CD45RO (Caltag, Burlingame, CA, USA), CD62L (BenderMedSystems, Vienna, 
Austria), CCR7 (R&DSystems, Minneapolis, MN, USA), PE-labeled CD28 (BD), CD45RA, 
CD40L (Beckman Coulter, Fullerton, CA, USA), CCR7 (R&DSystems), PerCP-labeled CD8 
(BD), APC-labeled CD4 (Beckman Coulter), CD45RA, CD45RO, and IFNγ (BD) monoclonal 













produced as described previously [31]. Fluorescent events were analyzed for each sample 
using a FACSCalibur and Cellquest software (BD). The limit of detection was defined as a 
cluster of at least 10 specific events, after correction for background events in negative 
control samples. 
 
Intracellular IFNγ staining 
PBMC were stimulated with 10-6 M HAdV 5 hexon peptides for 6 hours. During the last 5 
hours, 10 µg/ml brefeldin A (BFA, Sigma-Aldrich, Zwijndrecht, The Netherlands) was 
added. For detection of low frequencies of HAdV-specific T cells, PBMC were cultured 1 
week with 10-7 M HAdV 5 hexon peptides and 100 IU IL-2/ml (Chiron, Amsterdam, The 
Netherlands) prior to analysis. For the analysis of T cell lines, we used as stimulator cells 
autologous Epstein-Barr virus-transformed B cell lines (EBV-LCL) labeled with CFSE 
(Molecular Probes, Leiden, The Netherlands) for distinction in FACS analysis as previously 
described [32]. Stimulator cells were loaded overnight with 10-6 M HAdV 5 hexon peptides 
and the T cells were incubated with stimulator cells for 4 hours with 10 µg/ml BFA. After 
stimulation, cell-surface staining with mAbs was performed, followed by intracellular 
staining as previously described [33]. 
 
Isolation and culture of IFNγ-secreting cells 
25x106 PBMC were stimulated with 10-6 M HAdV 5 hexon protein-spanning 15-mer peptide 
pool for 4 hours. Cells were thoroughly washed in PBS and IFNγ-secreting cells were 
labeled using the IFNγ capture assay (Miltenyi Biotec) according to the manufacturer’s 
instructions, and isolated using the midi-MACS system (Miltenyi Biotec). The IFNγ-
enriched and IFNγ-depleted cell fractions were both cultured with 50 IU/ml IL-2 and 30 Gy-
irradiated feeder cells derived from the IFNγ-depleted fraction. Fresh medium and IL-2 
were supplemented every 3-4 days. 
 
Cytotoxicity assay 
Standard 51Cr release assay was performed as described previously [34]. Briefly, fibroblasts 
incubated with 200 U/ml IFNγ (Boehringer Ingelheim, Alkmaar, The Netherlands) for 5 
days, were incubated overnight with 10-6 M HAdV 5 hexon peptides or HAdV 5 virus 
particles (MOI 500). After washing, fibroblasts were labeled with Na251CrO4 (GE Healthcare, 
London, UK) for 1 hour at 37°C, and incubated with effector T cell lines. After 10 hours of 
















Uncultured donor PBMC or HAdV-specific T cell lines were incubated with allogeneic 
30Gy-irradiated PBMC to analyze residual alloreactivity. At day 6 of incubation, 
3H-thymidine (Amersham International, Amersham, UK) was added for a further 16 hours 
of incubation and 3H-thymidine uptake was measured subsequently. The residual 
alloreactivity was calculated by comparing the 3H-thymidine uptake of the HAdV-specific T 
cell lines with the uncultured PBMC. 
 
IFNγ ELISA 
As stimulator cells, EBV-LCL were loaded with the relevant HAdV hexon peptide at 10-6 M 
for 2 hours. After washing, stimulator cells were incubated with the HAdV-specific T cell 
line. After overnight incubation, supernatant was harvested and the IFNγ concentration was 




HAdV hexon-specific T cells in healthy donors 
To analyze the HAdV hexon-specific T cell response in PBMC from healthy adult donors, 
we determined frequencies of CD8+ and CD4+ T cells specific for HAdV serotype 5 hexon 
epitopes. Analysis of the kinetics of IFNγ production after stimulation showed maximal 
IFNγ production 4 hours after stimulation with the HAdV 5 hexon protein-spanning 15-mer 
peptide pool, which was similar for CMV-specific T cells as described recently [33]. 
Therefore, cumulative intracellular IFNγ staining was measured 6 hours after stimulation 
with the hexon 15-mer peptide pool. Intracellular IFNγ staining showed hexon-specific 
CD8+IFNγ+ T cell populations in 6/16 healthy donors (Figure 1A and 1B). Stimulation with 
minimal peptides corresponding to known hexon CD8+ epitopes induced responses in 3/16 
donors (Figure 1B). Addition of minimal peptides to the hexon 15-mer pool did not increase 
the number of donors responding, indicating that the hexon 15-mer pool efficiently induced 
activation of hexon-specific CD8+ T cells. Protein-spanning 15-mer peptide pools derived 
from cytomegalovirus or Epstein-Barr virus were used as irrelevant control peptides in 
cytomegalovirus and/or Epstein-Barr virus seronegative individuals. No T cell responses 
were observed using these control peptides (data not shown), confirming the specificity of 
HAdV hexon-specific IFNγ production. The presence of hexon-specific CD8+ T cells was 













corresponding to known hexon CD8+ epitopes, with frequencies of 0.06-0.46% of CD8+ T 
cells (data not shown). 
CD4+ T cells specific for HAdV hexon were detected by intracellular IFNγ and CD40L 
staining upon stimulation of PBMC with HAdV hexon peptide pool (Figure 1A). Hexon-
specific CD4+IFNγ+CD40L+ T cell populations could be detected in 13/16 donors (Figure 1C, 
range 0.03-0.39% of CD4+ T cells). Using 5 selected hexon 30-mer peptides, which have been 
described to contain immunodominant hexon CD4+ epitopes [17], lower frequencies of 
hexon-specific CD4+ T cells were activated. These data indicate that significantly more CD4+ 
T cells, presumably specific for other hexon CD4+ epitopes, were activated using the hexon 
protein-spanning 15-mer peptide pool than with the 5 selected 30-mer peptides. Addition of 
the 5 selected 30-mer peptides to the hexon 15-mer pool did not result in increased 
frequencies of IFNγ-producing CD4+ T cells, indicating that the hexon 15-mer pool also 





Figure 1. HAdV hexon-specific T cells in healthy donors. A) Example (donor 4) of detection of HAdV hexon-specific 
CD8+ T cells by peptide-MHC tetramer staining and HAdV hexon-specific CD8+ and CD4+ T cells by intracellular 
IFNγ and CD40L staining upon stimulation with the HAdV hexon 15-mer peptide pool. B) Frequencies of IFNγ-
producing cells among CD8+ T cells in PBMC of 16 healthy donors after stimulation with HAdV hexon minimal 
peptides, 15-mer peptide pool, or these 2 sets of peptides combined. C) Frequencies of IFNγ-producing CD40L+ cells 
among CD4+ T cells in PBMC of 16 healthy donors after stimulation with HAdV hexon selected 30-mers, 15-mer 
peptide pool, or these 2 sets of peptides combined. Filled symbols represent specific IFNγ-producing populations, and 














These data show that low frequencies of HAdV hexon-specific CD4+ T cells were detected 
directly ex vivo in peripheral blood from 81% of healthy adults, while hexon-specific CD8+ 
T cells could be detected directly ex vivo in 38% of donors. To determine whether the HAdV 
hexon-specific T cell response was below the threshold of detection in the donors where no 
HAdV hexon-specific responses could be detected directly ex vivo, PBMC were stimulated 
for 1 week with HAdV hexon peptide pool and IL-2 for specific expansion. Subsequently, 
restimulation with HAdV hexon peptide pool followed by intracellular IFNγ staining 
showed hexon-specific CD8+ and CD4+ T cells in PBMC from all healthy adults tested (data 
not shown), indicating that low frequencies of HAdV hexon-specific T cells were present in 
PBMC from all healthy adults. 
 
HAdV-specific T cell response in alloSCT recipients 
We next analyzed whether HAdV hexon-specific T cell responses were associated with 
clearance of HAdV infection in alloSCT recipients, using the same method as for the healthy 
individuals. From previously described cohorts of patients, we selected 7 pediatric and 6 
adult patients, who developed HAdV viremia as determined by positive HAdV DNA 
plasma load, and subsequently showed spontaneous resolution of disseminated infection 
[4,8]. HAdV-specific T cell responses could not be analyzed in patients who deceased from 
HAdV viremia, since only for a few patients peripheral blood samples were available and 
the lymphocyte numbers in these samples were too low for analysis. Peripheral blood 
samples obtained during positive HAdV plasma load were available for 10 patients, and 
peripheral blood samples obtained after resolution of HAdV viremia were available for all 
13 patients. During HAdV viremia hexon-specific CD8+ T cells could not be detected 
directly ex vivo and hexon-specific CD4+ T cells were detected in 2 patients (Figure 2A). 
After 1 week of culture with the hexon peptide pool and IL-2 for specific expansion, the 
presence of low frequencies of hexon-specific CD4+ T cells was observed in 5 patients, while 
no hexon-specific CD8+ T cells could be detected. Following resolution of HAdV viremia, 
direct intracellular staining showed hexon-specific CD8+ T cells in 7 patients, and hexon-
specific CD4+ T cells in all patients (Figure 2B). After 1 week culture of these cells with 
hexon peptides and IL-2, both hexon-specific CD8+ and CD4+ T cells were shown to be 
present in PBMC from 12 of the 13 patients. In 4 patients, part of hexon-specific CD8+ T cells 
were directed against previously described epitopes, as detected by peptide-MHC tetramer 

















Figure 2. HAdV-specific T cell responses in alloSCT recipients. Frequencies of CD8+ and CD4+ T cells producing IFNγ 
upon HAdV hexon peptide pool stimulation of PBMC derived from 7 pediatric and 6 adult patients A) during or B) 
after HAdV viremia as detected by HAdV DNA plasma load. HAdV-specific IFNγ production was analyzed directly in 
PBMC (ex vivo) or after 1 week culture of PBMC with HAdV hexon peptide pool and IL-2 (expanded). Filled symbols 
represent specific IFNγ-producing populations, and open symbols represent frequencies below the limit of detection. 
 
A more detailed analysis of development of HAdV-specific T cell responses is shown for 5 
patients, of whom multiple peripheral blood samples were available (Figure 3). During 
HAdV viremia, direct intracellular IFNγ staining upon hexon peptide pool stimulation 
showed no or low frequencies of hexon-specific CD8+ or CD4+ T cells in these patients. 
After clearance of the HAdV plasma load, high frequencies up to 30% of CD8+ T cells and 
16% of CD4+ T cells producing IFNγ upon hexon peptide pool stimulation appeared in 
peripheral blood. The hexon-specific T cells emerged directly after resolution of HAdV 
viremia in most patients, although proliferation of high frequencies of hexon-specific T cells 
was shown to continue for several months after clearance of the HAdV plasma load in 
pediatric patient 1 (Figure 3A). The relation between the development of hexon-specific T 
cells and control of HAdV infection was illustrated by the minor HAdV reactivation at day 
152 after transplantation in pediatric patient 2, which was followed by an increase in 
frequencies of HAdV hexon-specific CD8+ and CD4+ T cells and concomitant viral clearance 
(Figure 3C). These results demonstrate that a coordinated CD8+ and CD4+ T cell response 
specific for HAdV hexon epitopes was associated with clearance of HAdV infection in both 

















Figure 3. Detailed analysis of HAdV-specific T cell responses in alloSCT recipients. The dot plots show direct 
intracellular IFNγ and CD40L staining following HAdV hexon peptide pool stimulation of A) PBMC from pediatric 
patient 1 (patient 16 reference [8]), and B) PBMC from adult patient 1 (patient 3 reference [4]), obtained during and 
after resolution of HAdV viremia. The graphs show frequencies of IFNγ-producing cells among CD8+ T cells (black 
circles) and among CD4+ T cells (black triangles), and the HAdV DNA plasma load (open squares). Similar graphs are 
presented in C), D), and E) for pediatric patient 2, 3, and 4. 
 
Generation of HAdV hexon-specific CD8+ and CD4+ T cell lines  
As the presence of CD4+ as well as CD8+ HAdV hexon-specific T cells was associated with 
viral clearance after alloSCT, a clinical grade protocol was developed for the generation of 
HAdV hexon-specific T cell lines containing both T cell subsets. PBMC from healthy adult 
donors were stimulated with the hexon peptide pool, and IFNγ-secreting cells were isolated 
and cultured with autologous feeders and IL-2. The data of a representative T cell line 













cells were detected in PBMC (Figure 4A). In the T cell line generated from the enriched cell 
population (Figure 4B), 74% of CD8+ T cells (58% of total cells) were directed against the 
MPN/HLA-B35 epitope [19]. Restimulation of the T cell line with autologous EBV-LCL 
loaded with the hexon peptide pool induced specific IFNγ production by 94% of CD8+ T 
cells, indicating that additional hexon CD8+ epitopes were recognized. Furthermore, hexon-
specific IFNγ production upon restimulation was observed by 91% of CD4+ T cells. Only 
low frequencies of hexon-specific T cells could be detected in the IFNγ-depleted fraction 
(Figure 4C). Results from all 6 donors are summarized (Table 1). HAdV-specific T cell lines 
could be generated from donors with relatively high frequencies as well as from donors 
with low or undetectable frequencies of hexon-specific CD8+ and CD4+ T cells. To analyze 
residual alloreactivity, the HAdV-specific T cell lines derived from donor 1, 2, 3, and 5 were 
incubated with PBMC from 3 different allogeneic donors. The proliferation of the HAdV-
specific T cell lines compared with the uncultured PBMC was only 0.0-6.8%, indicating 
absent to very low levels of alloreactive capacity (data not shown).  
 
Table 1. Generation of T cell lines containing CD8+ and CD4+ T cells with high specificity for HAdV hexon derived 
from 6 healthy adult donors. 
 
  
Day 1 Day 14/15 

























1 0.04 0.06 8.4x104 2.9x106 77 20 3 74 94 91 
2 0.00 0.01 1.2x105 4.3x106 36 10 48 49 89 61 
3 0.02 0.02 2.3x105 3.0x106 53 24 23 10 49 13 
4 0.51 0.12 5.2x105 2.0x107 74 15 8 47 88 45 
5 0.00 0.04 1.6x105 1.2x106 3 92 5 24 25 92 
6 0.24 0.11 2.4x105 1.9x106 38 35 20 86 87 79 
* To analyze the frequency of HAdV hexon-specific T cells in donor PBMC and in generated T cell lines, the percentage 
of tetramer-positive T cells was determined after gating on CD8+ T cells, and the percentage of IFNγ-positive T cells 


















Figure 4. Example of a HAdV-specific T cell line containing CD8+ and CD4+ T cells with high specificity for HAdV 
hexon. (A) Peptide-MHC tetramer staining and intracellular IFNγ staining upon stimulation of PBMC from healthy 
donor 1 with HAdV hexon peptide pool. Specificity of IFNγ-enriched (B) and IFNγ-depleted (C) fraction after 14 days 
of culture as determined by peptide-MHC tetramer staining and intracellular IFNγ staining upon restimulation with 
autologous EBV-LCL, which were unloaded or loaded with HAdV hexon peptide pool. (D) Specific lysis of allogeneic 
HLA-A1 matched or mismatched (MM) fibroblasts, unloaded (X), loaded with HLA-A1 restricted minimal peptide 
(TDL), loaded with HAdV 5 hexon peptide pool (Pool), or infected with HAdV 5 (HAdV5) after 10 hours incubation 
with the HAdV-specific T cell line derived from donor 4 at 3 effector/target ratios. 
 
To investigate whether HAdV-specific T cell lines recognized HAdV-infected target cells 
which endogenously processed the synthesized HAdV antigen, specific lysis was 













hexon peptide, with the hexon 15-mer peptide pool, or infected with HAdV serotype 5. 
HAdV-specific T cell lines very efficiently lysed both HAdV peptide-loaded and HAdV-
infected fibroblasts, while fully mismatched HAdV-infected fibroblasts were not recognized 
(Figure 4D). Specific lysis of MHC class I restricted peptide-loaded fibroblasts demonstrated 
cytotoxic capacity of HAdV hexon-specific CD8+ T cells. Specific lysis by HAdV hexon-
specific CD4+ T cells was shown in the T cell line derived from donor 5, containing 
predominantly CD4+ T cells, which specifically lysed autologous EBV-LCL loaded with the 
hexon 15-mer peptide pool (67% specific lysis). Lysis by this T cell line could be blocked 
using anti-MHC class II antibodies (95% block). 
The phenotype of HAdV hexon-specific CD8+ and CD4+ T cells in donor PBMC and the T 
cell lines was investigated. In donor PBMC, HAdV hexon-specific CD8+ and CD4+ T cells 
were CD56-, CD45RO+, CD27+, CD28+, and CD62L+/-. After isolation and culture, the 
phenotype remained identical except for the expression of CD62L, which first increased and 
subsequently decreased on HAdV-specific CD8+ T cells and increased on HAdV-specific 
CD4+ T cells. This phenotypic analysis demonstrated that HAdV-specific T cells did not 
differentiate into end-stage effector T cells during in vitro activation and culture. 
These results show that IFNγ-based isolation after stimulation with hexon 15-mer peptide 
pool allowed rapid generation of T cell lines with high frequencies of both HAdV hexon-
specific CD8+ and CD4+ T cells from all healthy adult donors tested, including donors with 
very low frequencies of circulating HAdV hexon-specific T cells. Furthermore, the HAdV 
hexon-specific T cell lines induced specific and efficient lysis of HAdV-infected target cells. 
 
Characterization of HAdV hexon epitopes recognized 
To determine the repertoire of HAdV hexon epitopes recognized by HAdV-specific T cell 
lines, staining was performed with peptide-MHC tetramers covering all known HAdV 
hexon CD8+ epitopes restricted by prevalent MHC class I molecules. CD8+ T cell 
populations specific for 7 previously described hexon epitopes were detected in the HAdV-
specific T cell lines derived from 6 healthy donors (Table 2). Analysis of specific IFNγ 
production by CD8+ T cells upon restimulation with separate hexon overlapping 30-mer 
peptides showed recognition of 4 additional hexon peptides by the HAdV-specific T cell 
lines, of which 2 were recognized by CD8+ T cells from 2 different donors (Table 2). To 
investigate HLA-restriction of these epitopes, CD8+ T cell recognition of a panel of EBV-LCL 
sharing MHC class I molecules with the donor, loaded with specific hexon 30-mer peptide, 
was determined. Subsequently, minimal peptides were predicted to bind by algorithms, and 
were shown to be recognized by specific CD8+ T cells (Figure 5). Specific CD8+ T cells were 














restriction of this peptide. The HLA-restriction of the other peptides (FRKDVNMVL/HLA-
B7, ETYFSLNNKF/HLA-B52, and YSYKARFTL/HLA-B63) was confirmed by specific 
recognition of peptide-loaded EBV-LCL that expressed these HLA molecules (Figure 5). 
Despite the recognition of FRKDVNMVL peptide in HLA-B7 by specific CD8+ T cells, 
production of fluorescently labeled FRKDVNMVL/HLA-B*0702 tetramers was not 
successful. The HAdV hexon sequences recognized by CD8+ T cells in HAdV-specific T cell 
lines derived from all 6 donors are presented (Table 2). Both previously described and 
newly identified hexon CD8+ epitopes were largely conserved between different HAdV 
species (Table 3). Furthermore, CD4+ T cells in all T cell lines recognized multiple hexon 30-
mer peptides, indicating a broad specificity which included conserved HAdV hexon 
regions. These data demonstrate that HAdV-specific T cell lines generated by IFNγ-based 
isolation after hexon peptide pool stimulation recognized multiple CD8+ and CD4+ HAdV 
hexon epitopes, including both known and novel epitopes, thereby exploiting the full donor 
HLA repertoire. 
 
Table 2. Characterization of HAdV hexon CD8+ epitopes recognized by T cell lines as determined by peptide-MHC I 
tetramer staining or recognition of specific hexon peptides. 
 HAdV hexon CD8+ epitopes recognized 
 Previously described  Newly identified 

































 FRK 585-593 B7 
4 TDL 886-894 A1  YSY 78-86 B63 
5 TYF 37-45 A24     





















Figure 5. Confirmation of newly identified HAdV hexon CD8+ T cell epitopes. Intracellular IFNγ staining of HAdV-
specific T cell lines after restimulation with minimal MHC class I restricted HAdV hexon peptides. In addition, the 
HAdV-specific T cell line derived from donor 2 was stained with IPF/HLA-B35 tetramers. To confirm HLA-restriction 
of the other epitopes, IFNγ release was determined by ELISA upon incubation with autologous or partially HLA-
















 Table 3. Conservation of HAdV hexon CD8+ epitopes between different HAdV species. 




serotype AA 37-45 AA 114-124 AA 320-329 AA 705-713 AA 886-894 AA 917-926 
C 5 TYFSLNNKF KPYSGTAYNAL MPNRPNYIAF IPYLDGTFY TDLGQNLLY YVLFEVFDVV 
A 12 ---T-G--- ---------S- A---A----- --------- ------M-- ---------- 
B 35 ---N-G--- ---------S- --------G- --------- ------M-- -L-------- 
C 2 --------- ----------- ---------- --------- --------- ---------- 
D 30 -----G--- ---------S- --------G- --------- ------M-- -L-------- 
E 4 -----G--- ---------S- --------G- --------- ------M-- --V------- 
F 40 -----G--- ---------S- A-------G- V-------- ------M-- ---------- 




serotype AA 36-45 AA 78-86 AA 585-593 AA 873-882  
C 5 ETYFSLNNKF YSYKARFTL FRKDVNMVL IPFSSNFMSM  
A 12 D---T-G--- --------- -------I- ----------  
B 35 D---N-G--- ----V-Y-- --------- ----------  
C 2 ---------- --------- --------- ----------  
D 30 D-----G--- --------- -------I- ----------  
E 4 D-----G--- ----V-Y-- -------I- ----------  
F 40 D-----G--- ----V---- -------I- ----------  
HAdV hexon sequences were compared between serotype 5 (AP_000211), serotype 12 (AP_000121), serotype 35 
(AP_000585), serotype 2 (AP_000175), serotype 30 (ABA00012), serotype 4 (AAO24097), and serotype 40 (NP_040862). 
The sequence derived from serotype 5 is depicted for each HAdV hexon CD8+ epitope, and amino acids that differ are 
shown for the other serotypes. 
 
Discussion 
Based on our observation that resolution of HAdV viremia coincided with appearance of a 
coordinated CD8+ and CD4+ HAdV hexon-specific T cell response in patients following 
alloSCT, we developed a method for generation of CD8+ and CD4+ T cell lines with high 
and defined specificity for HAdV hexon for adoptive immunotherapy. HAdV-specific CD8+ 
T cells have been detected before in healthy adults and in patients following alloSCT 
[7,15,18-20,27]. Our study further shows a kinetic association between HAdV-specific CD8+ 
T cell responses and clearance of HAdV infection in alloSCT recipients.  
Since in previous studies predominantly HAdV-specific CD4+ T cells were detected in 
peripheral blood from healthy individuals, and since these CD4+ T cells showed direct 
cytotoxic capacity, the role of CD8+ T cells in protection from HAdV disease has been 













high sensitivity using peptide-MHC tetramer staining and intracellular cytokine staining 
following stimulation with a HAdV hexon peptide pool. Using these methods, low 
frequencies of HAdV hexon-specific CD8+ and CD4+ T cells were detected directly ex vivo 
in peripheral blood from 38% and 81% of healthy adults, respectively. Subsequently, 
activation of HAdV hexon-specific T cells with the hexon peptide pool followed by IFNγ-
based isolation allowed rapid expansion of both CD8+ and CD4+ T cells specific for HAdV 
hexon epitopes from all healthy donors tested. These data suggest that coordinated 
responses of CD8+ and CD4+ T cells specific for HAdV hexon epitopes contribute to control 
of HAdV infection in healthy individuals, and persist as memory T cells afterwards, which 
is similar to T cell responses described against most other viral infections. 
While the development of HAdV-specific T cell responses in patients after alloSCT has 
previously been shown to be associated with protection from HAdV disease, only HAdV-
specific CD4+ T cells, and no HAdV-specific CD8+ T cells have been detected [7-9]. To 
further investigate this, we analyzed T cell responses specific for the immunodominant 
HAdV hexon protein in patients that showed spontaneous resolution of disseminated 
HAdV infection. Using the same sensitive methods of detection as for the healthy donors, 
combined CD8+ and CD4+ T cell responses specific for HAdV hexon epitopes were 
demonstrated to be associated with clearance of HAdV infection in patients after alloSCT. 
The HAdV hexon-specific CD8+ and CD4+ T cells were shown to develop synchronously 
upon clearance of the HAdV plasma DNA load, supporting the coordinated action of 
HAdV-specific CD8+ and CD4+ T cells in viral control. It is unlikely that 
immunosuppressive drugs hampered the detection of HAdV hexon-specific T cells directly 
ex vivo, since only part of the patients used immunosuppressive drugs during the time 
points of analysis, and expansion of HAdV hexon-specific T cells was observed in PBMC 
from all patients. These data indicated that both CD8+ and CD4+ T cells specific for HAdV 
hexon epitopes contribute to resolution of HAdV infection in alloSCT recipients, and 
provide a rationale for the adoptive transfer of donor-derived HAdV hexon-specific CD8+ 
and CD4+ T cells for treatment of HAdV infection after alloSCT. 
Despite the low to undetectable frequencies of HAdV hexon-specific T cells in healthy 
individuals, using HAdV hexon peptide pool stimulation followed by IFNγ-based isolation, 
highly specific T cell lines could be generated from all donors tested. In contrast to previous 
studies, we demonstrated high and defined specificity of the T cell lines for HAdV hexon 
epitopes (median 87% of CD8+ T cells and 70% of CD4+ T cells). The risk of graft-versus-
host disease may be determined by the repertoire of non-HAdV-specific T cells, and 
therefore by the absolute number of non-HAdV-specific T cells isolated from donor PBMC. 














to result in a minimal risk of graft-versus-host disease. This assumption was supported by 
the absence or very low levels of residual alloreactive capacity of the HAdV-specific T cell 
lines generated. Furthermore, no adverse events associated with administration of HAdV- 
or cytomegalovirus-specific T cell lines generated by IFNγ-based isolation have been 
reported [23,35,36]. 
The vigorous expansion and central memory phenotype (CD45RO+, CD27+, CD28+, 
CD62L+/-) of HAdV hexon-specific T cells indicate a HAdV-specific memory T cell response 
present in most healthy individuals, that rapidly reacts upon specific activation. While 
expression of CD27 and CD28 was reported to be transiently upregulated upon activation 
and subsequently downregulated on CMV-specific T cells during culture [33,37], we here 
demonstrated that HAdV-specific T cells retained expression of CD27 and CD28. This 
phenotypic analysis indicated that cells did not differentiate to the end-stage effector cell 
type that might show impaired proliferative capacity in vivo.  
Stimulation of donor PBMC with the HAdV hexon protein-spanning pool of 15-mer 
peptides (11-mer overlapping) efficiently induced activation of HAdV-specific CD8+ and 
CD4+ T cells. Although the frequencies of HAdV hexon tetramer-positive CD8+ T cells were 
not sufficiently high to perform co-staining with intracellular IFNγ directly ex vivo, the 
activation of cytomegalovirus-specific CD8+ T cell populations upon stimulation with 15-
mer peptide pools has recently been confirmed by tetramer and IFNγ co-staining [38]. 
Although the mechanism of processing and presentation of these 15-mer peptides has not 
been investigated, the data suggested that stimulation with 15-mer peptides results in 
efficient presentation in both MHC class I and II, in contrast to endogenously synthesized 
antigen being predominantly presented in MHC class I, and exogenous antigens such as 
full-length protein or lysate being mainly presented in MHC class II [20,23-29]. The use of 
synthetic peptides, which can readily be produced under GMP regulations, may contribute 
to the general applicability of generating clinical grade virus-specific T cell lines. 
Furthermore, the flexibility of peptide synthesis allows inclusion of peptides derived from 
multiple viral proteins and viruses. 
From all healthy adults, T cells recognizing multiple MHC class I and II restricted epitopes 
derived from HAdV serotype 5 hexon protein were isolated. Like the HAdV hexon epitopes 
described previously, the HAdV hexon epitopes identified in this study are largely 
conserved between different HAdV serotypes [14,17-19,26]. The newly identified epitopes 
increase the repertoire of known immunodominant HAdV hexon epitopes, which may 
improve the analysis of HAdV-specific T cell lines generated for adoptive transfer, and the 
monitoring of HAdV-specific T cell responses in patients after alloSCT. T cells specific for 













HAdV serotypes [14,17,18,21,26]. The T cell lines generated in this study may therefore 
provide protection from infection with all prevalent HAdV serotypes. 
The presence of both CD8+ and CD4+ HAdV hexon-specific T cells in healthy individuals 
and in alloSCT recipients after clearance of HAdV viremia suggests that both subsets are 
required for adequate antiviral protection. This study provides a strategy for the adoptive 
transfer of donor-derived CD8+ and CD4+ T cells specific for multiple known and unknown 
HAdV hexon epitopes, which allows treatment of all patients irrespective of their HLA type. 
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Opportunistic viral infections can cause serious morbidity and mortality in 
immunocompromised patients after allogeneic stem cell transplantation (alloSCT). Clinical 
studies have demonstrated that adoptive transfer of donor-derived T cells specific for 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), or human adenovirus (HAdV) can be a 
safe and effective treatment of infections with these major viral pathogens. The aim of this 
study was to develop a method for the simultaneous isolation of coordinated CD8+ and 
CD4+ memory T cell responses against a broad repertoire of viral epitopes. To ensure that 
the method was applicable to a wide variety of virus-specific T cells that may differ in 
phenotypic and functional properties, we focused on T cells specific for the persistent 
viruses CMV and EBV, as well as T cells specific for HAdV and influenza (FLU), which are 
not repetitively activated in vivo after initial viral clearance. Following in vitro activation, 
nearly all T cells specific for these viruses produced IFNγ and TNFα, and expressed CD137, 
while the populations varied in production of IL-2, degranulation, and expression of 
phenotypic markers. Different kinetics of IFNγ production were observed in CMV/EBV-
specific T cells and HAdV/FLU-specific T cells. However, after stimulation of peripheral 
blood from seropositive donors with viral protein-spanning peptide pools, the activated 
virus-specific CD8+ and CD4+ T cells could be simultaneously isolated by either IFNγ-based 
or CD137-based enrichment. This study provides an efficient and widely applicable strategy 
for isolation of virus-specific T cells, which may be used for reconstitution of virus-specific 















Opportunistic viral infections are a major cause of morbidity and mortality in 
immunocompromised patients after allogeneic stem cell transplantation (alloSCT) [1,2]. 
Viral reactivations or de novo infections can not be controlled in the absence of an adequate 
antiviral T cell response. These T cells may be eradicated or functionally impaired by the 
conditioning regimen and immune suppression co-inciding the alloSCT. Treatment with 
pharmacological agents is limited by toxicity and often not sufficient for long-term control 
of these viral infections [3,4]. It has been shown that development of virus-specific T cell 
responses after alloSCT was associated with sustained protection from viral disease [5-9]. 
Clinical studies have demonstrated that the adoptive transfer of donor-derived virus-
specific memory T cells can be a safe and effective treatment for infections with 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human adenovirus (HAdV), which 
are the main viral pathogens after alloSCT [10-15]. Extensive characterization of T cell 
responses against these viruses in both patients and healthy individuals has shown 
coordinated CD8+ and CD4+ T cell responses against a broad repertoire of epitopes derived 
from multiple viral proteins [16-19]. Adoptive transfer of donor-derived CD8+ and CD4+ T 
cells against a broad repertoire of viral antigens may therefore be an effective strategy to 
provide immune reconstitution as prophylaxis or treatment of viral disease after alloSCT. 
Isolation of virus-specific memory T cells from donor peripheral blood allows the rapid 
generation of highly specific T cell products. Peptide-MHC multimers with high affinity for 
a specific T cell receptor (TCR) can be used for isolation of epitope-specific CD8+ T cell 
populations [15,20]. However, to generate T cell lines against multiple viral proteins and for 
every eligible patient, this method requires knowledge of defined epitopes restricted by 
prevalent MHC class I molecules, and production of a large number of clinical grade 
peptide-MHC multimers. Furthermore, virus-specific CD4+ T cells can not be isolated using 
this method due to the lack of functional peptide-MHC class II multimers. Stimulation of 
donor peripheral blood with synthetic pools of overlapping 15-mer peptides spanning 
immunodominant CMV, EBV, or HAdV proteins has recently been shown to induce 
efficient and simultaneous activation of virus-specific CD8+ and CD4+ T cells, irrespective of 
the donor HLA type and without the need of knowing exact epitopes [21-26,41]. The 
activated virus-specific T cells may subsequently be isolated based on the specific expression 
of an activation marker to generate highly specific T cell lines for adoptive transfer. 
CD8+ and CD4+ T cells specific for CMV, EBV, or HAdV can be isolated from peripheral 
blood based on IFNγ production induced by antigen-specific activation [11,26-28,41]. The 














studies [11,29,30]. Secreted IFNγ is captured by an antibody at the cell membrane, after 
which a secondary IFNγ-specific antibody attached to a magnetic bead can be used to isolate 
the labeled cells by magnetic separation. Detailed analysis of the kinetics of IFNγ production 
by CMV-specific CD8+ and CD4+ T cells has shown a rapid induction of IFNγ production 
following activation, which was maximal after 4 hours of stimulation, and decreased 
thereafter [26,31]. Comparable kinetics of IFNγ production by other virus-specific T cell 
populations would allow simultaneous IFNγ-based isolation of coordinated CD8+ and CD4+ 
T cell responses against multiple viruses for broad immune reconstitution. However, it is 
unknown whether T cell populations specific for other viruses than CMV show similar 
kinetics of IFNγ production upon activation. Furthermore, the IFNγ-based isolation 
procedure is technically demanding, which may have hampered a wider clinical application. 
Therefore, other molecules that are expressed at the cell surface of virus-specific T cells upon 
antigen-specific stimulation, like CD137 (4-1BB) and CD154 (CD40L), have been explored for 
suitability as isolation marker. 
Recently, CMV- and EBV-specific CD8+ T cells have been shown to specifically express the 
co-stimulatory molecule CD137 at the cell surface upon antigen-specific activation [32-34]. 
The expression of CD137 by activated CD8+ T cells was demonstrated to peak 24 hours after 
stimulation [32,34,35]. Prolonged expression of CD137 may provide more freedom in the 
timeframe for efficient isolation, which can contribute to the robustness of the isolation 
method. However, the kinetics of activation-induced CD137 expression was analyzed on 
cultured T cell clones and T cell lines, while the expression of CD137 by virus-specific T cells 
activated in donor peripheral blood directly ex vivo is unknown. Furthermore, conflicting 
results have been reported on the activation-induced expression of CD137 by virus-specific 
CD4+ T cells [33,34]. Since CD137 is expressed at the cell surface upon activation, a simple 
labeling with CD137-specific antibody and magnetic beads followed by magnetic separation 
was shown to result in isolation of the activated CD137-positive T cells. 
The aim of this study was to define a feasible method for simultaneous isolation of CD8+ 
and CD4+ T cells recognizing epitopes derived from different viral proteins from peripheral 
blood of seropositive donors. To ensure that the method was applicable to a wide variety of 
virus-specific T cells that may differ in phenotypic and functional properties, we focused on 
T cells specific for the persistent viruses CMV and EBV, as well as T cells specific for HAdV 
and influenza (FLU), which are not repetitively activated in vivo after initial viral clearance. 
We demonstrate that both IFNγ-based and CD137-based enrichment result in efficient 
isolation of CD8+ and CD4+ T cells specific for multiple viral proteins after stimulation of 
peripheral blood with viral protein-spanning peptide pools. The simple CD137 labeling 













more feasible and cost-effective production of virus-specific T cell lines. This study provides 
an efficient and widely applicable strategy for the simultaneous isolation of virus-specific T 
cells, which may be used for reconstitution of virus-specific immunity in alloSCT recipients. 
 
Materials and methods 
Donor cells and cell lines 
After informed consent, peripheral blood was obtained from healthy individuals, and 
mononuclear cells (PBMC) were cryopreserved after Ficoll-Isopaque separation. Stable 




Minimal peptides corresponding to previously described viral epitopes were synthesized 
using standard solid-phase strategies (Department of Immunohematology, Leiden 
University Medical Center, Leiden, The Netherlands). In addition, pools of 15-mer peptides 
overlapping with 11 amino acids spanning viral proteins were used (PepMixTM, JPT 
Peptide Technologies, Berlin, Germany, and PeptivatorTM, Miltenyi Biotec, Bergisch 
Gladbach, Germany). The minimal MHC I and II binding peptides and protein-spanning 
pools used are depicted in Table 1. 
 
Flow cytometric analyses 
Cells were stained with FITC-labeled CD3, CD4, CD25, CD27, CD28, IFNγ, CD107a (BD 
Biosciences, San Jose, CA), CD45RO (Caltag, Burlingame, CA), CCR7 (R&D Systems, 
Minneapolis, MN), CD62L (Bender MedSystems, Vienna, Austria), PE-labeled CD28, TNFα 
(BD), CD45RA (Beckman Coulter, Fullerton, CA), CCR7 (R&D Systems), PerCP-labeled 
CD3, CD4, CD8 (BD), APC-labeled CD4 (Beckman Coulter), CD45RA, CD45RO, CD137, 
IFNγ, and IL-2 (BD) monoclonal antibodies (mAbs). PE- and APC-labeled peptide-MHC I 
tetramers were produced as described previously [20]. PE-labeled CMV-pp65-ALP-DR1 
tetramer was obtained through the NIH Tetramer Facility (Emory University, Atlanta, GA) 
and PE-labeled FLU-HA-PKY-DR4 tetramer was kindly provided by T.N.M. Schumacher 
(The Netherlands Cancer Institute, Amsterdam, The Netherlands). Between 5x104 and 5x105 
















Analysis of cytokine production and degranulation 
After thawing, PBMC were resuspended in culture medium, consisting of Iscove’s modified 
Dulbecco’s medium (IMDM, Lonza, Basel, Switzerland) supplemented with 10% pooled 
human serum, 100 U/ml penicillin/streptomycin (Lonza), and 3 mM L-glutamine (Lonza). 
For cumulative intracellular cytokine staining, PBMC were stimulated in culture medium 
with 10-6 M viral peptides for 6 hours at 37°C and 5% CO2. After 1 hour of peptide 
stimulation, 10 µg/ml brefeldin A (BFA, Sigma-Aldrich, Zwijndrecht, The Netherlands) was 
added for the remaining 5 hours of incubation. For detection of degranulation, CD107a mAb 
was added during peptide stimulation. For real-time kinetic measurement of cytokine 
production, cells were stimulated for 2 to 48 hours, and 10 µg/ml BFA was added only 
during the last 2 hours of stimulation. After stimulation, cell-surface staining with mAbs 
was performed, followed by intracellular staining as described previously [31]. To analyze 
production of additional cytokines by virus-specific T cells, supernatant was harvested after 
peptide stimulation and analyzed by the human Th1/Th2/Th17 multi-analyte profiler 
ELISArrayTM kit (SA Biosciences, Frederick, MD), performed according to the 
manufacturer’s instructions. To allow analysis of frequencies of virus-specific T cells in T cell 
lines by intracellular cytokine staining, we used as stimulator cells autologous EBV-LCL 
labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, 
Leiden, The Netherlands) for distinction in FACS analysis as described before [37]. The 
stimulator cells were loaded overnight in culture medium with 10-6 M viral peptides, 
washed, and the T cell line was incubated with stimulator cells in an effector/stimulator 
ratio of 1:5 for 4 hours in the presence of 10 µg/ml BFA. After stimulation, cell-surface 
staining with mAbs was performed, followed by intracellular staining as described 
previously [31]. 
 
Isolation and culture of virus-specific T cells 
PBMC were stimulated with 10-6 M viral peptides in culture medium supplemented with 
10 IU/ml IL-2 (Chiron, Amsterdam, The Netherlands) for 4 to 96 hours at 37°C and 5% CO2. 
For isolation based on IFNγ production, cells were harvested after stimulation, thoroughly 
washed in PBS, and IFNγ-secreting cells were stained and isolated by the IFNγ secretion 
assay (Miltenyi Biotec) performed according to the manufacturer’s instructions. Briefly, cells 
were labeled with IFNγ-catch reagent and cultured for 45 minutes at 37°C. Subsequently, 
cells were counterstained with PE-labeled IFNγ mAb, bound to anti-PE microbeads, and 
isolated using the midi-MACS system (Miltenyi Biotec). For isolation based on CD137 
expression, cells were harvested after stimulation, thoroughly washed in PBS, and stained 













to anti-APC microbeads (Miltenyi Biotec), and isolated using the midi-MACS system. The 
enriched and depleted cell fractions were both cultured at 1x106 cells/ml in culture medium, 
containing 50 IU/ml IL-2 and 10 ng/ml IL-15 (Peprotech, Rocky Hill, NJ) and 5x106 cells/ml 
25 Gy-irradiated feeder cells derived from the depleted fractions. Cultures were 




Variability in phenotype and function of virus-specific T cells 
To investigate whether T cells specific for the persistent viruses CMV and EBV, which are 
frequently activated in vivo, differed from T cells specific for HAdV and FLU, which are not 
repetitively activated in vivo after viral clearance, we analyzed phenotypic and functional 
properties of these T cells. Peripheral blood samples were selected from 15 healthy CMV- 
and EBV-seropositive individuals, which were positive for at least one of the prevalent 
MHC molecules HLA-A1, -A2, -B7, -B8, or -B35. Although their serostatus was unknown for 
HAdV and FLU, the majority of the adult population has been exposed to these viruses. 
Virus-specific CD8+ T cell populations were analyzed using peptide-MHC I tetramers 
(n=18), which are presented in Table 1. The frequencies of CD8+ T cells specific for CMV 
(median 0.40%) and EBV (median 0.20%) epitopes were higher compared to frequencies of 
CD8+ T cells specific for HAdV and FLU (median 0.02%) epitopes. Phenotypic analysis 
showed that virus-specific CD8+ T cell populations were heterogeneous with regard to the 
expression of phenotypic markers CD27, CD28, CCR7, CD62L, CD45RA, and CD45RO, 
indicating the presence of different T cell subsets. Most CD8+ T cells specific for HAdV or 
FLU epitopes expressed CD27 (median 82%), and CD28 (median 85%) (Figure 1A-B). 
Furthermore, these T cells expressed CCR7, CD62L, and CD45RO (median 60%, 58%, 75% 
respectively). These results were mainly consistent with a central memory phenotype for 
HAdV- and FLU-specific CD8+ T cells. EBV-specific CD8+ T cells also showed expression of 
CD27, CD28, CCR7, CD62L and CD45RO, although T cells specific for EBV lytic epitopes 
showed lower percentages of CD62L expression (median 35%), indicative of a central 
memory or effector memory phenotype. In contrast, CD8+ T cells specific for CMV epitopes 
showed less expression of CD27 (median 51%), CD28 (median 32%), CCR7 (median 30%) 
and CD62L (median 30%), and showed higher percentages of CD45RA positive CD8+ T cells 
(median 68%). These results were consistent with an effector phenotype for CMV-specific 















Table 1. Viral peptides used for stimulation of specific CD8+ and CD4+ T cells. 




CMV pp50 VTEHDTLLY HLA-A1 












 EBV BMLF1 GLCTLVAML HLA-A2 
 EBV BRLF1 YVLDHLIVV HLA-A2 




 EBV EBNA1 HPVGEADYFEY HLA-B35 



























CMV pp65 1) 2) 

















 HAdV 5 Hexon 1) P04133 N.A. 






1) Obtained from Miltenyi Biotec, Bergisch Gladbach, Germany. 
2) Obtained from JPT Peptide Technologies, Berlin, Germany. 















Figure 1. Variability in phenotype and function of virus-specific T cells. (A) The percentage of CD27+ cells and (B) the 
percentage of CD28+ cells is shown of peptide-MHC I tetramer-positive CD8+ T cell populations specific for CMV 
(n=14), EBV (n=14), HAdV (n=3), and FLU (n=4) epitopes. (C) Representative example of intracellular staining of IFNγ, 
TNFα, and IL-2, and surface CD107a staining of PBMC without stimulation and after stimulation with the CMV pp65 
protein-spanning peptide pool. (D) The percentage of IFNγ-, TNFα-, and IL-2-producing T cells as measured by 
intracellular staining, and the percentage of degranulating T cells as measured by surface CD107a staining, of virus-
specific CD8+ T cells activated after stimulation with minimal MHC I binding peptides (n=13), and (E) of virus-specific 















To compare the functional profile of the T cells specific for the different viruses, cumulative 
intracellular staining and cell surface staining were performed following stimulation of 
PBMC from the healthy donors with viral peptides. Kinetic analyses showed maximal 
cumulative measurement of IFNγ, TNFα, IL-2, and CD107a after 6 hours of stimulation. As 
depicted for a representative example of PBMC after stimulation with CMV pp65 protein-
spanning peptide pool in Figure 1C, activated CMV pp65-specific T cells produced both 
IFNγ and TNFα, while only part of these T cells additionally produced IL-2 or showed 
degranulation by surface expression of CD107a. This functional profile was observed for the 
different specificities (CMV, EBV, HAdV, and FLU), and both after stimulation with 
minimal MHC class I binding peptides (Figure 1D), as well as after stimulation with protein-
spanning pools of overlapping 15-mer peptides (Figure 1E). Analysis of supernatant 
harvested after stimulation with minimal MHC class I binding peptides did not show 
production of other cytokines by virus-specific T cells. No correlation was observed between 
the phenotype or viral protein recognized by the CD8+ T cells, and their cytokine 
production or degranulation upon activation (data not shown). 
These results demonstrate that the T cells specific for the different viral proteins produced 
both IFNγ and TNFα upon activation, while the populations varied in production of IL-2, 
degranulation, and expression of phenotypic markers. It appeared that CMV-specific CD8+ 
T cells had a more differentiated phenotype. However, no differences were observed in 
cytokine production or degranulation between the T cells specific for the different viruses. 
 
Kinetics of IFNγ production by virus-specific T cells 
Since nearly all virus-specific T cells produced IFNγ upon stimulation and the IFNγ-based 
isolation method is clinical grade available, the kinetics of IFNγ production were 
investigated to determine whether the different CD8+ and CD4+ T cell populations can be 
isolated simultaneously. IFNγ production kinetics were analyzed following stimulation of 
PBMC directly ex vivo with minimal MHC I or II binding peptides corresponding to known 
CMV, EBV, HAdV and FLU epitopes. When no minimal MHC binding peptides were 
available for stimulation of virus-specific T cells, 15-mer peptide pools were used, which 
were previously shown to induce IFNγ production with similar kinetics [26]. Real-time 
kinetic analysis after stimulation of PBMC with minimal MHC I binding CMV or EBV 
peptides showed a rapid decrease in peptide-MHC tetramer staining, which coincided with 
the induction of IFNγ production by CMV- or EBV-specific CD8+ T cells. Production of IFNγ 
was maximal 4 hours after stimulation and rapidly decreased thereafter (Figure 2A-C). In 













after stimulation with minimal MHC I binding FLU peptide, which transiently decreased 
after 24 hours of stimulation, but continued up to 48 hours after stimulation (Figure 2D-E). 
The frequencies of HAdV-specific CD8+ T cells in PBMC were not sufficiently high to 
analyze kinetics of IFNγ production. 
 
 
Figure 2. Kinetics of IFNγ production by virus-specific CD8+ T cells. Real-time intracellular IFNγ staining, with 
addition of BFA only during the last 2 hours of incubation, after stimulation of PBMC for 0, 2, 4, 8, 24, and 48 hours (A) 
with HLA-B35 restricted EBV-BZLF1-EPL peptide, (B) with minimal MHC class I binding CMV peptides (n=13), (C) 
with minimal MHC class I binding EBV peptides (n=9), (D) with HLA-A2 restricted FLU-MP-GIL peptide, or (E) with 
minimal MHC class I binding FLU peptides or FLU peptide pools (n=6). In (B/C/E), the frequency of IFNγ-positive T 
















In line with the results from CD8+ T cells, CMV-specific CD4+ T cells showed a rapid 
induction of IFNγ production after stimulation with minimal MHC II binding peptides or 
CMV peptide pools, which peaked 4 hours after stimulation, and decreased thereafter 
(Figure 3A-B). After stimulation with the HAdV hexon peptide pool, HAdV-specific CD4+ T 
cells showed a slower induction of IFNγ production, which continued up to 48 hours after 
stimulation (Figure 3C-D). The frequencies of EBV- and FLU-specific CD4+ T cells in PBMC 
were not sufficiently high for kinetic analysis of IFNγ production.  
These kinetic measurements illustrate a difference in kinetics of IFNγ production between T 
cells specific for the persistent viruses CMV and EBV, showing rapid and brief IFNγ 
production following activation, and T cells specific for HAdV and FLU which are not 
repetitively activated in vivo after initial infection, showing a more prolonged IFNγ 
production. Despite these kinetic differences, our data suggest that the majority of virus-

















Figure 3. Kinetics of IFNγ production by virus-specific CD4+ T cells. Real-time intracellular IFNγ staining, with 
addition of BFA only during the last 2 hours of incubation, after stimulation of PBMC for 0, 2, 4, 8, 24, and 48 hours (A) 
with HLA-DR4 restricted CMV-pp65-IIK peptide, (B) with minimal MHC class II binding CMV peptides or CMV 
peptide pool (n=4), or (C) and (D) with HAdV 5 hexon peptide pool (n=5). In (B/D), the frequency of IFNγ-positive T 















Kinetics of CD137 expression by virus-specific T cells 
To investigate whether CD8+ and CD4+ T cells specific for different viruses can also be 
isolated from PBMC based on activation-induced CD137 expression, the expression and 
kinetics of CD137 after stimulation of T cells specific for CMV, EBV, HAdV, and FLU were 
determined. As shown for a representative example in Figure 4A, virus-specific CD8+ T cells 
expressed high levels of CD137 following peptide stimulation of PBMC directly ex vivo. 
Tetramer-positive CD8+ T cells expressed CD137 at day 1 after stimulation, but only part of 
the specific T cells could be discerned due to a decrease in tetramer staining. The expression 
of CD137 was shown to be maximal at day 2, and slowly decreased thereafter. As shown in 
Figure 4B, similar results were obtained for the CD8+ T cell populations specific for epitopes 
derived from CMV, EBV, HAdV, and FLU proteins (Table 1), demonstrating very low 
background CD137 expression before stimulation (day 0), and maximal mean fluorescence 
intensity (MFI) of CD137 staining at day 2 after stimulation. No CD137 MFI values are 
reported for day 1, since discrimination of specific T cells was not sufficient in most samples 
due to the decrease in tetramer staining. 
Due to the lack of functional peptide-MHC class II tetramers, the specific expression of 
CD137 can not be analyzed for most virus-specific CD4+ T cell populations. The CMV pp65-
ALP-DR1 and FLU HA-PKY-DR4 tetramers were available to stain virus-specific CD4+ T 
cells. However, the frequency of CD4+ T cells specific for these epitopes was not high 
enough for the analysis of CD137 expression in PBMC directly ex vivo. Therefore, a CMV 
pp65-ALP-specific CD4+ T cell clone was diluted in a PBMC background to analyze CD137 
expression. After peptide stimulation, the CMV-specific CD4+ T cells showed CD137 
expression, which also peaked at day 2, and decreased thereafter (Figure 4C). To investigate 
CD137 expression by virus-specific CD4+ T cells following stimulation of PBMC directly ex 
vivo, staining of CD4, CD25 and CD137 was performed to discern the specifically activated 
CD4+ T cells. As shown in Figure 4D, following stimulation of donor PBMC directly ex vivo 
with MHC II binding peptide KYQ, activated CD4+ T cells (CD25+CD137+) could be clearly 
observed from day 1 after stimulation. All CD137+CD4+T cells expressed high levels of 
CD25, indicating that these were the activated KYQ-specific CD4+ T cells, while most 
CD4+CD137- T cells did not express CD25. Similar results were obtained after stimulation of 
other CMV- and HAdV-specific CD4+ T cell populations (n=7, data not shown). 
These data demonstrate that both CD8+ and CD4+ T cell populations recognizing the 
different viruses expressed CD137 upon antigen-specific stimulation, with uniform kinetics 
that resulted in maximal CD137 expression at day 1 to 2 after activation. Therefore, it is 
likely that the majority of virus-specific CD8+ and CD4+ T cells can also be simultaneously 














Figure 4. Kinetics of CD137 expression by virus-specific T cells. (A) Representative example of CD137 and tetramer 
staining of CD8+ T cells specific for CMV-pp65-IPS-B35 in donor PBMC and (B) the mean fluorescence intensity (MFI) 
of CD137 staining of peptide-MHC tetramer-positive CD8+ T cell populations (n=28) specific for CMV, EBV, HAdV, or 
FLU epitopes in donor PBMC before stimulation, and 2, 3, and 4 days after stimulation with minimal MHC I binding 
peptides (Table 1). Horizontal lines mark the median. (C) Representative example of CD137 and tetramer staining of a 
CD4+ T cell clone specific for CMV-pp65-ALP-DR1 mixed in PBMC as background before stimulation and 1, 2, 3, and 4 
days after stimulation with the specific CMV-pp65 peptide. (D) Representative example of CD137 and CD25 staining 
of donor PBMC before stimulation, and 1, 2, 3, and 4 days after stimulation with HLA-DR52 binding CMV-pp65-KYQ 














Comparison between IFNγ-based and CD137-based isolation of virus-specific T cells  
Since production of IFNγ and expression of CD137 was observed following stimulation of all 
virus-specific CD8+ and CD4+ T cells, both IFNγ-based and CD137-based enrichment may 
be used for isolation of CD8+ and CD4+ T cells specific for multiple viral antigens. To define 
the optimal procedure for isolation of different virus-specific CD8+ and CD4+ T cell 
populations, the efficiency of IFNγ-based and CD137-based isolation was compared at 
different time-points after activation. Donor PBMC were stimulated with a minimal MHC 
class I or II binding peptide derived from CMV, EBV, or FLU, followed by IFNγ-based or 
CD137-based isolation after 4, 24, 48, or 96 hours. After 8 days of subsequent culturing, 
peptide-MHC tetramer staining was performed to detect the frequencies of peptide-specific 
CD8+ or CD4+ T cells in the enriched and depleted fractions. An example of IFNγ-based 
isolation of virus-specific CD8+ T cells is depicted in Figure 5A, showing high frequencies of 
FLU-specific CD8+ T cells in the fractions isolated after 4, 24, or 48 hours of stimulation, 
while a lower frequency of specific T cells was observed in the fraction isolated after 96 
hours of stimulation. Figure 5B shows the corresponding fractions after CD137-based 
isolation, with a low frequency of FLU-specific CD8+ T cells in the fraction isolated after 4 
hours of stimulation, and high frequencies of specific T cells in the fractions isolated after 24, 
48, or 96 hours of stimulation. Both the IFNγ-depleted and CD137-depleted fractions 
contained low frequencies of residual peptide-specific CD8+ T cells. As shown in 
Figure 5C-D, both IFNγ-based and CD137-based isolation resulted in enrichment of virus-
specific CD4+ T cells as well. The highest frequencies of CMV-specific CD4+ T cells in both 
IFNγ-enriched fractions and CD137-enriched fractions were observed after 48 or 96 hours of 
stimulation (Figure 5C-D). The IFNγ-depleted and CD137-depleted fractions contained low 
frequencies of residual peptide-specific CD4+ T cells. The results of IFNγ-based and CD137-
based isolation of 6 different virus-specific CD8+ and CD4+ T cell populations are 
summarized in Figure 5E-F. The highest frequencies of virus-specific CD8+ and CD4+ T cells 
were observed after 24 or 48 hours of peptide stimulation followed by either IFNγ-based or 
CD137-based isolation (Figure 5E). Consistently, the highest absolute numbers of virus-
specific CD8+ and CD4+ T cells were observed in these isolated fractions (Figure 5F). All 
samples were analyzed following the same time interval after initial stimulation, and also 
following the same time interval after isolation, to compensate for differences in the length 
of initial stimulation (4 to 96 hours). Similar results were obtained, indicating that the 
differences observed resulted from differences in isolation efficiency and did not result from 
differences in culture period. The modest frequencies of specific CD4+ T cells after isolation 
may be explained by the very low frequencies of CD4+ T cells specific for these selected 













These data demonstrate that stimulation of donor PBMC with viral peptides for 24 or 48 
hours followed by either IFNγ-based or CD137-based enrichment can be used for the 
efficient isolation of CD8+ and CD4+ T cells specific for multiple viral epitopes. 
 
 
Figure 5. Comparison between IFNγ-based and CD137-based isolation of virus-specific T cells. Donor PBMC were 
stimulated for 4, 24, 48, or 96 hours with minimal MHC I binding CMV-pp65-NLV, EBV-BZLF1-RAK, or FLU-MP-GIL 
peptide, or MHC II binding CMV-pp65-ALP or FLU-HA-PKY peptide, followed by IFNγ-based isolation or CD137-
based isolation. After 8 days of culture, the frequency of peptide-specific CD8+ or CD4+ T cells was determined by 
peptide-MHC tetramer staining in the enriched and depleted fractions. (A) Example of the tetramer-staining of FLU-
MP-GIL-A2-specific CD8+ T cells after 8 days of culture of the IFNγ-enriched and IFNγ-depleted fractions, and (B) of 
the CD137-enriched and CD137-depleted fractions. (C) Example of the tetramer-staining of CMV-pp65-ALP-DR1-
specific CD4+ T cells after 8 days of culture of the IFNγ-enriched and IFNγ-depleted fractions, and (D) of the CD137-
enriched and CD137-enriched fractions. (E) The frequency and (F) absolute number of peptide-specific CD8+ T cells 
(circles) or CD4+ T cells (triangles) after 8 days of culture in the IFNγ-enriched fractions (open symbols) or CD137-
















Generation of multivirus-specific CD8+ and CD4+ T cell lines 
Since separate CD8+ and CD4+ T cell populations specific for viral epitopes were efficiently 
isolated, we next investigated whether CD8+ and CD4+ T cells specific for epitopes from 
multiple viral proteins could be isolated simultaneously. PBMC from 4 healthy CMV- and 
EBV-seropositive donors were stimulated with a combination of 3 peptide pools spanning 
viral proteins derived from CMV, EBV, HAdV, or FLU. After 24 or 48 hours of incubation, 
IFNγ-based or CD137-based isolation was performed, and the enriched fractions were 
cultured with IL-2 and IL-15. After 8 days of culture, the T cell lines contained 44-94% CD8+ 
T cells and 1-33% CD4+ T cells. The specificity of the T cell lines was analyzed by staining 
with peptide-MHC tetramers for immunodominant viral epitopes (Table 1) and by 
intracellular cytokine staining upon restimulation with the viral protein-spanning peptide 
pools. The overall specificity of the T cell lines was high, since a median of 84% of CD8+ T 
cells (range 56-100%) and 46% of CD4+ T cells (range 29-84%) were specific for the 3 viral 
proteins. As shown in Figure 6A-D, no significant differences in frequencies of virus-specific 
CD8+ and CD4+ T cells were observed between the T cell lines generated by IFNγ-based or 
CD137-based isolation after 24 or 48 hours of incubation. Although dominant virus-specific 
T cell populations were present in the T cell lines, CD8+ and CD4+ T cells specific for each of 
the 3 viral proteins could be detected. For example, the T cell lines described in Figure 6C 
contained predominantly CMV-specific CD8+ T cells directed against CMV pp65-NLV-A2 
and CMV pp65-IPS-B35, but smaller populations of CD8+ T cells specific for EBV EBNA1-
HPV-B35 and HAdV hexon-MPN-B35 could also be detected (Figure 6E). Likewise, the T 
cell lines described in Figure 6D contained mainly EBV-specific CD8+ T cells directed 
against EBV BZLF1-EPL-B35, but other CD8+ T cell populations were specific for EBV 
EBNA1-HPV-B35 and EBV EBNA3A-YPL-B35 (Figure 6F). Furthermore, no functional 
differences were observed between T cells isolated based on IFNγ or CD137 after 24 or 48 
hours of incubation (Figure 6G). Specific T cells produced IFNγ and part of the cells 
additionally produced TNFα, IL-2 or showed degranulation by surface expression of 
CD107a, which was similar to the T cells in the starting material. Low frequencies of 
residual virus-specific CD8+ and CD4+ T cells were detected in the IFNγ-depleted and 
CD137-depleted fractions. 
These data demonstrate that stimulation of donor PBMC with viral protein-spanning 
peptide pools followed by either IFNγ-based or CD137-based enrichment can be used to 
generate T cell lines for adoptive immunotherapy containing high frequencies of CD8+ and 















Figure 6. Generation of multivirus-specific CD8+ and CD4+ T cell lines. (A-D) PBMC from 4 healthy donors were 
stimulated for 24 or 48 hours with 15-mer peptide pools spanning 3 proteins derived from CMV, EBV, HAdV, or FLU, 
followed by IFNγ-based isolation or CD137-based isolation. After 8 days of culture, the frequency of T cells specific for 
each of the 3 viral proteins was determined by peptide-MHC tetramer staining and by intracellular IFNγ-staining upon 
restimulation with the viral peptide pools. The frequency of specific cells among CD8+ T cells (open symbols) and 
among CD4+ T cells (black symbols) are shown for each of the 3 viral proteins. (E-F) Peptide-MHC tetramer staining of 
multiple virus-specific CD8+ T cell populations in the T cell lines shown in (C-D), generated by CD137-based isolation 
after 48 hours of stimulation. (G) Intracellular staining of IFNγ, TNFα, IL-2, and surface CD107a staining without 
restimulation and after EBV BZLF1 peptide pool restimulation of the T cell lines shown in (D), generated by IFNγ-















In this study, we developed an efficient method for the simultaneous isolation of CD8+ and 
CD4+ T cells specific for a broad repertoire of viral antigens from peripheral blood, which 
may be used for adoptive transfer to alloSCT recipients to provide antiviral immune 
reconstitution. To ensure that the method was applicable to a wide variety of virus-specific 
T cells that may differ in phenotypic and functional properties, we focused on T cells 
specific for the persistent viruses CMV and EBV, as well as T cells specific for HAdV and 
FLU, which are not repetitively activated in vivo after initial viral clearance. Phenotypic 
analysis of the different virus-specific CD8+ T cells showed heterogeneous CD8+ T cell 
populations, containing diverse T cell subsets. The CMV-specific CD8+ T cell populations 
contained more CD27- and CD28- T cells compared to EBV-, HAdV- and FLU-specific CD8+ 
T cells. Functional analysis did not show a correlation between the phenotype or specificity 
of the CD8+ T cells and their functional profile. Nearly all virus-specific CD8+ and CD4+ T 
cells produced both IFNγ and TNFα upon activation. However, differences were observed 
in the kinetics of IFNγ production upon activation, which appeared to correlate with 
specificity. CMV- or EBV-specific T cells showed a rapid and brief IFNγ production, while T 
cells specific for HAdV or FLU showed a more prolonged IFNγ production. The more 
differentiated phenotype of CMV-specific T cells is consistent with previously published 
data, and may result from frequent antigenic activation in vivo due to viral reactivations 
[38]. Likewise, the difference in kinetics of IFNγ production may result from the repetitive 
antigenic activation of CMV- and EBV-specific T cells in vivo due to viral persistence, while 
HAdV- and FLU-specific T cells are not repetitively activated in vivo. 
Both CD8+ and CD4+ virus-specific T cells were shown to express high levels of CD137 after 
antigen-specific activation. The kinetics of CD137 expression was uniform, with CD137 
expression from 24 hours to more than 96 hours after stimulation, and peak expression at 48 
hours after stimulation. Previous studies have reported maximal CD137 expression on 
cultured T cell lines and clones recognizing various antigens after 24 hours of stimulation, 
which decreased thereafter [32,34,35]. In contrast to these studies, we analyzed CD137 
expression on virus-specific T cells activated in PBMC directly ex vivo, which may explain 
the difference in CD137 kinetics observed. Although it has been previously shown that 
CD4+ T cells specific for CMV pp65 could be isolated based on CD137 expression [33], 
another study has reported very low CD137 expression on activated CD4+ T cells specific for 
EBV EBNA1, which was not sufficient for isolation [34]. We here demonstrated high levels 
of CD137 expressed by CMV- and HAdV-specific CD4+ T cells following activation. The 













analysis of CD137 expression directly ex vivo. However, CD137-based isolation of virus-
specific CD4+ T cells confirmed CD137 expression by CD4+ T cells specific for CMV, EBV, 
HAdV, and FLU epitopes, including epitopes derived from the EBV EBNA1 protein. 
Based on the analysis of IFNγ production and CD137 expression, we anticipated efficient 
isolation of the virus-specific CD8+ and CD4+ T cell populations using either IFNγ-based or 
CD137-based isolation, although CD137-based isolation might be superior due to more 
uniform kinetics. Indeed, both methods of enrichment resulted in high frequencies and 
absolute numbers of virus-specific T cells in the isolated fractions. CD137-based isolation 
was most efficient after 24 or 48 hours of stimulation, which was consistent with the kinetics 
of CD137 expression. However, IFNγ-based isolation also resulted in highest frequencies 
and numbers of virus-specific T cells in the isolated fractions after 24 or 48 hours of 
stimulation, while the kinetic analysis showed maximal IFNγ production after 4 to 8 hours 
of stimulation for most T cell populations. The detection of IFNγ production by intracellular 
staining has previously been shown to be synchronous with the detection of IFNγ secretion 
by the IFNγ capture assay, which is used for IFNγ-based isolation [31]. Apparently, the 
virus-specific T cells that produce IFNγ after 24 to 48 hours are the cells that can be 
expanded most efficiently, providing high numbers of virus-specific T cells in the final 
product. Although, both IFNγ-based and CD137-based isolation were demonstrated to result 
in efficient enrichment of CD8+ and CD4+ T cells specific for multiple viral epitopes from 
peripheral blood, the simple CD137 labeling procedure has a logistic advantage over the 
more laborious IFNγ labeling procedure. This may save costs of training personnel and of 
reagents and may make the treatment strategy more widely applicable. However, only 
IFNγ-based isolation is currently available for the generation of clinical grade virus-specific 
T cell lines. 
Previous studies have used EBV-LCL transduced with cDNA encoding additional viral 
proteins as stimulator cells to generate multivirus-specific T cell lines [13,28,39,40]. Although 
the different approaches can not be directly compared, the efficiency of isolation of CD8+ 
and CD4+ T cell populations against multiple viral proteins using the method described in 
this study appears to be at least similar. The availability of clinical grade synthetic protein-
spanning pools of overlapping peptides and IFNγ-based or CD137-based isolation kits will 
allow the generation of T cell lines with high specificity against multiple viral proteins in a 
large number of treatment centers. 
This study provides an efficient and widely applicable method for the simultaneous 
isolation of both CD8+ and CD4+ T cells specific for a broad repertoire of antigens from 
multiple viral pathogens from donor peripheral blood. These multivirus-specific T cell lines 














Alternatively, selected viral protein-spanning peptide pools can be used for isolation and 
adoptive transfer of CD8+ and CD4+ T cells specific for a single virus for treatment of 
refractory viral disease after alloSCT. 
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Synthetic long peptides that contain immunogenic T cell epitopes have been used to induce 
activation of antigen-specific CD8+ T cells in vitro for immune monitoring or adoptive 
transfer, or in vivo following peptide vaccination. However, the efficiency and mechanisms 
of presentation of exogenous long peptides in HLA class I remain to be elucidated. In this 
study, we demonstrated that the efficiency of antigen-specific CD8+ T cell activation using 
extended peptide variants of common viral epitopes is variable. We demonstrated that 
processing and HLA class I presentation of the long peptides was not dependent on the 
proteasome and TAP, illustrating that the classical route of HLA class I presentation was not 
required for activation of specific CD8+ T cells by exogenous synthetic long peptides. 
Although long peptides were shown to bind to the relevant HLA class I molecules, peptide 
trimming was likely to be essential for optimal HLA class I presentation and T cell 
activation. Since the proteasome was not required for processing of exogenous peptides, it is 
very likely that peptide trimming was mediated by peptidases, which may be located either 
extracellularly at the cell surface, or in endosomal compartments. Furthermore, the results 
suggested that processing of the correct minimal peptides was facilitated by binding in HLA 
class I molecules. This mechanism of HLA-guided processing may be important in HLA 















The availability of labeled peptide-HLA class I multimers has facilitated the detection of 
antigen-specific CD8+ T cells in peripheral blood mononuclear cells (PBMC) for immune 
monitoring, as well as the isolation of antigen-specific CD8+ T cells from PBMC for adoptive 
immunotherapy [1,2]. However, this technique requires knowledge of the minimal HLA 
class I binding peptides recognized, and production of a large number of peptide-HLA 
multimers to cover CD8+ T cell responses directed against multiple epitopes. Furthermore, 
antigen-specific CD4+ T cells can not be identified using this method due to the lack of 
functional peptide-HLA class II multimers. To detect or isolate antigen-specific T cells 
without the need of knowing the exact epitopes, stimulation of PBMC with whole proteins 
can be performed, after which the responding T cells can be identified based on their 
activation-induced effector functions. Following antigen-specific stimulation, activated T 
cells are routinely detected by analysis of cytokine production using intracellular staining, 
surface mobilization of the degranulation marker CD107a, expression of the co-stimulatory 
activation markers CD40L or CD137, or proliferation by dilution of dyes such as 
carboxyfluorescein diacetate succinimidyl ester (CFSE) [3-6]. Furthermore, isolation of 
antigen-specific T cells based on activation-induced IFNg production or CD40L or CD137 
expression is widely applied [7-9]. 
The use of whole proteins for stimulation of PBMC circumvents the need of knowing the 
exact epitopes, and may induce activation of antigen-specific CD8+ and CD4+ T cells 
irrespective of the HLA type. In contrast to the use of full-length recombinant proteins, 
pools of overlapping synthetic long peptides consisting of 15-20 amino acids have been 
demonstrated to efficiently induce activation of both CD8+ and CD4+ antigen-specific T cells 
in PBMC [10-14]. Currently, a wide variety of overlapping peptide pools spanning whole 
infectious and tumor-associated proteins is being used for the detection and isolation of 
CD8+ and CD4+ antigen-specific T cells [11-20]. The processing of exogenous antigen 
followed by presentation in HLA class II has been extensively described, and the 
exogenously added long peptides may also directly bind in HLA class II molecules at the 
cell surface [21]. However, the pathways that lead to processing and presentation of 
exogenously added long peptides in HLA class I are not clear. 
Synthetic long peptides have also been used to induce or boost antigen-specific T cell 
responses in vivo by peptide vaccination. Superior in vivo CD8+ T cell responses have been 
reported following vaccination with long peptides compared with the corresponding 
minimal HLA class I binding peptides, which was attributed to selective uptake, processing, 














presentation of long peptides in the stimulatory context of activated professional APCs in 
the draining lymph node was suggested to result in optimal induction of a specific CD8+ T 
cell response. In contrast, vaccination with minimal HLA class I binding peptides resulted in 
systemic presentation by non-professional APCs, and suboptimal development of specific 
CD8+ T cells. A tolerizing effect of vaccination with minimal HLA class I binding peptides 
has been described before [26]. Although these data suggest that long peptides are 
preferentially processed and presented by professional APCs, it has been demonstrated that 
exogenous long peptides can also be presented in HLA class I by non-professional APCs 
[27]. The capacity to internalize, process, and present synthetic long peptides has not been 
directly compared between different types of APC. The mechanisms that result in HLA class 
I presentation in vivo after vaccination with long peptides remain to be elucidated [28]. 
Various mechanisms explaining the presentation of exogenous long peptides in HLA class I 
molecules have been proposed. Elution of endogenously synthesized and processed 
peptides from surface HLA class I molecules has demonstrated the presentation of different 
length variants of minimal HLA class I binding motifs extended at the N- or C-terminus, 
indicating that some long peptide variants may directly bind in HLA class I [29-33]. Long 
peptides that bind in HLA class I molecules have been shown to adapt a centrally bulged 
conformation, or to protrude from one side of the peptide binding groove [34-38]. 
Furthermore, degradation of exogenous long peptides by serum peptidases or membrane-
bound peptidases may allow extracellular binding of trimmed peptides to cell surface HLA 
class I molecules [39-42]. Binding of long peptides in HLA class I molecules and peptidase 
editing can also occur simultaneously. The binding of long peptide variants in HLA class I 
may even facilitate the processing of the correct minimal peptide bound in the HLA class I 
groove, which has been described before as the model of HLA-guided processing [43]. 
Alternatively, following uptake of exogenous long peptides, transport over endosomal 
membranes to the cytosol may result in the classical route of presentation which is 
dependent on proteasomal degradation and the transporter associated with antigen 
processing (TAP) [44]. Internalized peptides may also enter endosomal compartments which 
have fused with the endoplasmic reticulum (ER), and therefore contain the machinery for 
peptide loading of HLA class I molecules [45]. Finally, entrance of HLA class I molecules in 
the recycling endocytic HLA class II pathway has been demonstrated to allow exchange 
with exogenous peptides, which can be edited by endosomal peptidases [46-49].  
In this study, we demonstrated that the efficiency of CD8+ T cell activation by several 
extended variants of minimal HLA class I binding peptides was highly variable. Since 
processing and HLA class I presentation was demonstrated not to be dependent on the 













was not required for activation of specific CD8+ T cells by exogenous synthetic long 
peptides. Although long peptides were shown to bind to the relevant HLA class I molecules, 
peptide trimming was likely to be required for optimal HLA class I presentation and T cell 
activation. The results indicated that HLA-guided processing may be important in HLA 
class I presentation of exogenous long peptides to allow activation of specific CD8+ T cells. 
 
Materials and methods 
Synthetic peptides 
Minimal HLA class I binding peptides corresponding to previously described 
cytomegalovirus (CMV) epitopes were synthesized. In addition, extended peptide variants 
of these minimal HLA class I binding peptides were constructed by addition of 6 naturally 
flanking amino acids at the N-terminal end, at the C-terminal end, or at both ends. Peptide 
sequences are shown in Table 1. The peptides were synthesized using standard solid-phase 
strategies (Department of Immunohematology and Blood Transfusion, Leiden University 
Medical Center, Leiden, The Netherlands).  
 
T cells and antigen-presenting cells 
After informed consent, peripheral blood was obtained from healthy CMV-seropositive 
individuals, and mononuclear cells (PBMC) were isolated by Ficoll-Isopaque separation. To 
generate CMV peptide-specific CD8+ T cell lines, peptide-HLA class I tetramers containing 
minimal CMV peptide were used to stain CMV-specific CD8+ T cells in donor PBMC. 
Subsequently, the CMV peptide-HLA tetramer-positive CD8+ T cells were selected by flow 
cytometric sorting using a FACSDiva and Cellquest software (BD Biosciences, San Jose, CA, 
USA). The peptide-specific CD8+ T cells were cultured in culture medium, consisting of 
Iscove’s modified Dulbecco’s medium (IMDM, Lonza, Basel, Switzerland) supplemented 
with 5% pooled human serum, 5% fetal calf serum (Lonza), 100 U/ml 
penicillin/streptomycin (Lonza), 3 mM L-glutamine (Lonza), and 100 IU/ml IL-2 (Chiron, 
Amsterdam, The Netherlands). Stable Epstein-Barr virus (EBV)-transformed B cell lines 
(EBV-LCL) were generated using standard procedures [50]. The transporter associated with 
antigen processing (TAP)-competent T1 and TAP-deficient T2 cell lines were obtained from 















Table 1. Minimal peptides and extended peptide variants with 6 naturally flanking amino acids at the N-terminal end 
(6-PEP), at the C-terminal end (PEP-6), or at both ends (6-PEP-6). 
Source protein HLA-restriction   Peptide                         Sequence 
CMV pp65 HLA-A1   YSE 
6-YSE 
  YSE-6 
6-YSE-6 
      YSEHPTFTSQY 
LQRGPQYSEHPTFTSQY 
      YSEHPTFTSQYRIQGKL 
LQRGPQYSEHPTFTSQYRIQGKL 
CMV pp65 HLA-A2   NLV 
6-NLV 
  NLV-6 
6-NLV-6 
      NLVPMVATV 
AGILARNLVPMVATV 
      NLVPMVATVQGQNLK 
AGILARNLVPMVATVQGQNLK 
CMV IE1 HLA-A2   VLE 
6-VLE 
  VLE-6 
6-VLE-6 
      VLEETSVML 
RVLCCYVLEETSVML 
      VLEETSVMLAKRPLI 
RVLCCYVLEETSVMLAKRPLI 
CMV pp65 HLA-B7   TPR 
6-TPR 
  TPR-6 
6-TPR-6 
      TPRVTGGGAM 
VTTERKTPRVTGGGAM 
      TPRVTGGGAMAGASTS 
VTTERKTPRVTGGGAMAGASTS 
CMV pp65 HLA-B7   RPH 
6-RPH 
  RPH-6 
6-RPH-6 
      RPHERNGFTVL 
NPQPFMRPHERNGFTVL 
      RPHERNGFTVLCPKNMI 
NPQPFMRPHERNGFTVLCPKNMI 
CMV IE1 HLA-B8   ELR 
6-ELR 
  ELR-6 
6-ELR-6 
      ELRRKMMYM 
ARAKKDELRRKMMYM 
      ELRRKMMYMCYRNIE 
ARAKKDELRRKMMYMCYRNIE 
CMV IE1 HLA-B8   QIK 
6-QIK 
  QIK-6 
6-QIK-6 
      QIKVRVDMV 
LAELVKQIKVRVDMV 
      QIKVRVDMVRHRIKE 
LAELVKQIKVRVDMVRHRIKE 
 
Analysis of specific CD8+ T cell activation 
As stimulator cells, 1.0x103 to 3.0x104 EBV-LCL were loaded with 10-5 to 10-12 M peptide for 4 
hours in serumfree medium, consisting of IMDM supplemented with 2% human albumin 
(Octapharma, Langenfeld, Germany). Subsequently, the stimulator cells were incubated 
with 5.0x103 peptide-specific CD8+ T cells. After overnight incubation, supernatant was 
harvested and IFNγ production was analyzed by enzyme-linked immunosorbent assay 
(ELISA, CLB, Amsterdam, The Netherlands). The peptide concentration that resulted in half 
of the maximal IFNγ signal was defined as the half maximal effective concentration EC50. To 
analyze proteasome dependency, stimulator cells were incubated with 10-5 M lactacystin 














Mass spectrometry and HPLC fractionation  
Stock solutions of 10-2 M peptide in dimethylsulfoxide (DMSO, Lonza) were diluted to 10-12 
M and analyzed by high resolution mass spectrometry (LTQ-FT Ultra, Thermo, Bremen, 
Germany). In addition, peptides were purified by high-performance liquid chromatography 
(HPLC) as described before [53]. Briefly, peptide stock solutions were injected on a HPLC 
system (Agilent, Amstelveen, The Netherlands) and subjected to reversed-phase HPLC on a 
home-made 10 cm x 2.1 mm Reprosil-Pur C18-AQ 3 µm nano HPLC column (Dr. Maisch 
GmbH, Ammerbruch, Germany). A gradient from 20% to 60% acetonitrile containing 0.1% 
trifluoric acetic acid was run at 0.1 ml/min, while fractions of 1.0 minute were collected in 96 
wells plates. The collected HPLC fractions were loaded on EBV-LCL to analyze activation of 
peptide-specific CD8+ T cells. 
 
HLA class I binding assay 
The efficiency of peptide binding in HLA class I molecules was analyzed by competition 
between the test peptide and a fluorescently labeled reference peptide for binding HLA 
class I monomers as described before [54]. Briefly, 10-4 to 10-12 M test peptide and 10-10 M 
fluorescently labeled strongly binding reference peptide were added to HLA class I heavy 
chain and beta-2-microglobulin to allow folding of stable peptide-HLA monomers. Peptide-
HLA monomers were purified by size-exclusion chromatography and fluorescent signal 
was measured. The concentration of test peptide that resulted in a decrease of half of the 
fluorescent signal was defined as the half maximal inhibitory concentration IC50. 
 
Elution of peptides from HLA 
To verify the content of the HLA molecules in the stable peptide-HLA monomers, 200 pmol 
of peptide-HLA monomers were acidified with 10% acetic acid and peptides were separated 
from proteins by size-exclusion centrifugation (Amicon Ultrafree-MC 5 kDa, Millipore, 
Billerica, MA, USA). Peptide concentrates were injected on the reversed phase HPLC system 
run, while fractions of 0.5 minute (flow 0.2 ml/min) were collected in siliconized vials and 
stored at -80°C. The collected HPLC fractions were loaded on EBV-LCL to analyze activation 
of peptide-specific CD8+ T cells. To confirm peptide sequences by mass spectrometry, 
reactive fractions were injected on a home-made 20 cm x 50 µm Reprosil-Pur C18-AQ 3 µm 
nano HPLC column. Subsequently, the eluent was sprayed into the LTQ-FT Ultra mass 
spectrometer to acquire full scan mass spectra. The selected ions were then fragmented in 















Transduction of minigenes for analysis of endogenous peptide expression 
To allow endogenous expression of peptide sequences, retroviral vectors were constructed 
encoding the minimal or extended peptide variants listed in Table 1 fused to the C-terminus 
of ubiquitin, which results in efficient liberation of the exact peptide sequence as described 
previously [55,56]. Briefly, plasmid encoding for ubiquitin with SIINFEKL peptide fused to 
the C-terminus was kindly provided by Dr. J. Neefjes (Divison of Tumor Biology, The 
Netherlands Cancer Institute, Amsterdam, The Netherlands). From this template, 
oligonucleotides were produced using a ubiquitin forward primer and ubiquitin-
overlapping peptide-encoding reverse primers. These ubiquitin-peptide-encoding 
oligonucleotides were cloned into the retroviral MP71 vector, containing the truncated 
human nerve growth factor receptor (NGFR) selection marker gene linked by an IRES 
sequence, as described previously [57]. Retroviral vector supernatants were produced by 
transfecting packaging F-NX-A cells with retroviral vectors. Subsequently, EBV-LCL, T1, or 
T2 cells were transduced with retroviral vector supernatants. The cells were stained with 
PE-labeled NGFR monoclonal antibodies (BD) for 30 minutes at 4°C and the NGFR-positive 
















Activation of specific CD8+ T cells using synthetic long peptides 
To investigate the capacity of synthetic long peptides to induce activation of peptide-specific 
CD8+ T cells, extended peptide variants were produced of immunodominant minimal HLA 
class I binding peptides by addition of 6 naturally flanking amino acids to the N-terminal 
end, to the C-terminal end, or to both ends (Table 1). EBV-LCL were loaded with 10-5 to 10-12 
M of the minimal HLA class I binding peptides or the long peptide variants. The 
experiments were performed in serumfree medium to exclude peptide modification by 
serum peptidase activity. After 4 hours of incubation, peptide-specific CD8+ T cells were 
added at an effector to stimulator ratio of 1:6 for 16 hours, and the concentration of IFNγ was 
analyzed in supernatant to determine specific CD8+ T cell activation. As shown for the 
HLA-A2 restricted CMV pp65-derived NLV epitope in Figure 1A, the minimal HLA class I 
binding peptide NLV was most efficient in CD8+ T cell activation, resulting in half of 
maximal IFNg signal at a peptide concentration of 2.4x10-10 M, which was defined as the half 
maximal effective concentration EC50. The N-terminally extended peptide 6-NLV was 
slightly less efficient in CD8+ T cell activation, with a 10-fold increase of the EC50 to 2.4x10-9 
M. Extending the minimal peptide with 6 amino acids at the C-terminus or at both ends 
(NLV-6 or 6-NLV-6) resulted in a low efficiency of CD8+ T cell activation, as indicated by a 
4,000- and 25,000-fold (EC50 1.0x10-6 M and 5.9x10-6 M)  increase of the EC50 compared to the 
minimal peptide, respectively. 
The results for 7 viral epitopes are depicted in Figure 1B, showing a large variability in the 
efficiency of CD8+ T cell activation after incubation with the extended peptide variants, 
ranging from efficiencies that are similar to the minimal peptide (for example 6-YSE: no 
increase in EC50) to very low activation efficiencies (for example 6-ELR-6: 75,000-fold 
increase in EC50). For each epitope tested, the N-terminally extended peptide induced CD8+ 
T cell activation more efficiently compared to the C-terminally extended peptide, and the 
peptides extended at both ends showed lowest efficiency of T cell activation. These data 
demonstrate that all extended peptide variants of HLA class I binding epitopes could result 
in activation of specific CD8+ T cells. However, the efficiency of CD8+ T cell activation was 
highly variable, and appeared to be better for N-terminally extended peptides than for C-

















Figure 1. Activation of peptide-specific CD8+ T cells with minimal and N- and C-terminally extended peptides. (A) 
The concentration of IFNγ in supernatant is shown after incubation of NLV-specific CD8+ T cells with EBV-LCL loaded 
with 10-5 to 10-12 M of the HLA-A2 binding peptide NLV and extended NLV peptide variants. The curves were used to 
determine the half maximal effective concentration EC50 for each peptide variant. (B) The EC50 values for peptide 
variants corresponding to 7 viral epitopes are presented as compared to the EC50 value of the minimal peptide. 
 
Absence of contaminating shorter peptide fragments 
To exclude the possibility that contaminating shorter peptide fragments, which may have 
been produced during peptide synthesis, contributed to the activation of the antigen-specific 
CD8+ T cells, the presence of shorter peptides in the stock solutions of the extended peptide 
variants was investigated. Analysis by high resolution mass spectrometry demonstrated 
that all stock solutions contained the correct peptide sequences. No traces of minimal 
peptide were detected in any of the extended peptide stock solutions (data not shown). 
To confirm that the extended peptides could induce CD8+ T cell activation, the minimal and 













fractions were collected to analyze CD8+ T cell reactivity. As shown in Figure 2A, the 
minimal peptide NLV eluted after 45 minutes, and was collected in fraction 14 and 15. After 
loading of the eluted fractions on HLA-A2-positive EBV-LCL, fractions 14 and 15 were 
recognized by NLV-A2-specific CD8+ T cells (Figure 2C). As shown in Figure 2B, the N-
terminally extended peptide 6-NLV eluted after 49 minutes, and was collected in fraction 20. 
Figure 2D shows that EBV-LCL loaded with fraction 20 were indeed recognized by NLV-
A2-specific CD8+ T cells. The presence of the correct sequences and the absence of shorter 
contaminating peptide fragments in the eluted fractions was confirmed by mass 
spectrometry (data not shown). These data demonstrate that CD8+ T cell activation resulted 
from stimulation with the synthetic long peptides, and was not due to the presence of 
contaminating shorter peptides. 
 
Figure 2. Absence of contaminating shorter peptide fragments. (A) Detection of the minimal peptide NLV and (B) the 
N-terminally extended peptide 6-NLV during fractionation on a HPLC system. (C) and (D) Recognition of the eluted 
fractions loaded on HLA-A2 positive EBV-LCL by NLV-specific CD8+ T cells as determined by the concentration of 
IFNγ in supernatant. 
 
Classical route of HLA class I peptide presentation 
To determine whether exogenously added long peptides were processed and presented in 
the classical route of HLA class I presentation, the roles of the proteasome and TAP were 
investigated. Minigenes were constructed encoding the minimal or extended peptide 














exact peptide sequence, as described previously [55,56]. To investigate the role of the 
proteasome in the presentation of the endogenously expressed peptides, the effect of the 
irreversible proteasome inhibitor lactacystin was analyzed [58]. As shown in Figure 3A, 
lactacystin profoundly inhibited CD8+ T cell activation by EBV-LCL which endogenously 
expressed the C-terminally extended NLV-6 or 6-NLV-6 peptide, as expected. In contrast, 
proteasome inhibition only marginally decreased CD8+ T cell activation by EBV-LCL which 
endogenously expressed the NLV or 6-NLV peptide. The slight decrease in activation was 
likely to represent a non-specific effect of lactacystin on the stimulator cells. To investigate 
the role of TAP in the presentation of the endogenously expressed peptides, the presentation 
of the endogenously expressed peptides was compared between TAP-competent T1 cells 
and TAP-deficient T2 cells. As shown in Figure 3B, CD8+ T cell activation by T2 cells 
expressing endogenous peptides 6-NLV, NLV-6, and 6-NLV-6 was significantly reduced or 
completely inhibited compared with T1 cells. CD8+ T cell activation by TAP-deficient T2 
cells expressing endogenous minimal peptide NLV was comparable to TAP-competent T1 
cells, which might be due to the large amount of peptide expressed after minigene 
transduction. These results demonstrated that endogenously expressed peptides that are 
extended at the C-terminus require proteasomal processing and that transport via TAP is 
required for HLA class I presentation of all endogenously expressed extended peptides. 
Subsequently, similar experiments were performed to investigate the role of the proteasome 
and TAP in the presentation of exogenously added peptides. The activation of CD8+ T cells 
by the exogenously added peptide variants (NLV, 6-NLV, NLV-6, 6-NLV-6) was only 
partially inhibited following lactacystin incubation (Figure 4A). As shown in Figure 4B, the 
activation of specific CD8+ T cells by TAP-deficient T2 cells loaded with all exogenously 
added peptides (NLV, 6-NLV, NLV-6, 6-NLV-6) was even increased compared to TAP-
competent T1 cells. These results indicate that, while the processing of endogenous C-
terminally extended peptides was dependent on proteasome activity, the processing of 
exogenous long peptides was predominantly independent of proteasome activity. 
Furthermore, while the presentation of endogenous peptides was dependent on 
transportation by TAP, the presentation of exogenous peptides was TAP-independent. Since 
processing and HLA class I presentation of exogenous peptides was not dependent on the 
proteasome and TAP, these data illustrated that the classical route of HLA class I 
















Figure 3. Role of proteasome and TAP in processing of endogenously expressed peptides. (A) The concentration of 
IFNγ in supernatant is shown after incubation of NLV-specific CD8+ T cells with 1.0x103 to 3.0x104 EBV-LCL 
transduced with minigenes encoding minimal peptide NLV or extended NLV peptide variants in the absence (white) 
or presence (black) of the proteasome inhibitor lactacystin. (B) The concentration of IFNγ in supernatant is shown after 
incubation of NLV-specific CD8+ T cells with 1.0x103 to 3.0x104 TAP-competent T1 cells (white) or TAP-deficient T2 















Figure 4. Role of proteasome and TAP in processing of exogenously added peptides. (A) The concentration of IFNγ in 
supernatant is shown after incubation of NLV-specific CD8+ T cells with 3.0x104 EBV-LCL loaded with 10-5 to 10-11 M 
minimal peptide NLV or extended NLV peptide variants in the absence (white) or presence (black) of the proteasome 
inhibitor lactacystin. (B) The concentration of IFNγ in supernatant is shown after incubation of NLV-specific CD8+ T 
cells with 3.0x104 TAP-competent T1 cells (white) or TAP-deficient T2 cells (black) loaded with 10-5 to 10-11 M minimal 













Binding of long peptides in HLA class I 
Since the classical route of HLA class I presentation was not required for activation of 
specific CD8+ T cells, we next determined whether the synthetic long peptides could directly 
bind to HLA class I molecules or needed processing by other mechanisms to allow binding 
of the minimal peptides in the groove of HLA class I. The HLA class I binding capacity of 
the peptide variants was determined using a competition assay. As shown for the HLA-A2 
restricted NLV peptides in Figure 5A, the minimal peptide NLV was most efficiently bound, 
resulting in a decrease of half of the fluorescent signal at a peptide concentration that was 
30-fold higher than the concentration of fluorescent reference peptide, which was defined as 
the half maximal inhibitory concentration IC50. The N-terminally extended peptide 6-NLV 
was less efficient for binding in HLA-A2, with a 140-fold increase of the IC50 compared to 
the minimal peptide. Extending the minimal peptide with 6 amino acids at the C-terminus 
or at both ends (NLV-6 or 6-NLV-6) resulted in a low efficiency of HLA-A2 binding, as 
indicated by a 1,300- and 3,000-fold increase of the IC50 compared to the minimal peptide, 
respectively. 
The efficiency of HLA class I binding of the extended peptides variants containing the 7 
different epitopes is shown in Figure 5B. The binding efficiency of the long peptides was 
very variable, ranging from a similar binding efficiency compared to the binding of the 
minimal peptide (YSE-6: no increase in IC50) to very low efficiencies of binding (6-TPR-6: 
29,000-fold increase in IC50). For epitopes NLV, VLE, and QIK the N-terminally extended 
peptide showed the highest binding efficiency compared to the minimal peptide, while for 
epitopes YSE, TPR, RPH, and ELR the C-terminally extended peptide showed the highest 
binding efficiency. The peptides extended at both ends showed lowest binding efficiencies. 
For the extended peptide variants, no relation was observed between the efficiency of HLA 
binding and the efficiency of CD8+ T cell activation, as expressed by the IC50 and the EC50 
values (Figure 1B and 5B). Therefore, the data indicate that direct binding of long peptides 
in HLA class I is not sufficient for CD8+ T cell activation, and that peptide trimming is likely 















Figure 5. Binding of long peptides in HLA class I. (A) The fluorescent signal of a reference peptide strongly binding to 
HLA-A2 monomers is shown after incubation with different concentrations of the HLA-A2 binding peptide NLV and 
extended NLV peptide variants. The curves were used to determine the half maximal inhibitory concentration IC50 for 
each peptide variant. (B) The IC50 values for peptide variants corresponding to 7 viral epitopes are presented as 
compared to the IC50 value of the minimal peptide. (C) The IC50 values for the same minimal, N-terminally extended, 
C-terminally extended, and both N- and C-terminally extended peptides as in (B) are shown using the matched or 
mismatched HLA molecules. The p value is calculated by the Wilcoxon t-test for paired samples.  
 
We next assessed whether the binding of extended peptides in HLA class I molecules was 
based on specific binding of the minimal epitope sequence. For this purpose, the IC50 values 
of the peptides in the matched HLA class I molecule were compared with IC50 values using 
the same peptides in a mismatched HLA class I molecule. As shown in Figure 5C, the IC50 of 
the minimal peptides in the matched HLA class I molecules were low, and the IC50 of the 













(p=0.016). These measurements indicated specific binding of the minimal peptides in the 
matched HLA class I molecule, and a very low level of binding in the mismatched HLA 
class I molecule. Binding of the peptides extended at the N-terminus or C-terminus was also 
better in the matched HLA class I molecules compared to the mismatched HLA class I 
molecules, although the difference was only significant for C-terminally extended peptides 
and not for N-terminally extended peptides (p=0.016 and p=0.094, respectively), 
demonstrating specific interaction of the minimal epitope sequence in these extended 
peptides with the matched HLA class I molecule. However, binding of the peptides 
extended both at the N- and C-terminus was not statistically different in the matched and 
mismatched HLA class I molecules (p=0.813). Therefore, specific interaction between the 
minimal epitopes sequence in these N- and C-terminus extended long peptides and the 
matched HLA class I molecules could not be demonstrated. 
Since no relation was observed between the efficiency of HLA binding and the efficiency of 
CD8+ T cell activation for the extended peptide variants, we hypothesized that peptide 
trimming might have occurred to result in activation of specific CD8+ T cells. The extended 
peptides that showed the highest efficiency of HLA class I binding compared to minimal 
peptides were the N-terminally extended peptides 6-VLE and 6-QIK, and the C-terminally 
extended peptides YSE-6 and RPH-6, with a 1- to 10-fold increased IC50 compared to the 
corresponding minimal peptides (Figure 5B). To investigate whether these extended 
peptides were directly presented in HLA class I, we attempted to generate stable multimeric 
complexes of the long peptides in HLA class I molecules. The selected long peptides were 
added to the correct HLA class I heavy chain and beta-2-microglobulin to produce stable 
peptide-HLA monomers. Analysis by size exclusion chromatography showed that stable 
peptide-HLA monomers were formed for YSE-6-A1, 6-VLE-A2 and RPH-6-B7, while no 
stable complexes were detected for 6-QIK-B8. Fluorescently labeled streptavidin was added 
to the stable peptide-HLA monomers to produce fluorescent peptide-HLA tetramers, which 
showed specific staining of VLE-A2- and RPH-B7-specific CD8+ T cells, but no specific 
staining of YSE-A1-specific CD8+ T cells (data not shown). Subsequently, the peptides were 
eluted from the peptide-HLA monomers. Mass spectrometric analysis showed that both the 
initial extended YSE-6, 6-VLE, and RPH-6 peptides and various (partially) degraded 
peptides were detected (Table 2) The minimal immunogenic YSE, VLE, and RPH peptides 
were dominantly present in the elution fractions. These data indicate that the long peptides 
had been partly degraded to the minimal HLA binding peptides during the process of 
peptide-HLA tetramer production. Although long peptides were shown to bind to the 
relevant HLA class I molecules, peptide trimming was likely to be required for HLA class I 














Table 2. Mass spectrometric analysis of peptides eluted from peptide-HLA monomers formed with extended peptide 
variants with 6 naturally flanking amino acids at the N-terminal end (6-PEP) or at the C-terminal end (PEP-6). 
Peptide Sequence Charges detected Relative abundance 1) (%) 
Input: YSE-6 YSEHPTFTSQYRIQGKL 3+,4+ 38.1 
 YSEHPTFTSQYR 3+ 1.5 
Immunogenic 3) YSEHPTFTSQY 2+ 28.8 
Immunogenic 3) YSEHPTFTSQ 2+ 31.6 
Input: 6-VLE RVLCCYVLEETSVML Not detected 2) Not detected 2) 
   LCCYVLEETSMVL 2+ 1.9 
      YVLEETSMVL 1+,2+ 36.1 
Immunogenic 3)       VLEETSMVL 1+,2+ 61.3 
Input: RPH-6 RPHERNGFTVLCPKNMI 2+,3+,4+,5+ 7.9 
Immunogenic 3) RPHERNGFTVL 2+,3+,4+ 34.3 
Immunogenic 3) RPHERNGFTV 2+,3+,4+ 5.4 
 RPHERNGFT 2+,3+ 3.5 
 RPHERNGF 2+,3+ 46.3 
1) Relative abundance is expressed as percentage of total ion counts. Fragments with a relative abundance of more 
than 1% are presented. 
2) The input peptide 6-VLE could not properly be detected due to cystein-cystein interactions. 
3) These immunogenic peptides have been reported before as minimal peptides to efficiently induce activation of 
antigen-specific T cells. 
 
Discussion 
In this study, we demonstrated that the efficiency of antigen-specific CD8+ T cell activation 
using extended peptide variants of common viral epitopes can be highly variable, ranging 
from a similar efficiency compared to the minimal peptide to a 75,000-fold decreased 
efficiency. Processing and HLA class I presentation of the exogenous long peptides was 
demonstrated not to be dependent on the proteasome and TAP, illustrating that the classical 
route of HLA class I presentation was not required for activation of specific CD8+ T cells. 
Although long peptides were shown to bind to the relevant HLA class I molecules, peptide 
trimming was likely to be required for HLA class I presentation and T cell activation. Since 
the proteasome was not required for processing of the exogenous peptides, it is very likely 
that peptide trimming was mediated by peptidases, which may be located either 
extracellularly at the cell surface, or in endosomal compartments. 
The efficiency of CD8+ T cell activation by extended peptide variants may be an important 
factor in the design of strategies that use synthetic long peptides for detection or isolation of 
T cells in vitro. An optimal strength of antigenic presentation has been shown to result in 













class I may not result in proper CD8+ T cell activation, high levels of peptide presented in 
HLA class I can result in overstimulation and activation-induced cell death. When the 
minimal epitope is known, the optimal dose of minimal peptide may be empirically 
determined. However, when immunogenic epitopes are not known, the large variability in 
efficiency of CD8+ T cell activation using the extended peptide variants in this study 
indicates that the inclusion of many different overlapping peptide variants in peptide pools 
may increase the repertoire of specific CD8+ T cells that can be properly activated. 
For approaches of peptide vaccination in vivo, the relation between strength of peptide 
stimulation and efficiency of T cell activation has not been investigated in detail. The doses 
of peptide used in most murine (10-40 µg) and human (200-1500 µg) vaccination studies are 
likely to result in very high peptide concentrations at the site of injection, which may result 
in overstimulation and activation-induced cell death. A tolerizing effect of minimal peptide 
vaccination has been shown to be most prominent when using high doses of 50 µg peptide 
in murine studies, while no tolerance was induced at low peptide doses [26]. The more 
limited efficiency of HLA class I presentation of synthetic long peptides may therefore have 
contributed to the superior in vivo CD8+ T cell responses that were reported following 
vaccination with long peptides compared with the corresponding minimal HLA class I 
binding peptides [22-25].  
The efficiency of HLA class I binding of the long peptides investigated in this study was 
shown to be very variable as well, ranging from a similar binding efficiency compared with 
the minimal peptide to a 29,000-fold lower binding efficiency. No relation was observed 
between the efficiency of HLA binding and the efficiency of CD8+ T cell activation, as 
expressed by the IC50 and the EC50 values, indicating that direct binding of long peptides in 
HLA class I may not be sufficient for CD8+ T cell activation, and that peptide trimming is 
likely to occur resulting in HLA class I presentation of the minimal epitope to CD8+ T cells. 
The elution of both the initial extended peptide variants and the minimal peptides from 
HLA class I monomers that were generated using the extended peptides indicated that, 
although direct binding of long peptides can occur, trimming of long peptides to minimal 
HLA class I binding epitopes is a highly efficient process. Our data do not indicate whether 
the long peptides were trimmed first, and subsequently bound in HLA class I molecules, or 
first bound in HLA class I, and were subsequently trimmed, as was described before as the 
model of HLA-guided processing [43]. These processes may also occur simultaneously. 
However, it is likely that processing of the correct minimal peptide is facilitated by binding 
in HLA class I molecules, since the long peptides were trimmed predominantly to the exact 
minimal binding and immunogenic peptides, suggesting that the HLA class I groove 














The activation of specific CD8+ T cells was more efficient using N-terminally extended 
peptides compared with C-terminally extended peptides, while the binding of N-terminally 
extended peptides in HLA class I was similar or even less efficient compared with C-
terminally extended peptides. These results may illustrate the efficient trimming of N-
terminal amino acids by aminopeptidases, in contrast to the low efficiency of C-terminal 
amino acid cleavage by carboxypeptidases or endopeptidases [44]. Therefore, the difference 
in results between N-terminally extended peptides and C-terminally extended peptides is 
also consistent with the model in which peptidase trimming is required for HLA class I 
presentation and CD8+ T cell activation. 
Although the mechanisms of trimming of exogenous peptides by peptidases remain to be 
elucidated in more detail, we demonstrated that EBV-LCL were capable of processing and 
presentation of synthetic long peptides in HLA class I, resulting in CD8+ T cell activation. 
Previous studies have demonstrated that PBMC can also process and present synthetic long 
peptides in HLA class I [10-14]. Data from the studies that explored the use of synthetic long 
peptides for vaccination in vivo indicated that professional APCs are more capable to 
acquire, process and present long peptides [22-25]. Direct comparison of the mechanisms 
and capacity of processing and presentation of long peptides between different APC 
populations may be helpful in designing improved strategies for peptide vaccination. The 
results from our study illustrate that trimming of exogenous long peptides by peptidases to 
minimal epitopes, which is facilitated by binding to HLA class I molecules, is likely to result 
in optimal activation of antigen-specific CD8+ T cells. 
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To treat patients with refractory cytomegalovirus (CMV) reactivation after allogeneic stem 
cell transplantation a phase I/II clinical study on adoptive transfer of in vitro generated 
donor or patient derived CMV pp65-specific CD8+ T cell lines was performed. Peripheral 
blood mononuclear cells from CMV seropositive donors or patients were stimulated with 
HLA-A*0201 and/or HLA-B*0702 restricted pp65 peptides (NLV/TPR) and one day after 
stimulation interferon-gamma (IFNγ) producing cells were enriched using the IFNγ capture 
assay, and cultured with autologous feeders and low dose IL-2. After 8-14 days of culture 
quality controls were performed and the CMV-specific T cell lines were administered or 
cryopreserved. The T cell lines generated contained 1-17x106 cells, comprising 54-96% CMV 
pp65-specific CD8+ T cells, and showed CMV-specific lysis of target cells. To date 14 CMV-
specific T cell lines were generated of which 7 were administered to patients with refractory 
CMV reactivation. After administration no adverse events were observed and CMV load 
decreased and remained negative. In several patients a direct relation between 
administration of the T cell line and the in vivo appearance of CMV pp65-specific T cells 
could be documented. In conclusion, administration of CMV pp65-specific CD8+ T cell lines 
was found to be feasible and safe, and efficacy of administered CMV pp65-specific CD8+ T 















Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for a 
variety of hematological malignancies and inherited hematopoietic disorders. A significant 
complication of alloSCT is the development of severe graft versus host disease (GvHD), 
which can be treated by immune suppression. Depletion of T cells from the stem cell graft 
can also be performed to prevent the development of severe GvHD after alloSCT. However, 
T cell depletion or immune suppression significantly delays immune reconstitution in 
patients after alloSCT, which is associated with an increased risk of opportunistic infections 
including CMV infection [1-3]. Reactivation of CMV can cause serious morbidity and 
mortality during the prolonged period of immune deficiency following alloSCT, which is 
also illustrated by increased CMV-related morbidity in patients receiving a graft from a 
CMV seronegative donor [4,5]. The availability of antiviral agents like ganciclovir and 
foscarnet has contributed to a significant reduction of CMV-related morbidity and mortality 
following alloSCT. However, if appropriate T cell responses against CMV do not develop 
after alloSCT subsequent viral reactivations and refractory disease are commonly observed. 
Reconstitution of the CMV-specific T cell repertoire directed against immunodominant 
proteins, like CMV pp65, in the first year after alloSCT has been demonstrated to confer 
sustained protection from CMV disease. Furthermore, for the long-term protection against 
CMV the development of CMV-specific T cell immunity has been found to be essential [6-9]. 
Therefore, adoptive transfer of donor-derived virus-specific T cells is an attractive strategy 
for treatment of viral disease in alloSCT recipients. Clinical studies have demonstrated that 
the adoptive transfer of donor-derived CMV-specific memory T cells can be a safe and 
effective treatment for patients with refractory CMV reactivation [10-18].  
In most clinical studies CMV-specific CD8+ T cell lines were generated by repetitive 
stimulation of the T cells in vitro for several weeks to obtain highly pure T cell lines to 
minimize the risk of the induction of GvHD [10-16]. However, isolation of CMV-specific 
T cells from peripheral blood also allows the generation of highly specific T cell lines 
without prolonged culture and repetitive stimulation.  Since it has been demonstrated that 
adoptive transfer of interferon-gamma (IFNγ)-producing memory T cells can provide long-
lived functional memory T cell reconstitution and that the presence of IFNγ producing 
CMV-specific T cells is associated with protection from CMV reactivation isolation of CMV-
specific memory CD8+ T based on their IFNγ production is an attractive strategy for 
generating effective CMV-specific CD8+ T cell lines [4,6,7,9,15,18,19]. Although clinical 














these studies the infusion of CMV specific CD8+ T cells could not always be directly 
correlated to a clinical effect. 
In this study, a phase I/II clinical protocol for the adoptive transfer of donor or patient 
derived CMV pp65-specific CD8+ T cell lines for patients with refractory CMV reactivation 
after alloSCT was conducted. CMV-specific T cells were isolated using a IFNγ-based 
isolation technique and cultured for 1 to 2 weeks. Five patients with CMV reactivation 
failing antiviral therapy were treated with these CMV pp65-specific CD8+ T cell lines. In all 
five patients CMV DNA load turned negative and CMV-specific T cells could be detected in 
the peripheral blood. In two patients a direct relation was shown between the 
administration of CMV-specific T cells, the appearance of CMV-specific T cells in the 
peripheral blood and the clearance of CMV reactivation. 
 
Materials and Methods 
Study design 
Adult and pediatric patients with refractory CMV reactivation after alloSCT were eligible. 
Patients were weekly monitored for CMV reactivation after receiving a stem cell transplant. 
Refractory CMV reactivation was defined as high CMV load for more than two weeks while 
receiving pharmacotherapy or as early relapse after therapy. Since only peptides binding 
HLA-A*0201 or HLA-B*0702 were available for clinical use and therefore only T cells 
specific for these epitopes could be isolated, only HLA-A*0201 and/or HLA-B*0702 positive 
patients were eligible. When the donor was CMV seropositive a donor-derived T cell line 
was generated, when the donor was CMV seronegative a patient-derived T cell line was 
generated. When the CMV pp65-specific T cell line met the release criteria and CMV load 
was still positive the T cell line was administered to the patient. The procedure could be 
repeated two times in case of stable or progressive disease and no severe toxicity. 
 
Collection of peripheral blood cells 
After informed consent at least 2x109 peripheral blood mononuclear cells (PBMC) were 
harvested by leukopheresis from each donor or patient. Red blood cells were lysed using a 
NH4Cl (8.4 g/l) and KHCO3 (1 g/l) buffer (pH=7.4) (Leiden University Medical Center, 
Department of Clinical Pharmacy, Leiden, The Netherlands). PBMC were directly used or 
cryopreserved in the vapor phase of liquid nitrogen until further use. Cells were 
cryopreserved in Iscove's modified Dulbecco's medium (IMDM) (Lonza, Basel, Switzerland) 













dimethyl sulphoxide (DMSO) (Leiden University Medical Center, Department of Clinical 
Pharmacy, Leiden, The Netherlands).  
 
Generation and administration of clinical grade CMV-specific CD8+ T cell lines 
Donor or patient PBMC were resuspended in medium consisting of IMDM  supplemented 
with 3 mmol/L L-glutamine (Lonza) and 100 U/ml penicillin and 100 µg/ml streptomycin 
(Lonza) plus 10% heat-inactivated pooled prescreened AB serum from healthy blood bank 
donors. Cells were cultured at a cell concentration of 10x106 cells/ml and 1 µg/ml of peptide 
was added. Peptides used were the HLA-A*0201 binding peptide NLVPMVATV (NLV) and 
the HLA-B*0702 binding peptide TPRVTGGGAM (TPR) both purchased from Bachem 
(Bubendorf, Switzerland).  
After overnight stimulation IFNγ secreting cells were isolated using the CliniMACS cytokine 
capture system (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s 
instructions. After washing the positive fraction was resuspended in culture medium 
containing 10 IU/ml IL-2 (Proleukin, Novartis Pharma B.V., Arnhem, The Netherlands). 
Cells were cultured at a 1:10 ratio with irradiated (30 kGy) feeder cells, which were obtained 
from the negative fraction after isolation. Cultures were refreshed every 3 to 4 days and after 
8 to 14 days the T cell lines were analyzed. Cultures were evaluated for the presence of CMV 
NLV- and/or TPR-specific CD8+ T cells by tetramer staining and quality control was 
performed. Quality assurance specifications included: (1) no microbiological contamination, 
(2) confirmation of the origin of the material (donor or patient), (3) the presence of 
minimally 50% of CMV-specific CD8+ T cells within the CD3+ population, (4) the presence 
of maximally 10% CD19+ B-cells and (5) functionality in a 51Cr release assay defined as 
minimally 20% lysis of positive target cells and maximally 10% lysis of negative target cells. 
When released for administration, the CMV-specific T cell lines were resuspended in 100 ml 
NaCl 0.9% (LUMC Pharmacy) supplemented with 2% human albumin (Sanquin) in a 500 ml 
Cryocyte Freezing Container (Baxter, Deerfield, IL) . 
 
Phenotypic analysis 
To determine the composition and phenotype of the starting material, the fractions after 
isolation and the T cell line, cells were stained using FITC-labeled TCRαβ, CD14, CD4 and 
HLA-DR (BD Biosciences, San Jose, CA), PE-labeled TCRγδ, CD56, CD25 (BD) and IFNγ 
(Miltenyi Biotec), PerCP-labeled CD8 and CD3 (BD), APC labeled CD19, CD33 (BD) and 
CD4 (Beckman Coulter, Fullerton, CA) and PE- or APC-labeled tetramers of the 


















To determine the cytotoxicity of the T cell lines standard 51Chromium (51Cr) release assays 
were performed as described previously [21]. Target cells (donor and patient 
phytohemagglutinin (PHA) blasts) were loaded with 100 µCi of Na51Cr2O4 (Amersham, 
Roosendaal, The Netherlands) for 1 hour and when necessary 1µM of peptide (NLV or TPR) 
was also added. Effector/Target (E/T) ratios ranged from 30:1 to 1:1 and after 4 hours of 
incubation 51Cr release was determined.  
 
Ex vivo identification of CMV-specific CD8+ T cells 
To identify donor or recipient origin of CMV-specific T cells reconstituting in peripheral 
blood after infusion of the CMV pp65-specific CD8+ T cell lines, PBMC from the patient 
were stained using HLA class I tetramers specific for NLV or TPR.  Subsequently, the-HLA 
tetramer-positive CD8+ T cells were selected by flow cytometric sorting using a FACSDiva 
and Cellquest software (BD). The DNA profile of the sorted cells was established by 




Generation of clinical grade CMV specific CD8+ T cell lines 
A total of 11 donor-derived and 3 patient-derived CMV-specific T cell lines specific for the 
HLA-A*0201 restricted NLV epitope and/or for the HLA-B*0702 restricted TPR epitope were 
generated for patients failing antiviral therapy after alloSCT. Donor-derived T cell lines 
were generated when both donor and patient were CMV seropositive, whereas patient 
derived T cell lines were generated when the donor was CMV seronegative and the patient 
CMV seropositive.  Figure 1 shows the data of a representative donor-derived (1A - 1D) and 
patient-derived (1E – 1H) CMV specific T cell line. The precursor frequencies of the NLV-
specific T cells in the PBMC starting material were 0.4% in the donor material (Figure 1A) 
and 1.45% in the patient material (Figure 1E). After overnight stimulation with the 
HLA-A*0201 binding NLV peptide, IFNγ producing cells were isolated using the Cytokine 
Capture System. The positive fraction contained between 20 – 25% IFNγ positive CD8+ 
T cells within the T cell fraction (Figure 1B and Figure 1F). Other T cells present in the 













days of culture respectively (Figure 1C and 1G), specific proliferation of the NLV-specific 
CD8+ T cells resulted in the donor-derived T cell line containing 83% NLV-specific CD8+ 
T cells and the patient-derived T cell line containing 66% NLV-specific CD8+ T cells.  
 
Figure 1. Composition and functionality of donor derived (A-D) and patient derived (E-H) CMV-specific T cell lines. 
(A, E) the percentage of NLV (A) and TPR (E) -specific T cells in the starting material (day 0); (B, F) the percentage of 
IFNγ positive cells in the positive fraction directly after isolation; (C, G) the percentage of NLV (C) or TPR (G) in the 
T cell line after culture (day 7); (D, H) functionality of the T cell lines in a 51Cr release assay. Dot plots are shown and 
events shown are gated on lymfogate and PI-negative gate. Percentage lysis after 4 hours in a 51Cr release assay at an 














Less than 1% of CD19+ B-cells were detected in the T cell lines (data not shown). As is 
shown in Figure 1D and 1H both T cell lines showed reactivity against NLV- or 
TPR peptide-loaded target cells and no reactivity against donor or patient cells. 
Furthermore, both T cell lines also showed recognition of endogenously presented antigen 
using pp65 transduced EBV-LCL. 
Table 1 shows the results of all the CMV-specific T cell lines generated. Precursor 
frequencies of NLV- and/or TPR-specific CD8+ T cells in the donor or patient starting 
material used for the generation of the T cell lines ranged from 0.02 – 1.45% of total PBMC. 
Cell numbers obtained direct after isolation ranged from 1.0 to 14.4x106 cells and contained 
between 3 to 45 % IFNγ positive CD8+ T cells within the T cell population. Total cell 
numbers obtained after culture ranged from 1.0 to 17.1x106 cells. During culture no increase 
in total cell numbers was observed, however, enrichment of CMV-specific T cells was 
observed, since the T cell lines contained between 54- 96% of NLV-and/or TPR-specific 
T cells. 
 
Table1. Characteristics of the CMV-specific T cell lines 
Cytotoxicity2,3 Phenotype 



















- peptide + peptide  
P1-a TPR 0.28 3.4 26 71 68 2.3 1 53 4 
P1-b TPR 0.28 3.8 10 88 72 2.7 2 70 0 
P2-a TPR 0.3 7.5 9 91 81 6.1 2 56 2 
P3-a TPR 0.02 5.0 20 80 72 3.6 1 41 4 
P4-a NLV/TPR <0.01 / 0.25 5.9 11 85 5 / 69 3.8 3 66 0 
P4-b NLV/TPR <0.01 / 0.25 17.1 5 73 14 / 50 12.7 1 39 0 
P5-a TPR 0.14 4.8 4 95 95 3.1 0 26 1 
P7-a  NLV/TPR 0.04 / 0.52 10 7 96 4 / 92 9.6 9 65 0 
P8-a1 TPR 0.7 3.0 11 77 66 2.1 1 62 1 
P9-a  NLV 0.48 1.0 22 77 65 0.7 1 804 0 
P9-b NLV 0.98 3.3 7 93 83 2.7 2 30 1 
P10-a1 NLV 1.45 6.0 8 90 79 4.7 1 58 2 
P11-a1 NLV 1.1 6.7 27 61 54 3.6 2 25 4 
P12-a NLV 0.4 16.8 9 85 82 13.8 1 36 2 
1patient-derived T cell line;  
2 after 7-14 days culture;  
3 percentage lysis after 4 hours in a 51Cr release assay, E:T ratio of 3:1; 














All 14 donor and patient derived CMV specific T cell lines generated met the quality control 
criteria. No microbiological contamination was detected in any of the T cell lines and 
chimerism analysis showed the correct origin of the material. As is shown in Table 1 all 
T cell lines contained more than 50% of NLV- and/or TPR- specific T cells within the CD3+ 
population and all T cell lines showed recognition of peptide-loaded PHA blasts and no 
reactivity against donor or patient derived PHA blasts. 
 
Administration of CMV-specific CD8+ T cell lines 
In a phase I/II study the toxicity and the potential antiviral effect of treatment with CMV 
pp65-specific T cell lines for refractory CMV reactivation following allogeneic SCT was 
investigated. Five patients with refractory CMV reactivation following alloSCT received 
donor derived CMV pp65-specific T cell line(s). Three patients (patient 2, 3 and 4) received 
one CMV pp65-specific T cell line and two patients (patient 1 and 9) received two CMV 
pp65-specific T cell lines. The other T cell lines generated were not administrated, since 
patients were CMV load negative (n=4), had relapsed (n=1) or deceased due to CMV disease 
(n=2) at the time the production of the CMV pp65-specific T cell line was completed.  
Despite treatment with antiviral agents all five patients who received a CMV pp65-specific 
T cell line had positive CMV DNA loads (log 2.5 to log 3.2) at the time of administration of 
the CMV specific T cell lines. The patients received a total cell dose ranging from 1.0 to 
7.5x106 cells, corresponding to 0.6 to 6.1x106 NLV- and/or TPR-specific T cells. None of the 
five patients developed any complications during infusion of the T cell lines and all patients 
cleared CMV reactivation within weeks after administration of the CMV pp65-specific T cell 
line.  
 
Reconstitution of CMV-specific T cells after administration of the CMV-specific CD8+ 
T cell lines 
In all patients CMV-specific NLV- and/or TPR-specific CD8+ T cells could be detected after 
administration of the T cell lines. To determine the correlation between the infusion of the 
CMV-specific T cell lines and the appearance of CMV-specific T cells in peripheral blood of 
the patients, the presence of CMV-specific T cells was analyzed at different time points 
before and after administration of the T cell lines. Prior to infusion of the CMV-specific T cell 
lines in 3 of the 5 patients CMV pp65-specific T cells with the same specificity as the T cell 
line could already be detected in peripheral blood. In two of these patients a rise in CMV-
specific T cells in peripheral blood was observed after infusion of the T cell line. In the other 














patient a very high level of CMV-specific T cells was already observed prior to infusion of 
the T cell line. In 2 of the 5 patients (patient 4 and 9) no CMV-specific T cells were detected 
prior to infusion of the T cell line, and a direct relation was observed between infusion of the 
CMV pp65-specific T cell line, the appearance of CMV-pp65 specific T cells in peripheral 
blood, and the clinical effect. 
Patient 4 developed CMV reactivation within the first month after alloSCT which was 
treated with antiviral drugs (Figure 2). The rise in CMV coincided with a rise in CMV TPR-
specific T cells. Four months after alloSCT the patient received unmanipulated donor 
lymphocyte infusion (DLI), and six months after alloSCT the patient developed GvHD for 
which he was treated. The CMV-specific T cells disappeared, and the patient developed 
refractory CMV reactivation. A CMV TPR-specific T cell line was administered 8 months 
after alloSCT (1x105 T cells/kg) and within 2 weeks TPR-specific CD8+ T cells appeared in 
peripheral blood and the CMV load turned negative and remained negative (follow up >4 
years). To asses why no persistence of the TPR-specific T cells from the first peak response 
was observed and to determine whether the TPR-specific T cells appearing in the second 
peak response were the same as the T cells in the first peak response, the patient or donor 
origin of the CMV-specific T cells from both peak responses (day 33 and day 289 after 
alloSCT respectively) was determined. The TPR-specific T cells were isolated from both 
peak responses by FACS sorting and DNA profiling showed that the CMV-specific T cells 
during the first response (day 33) were patient derived, and that the CMV-specific T cells 
that appeared after administration of the T cell line (day 289) were completely donor 
derived, illustrating the correlation between the infusion of the TPR-specific T cell line and 
the in vivo appearance of the donor derived TPR-specific T cells. 
Patient 9 developed refractory CMV reactivation post alloSCT in the absence of CMV-
specific T cells (Figure 3). A CMV NLV- specific T cell line was administrated (day 72), but 
no CMV NLV-specific T cells appeared in peripheral blood and the CMV load remained 
positive. The quality of this T cell line was very poor due to poor quality of the starting 
material and this might explain that there was non in vivo persistence of the infused T cells. 
A second CMV NLV-specific T cell line was generated, from new starting material, that was 
administered at day 116 after alloSCT (3.1x105 T cells/kg) and after two weeks CMV NLV-
specific T cells appeared in peripheral blood, which was coincided with a disappearance of 
















Figure 2. CMV pp65-specific T cells in peripheral blood from patient 4 in relation to the CMV DNA load in peripheral 
blood. CMV-specific T cells (CD8+/tetramer+) are expressed as absolute numbers per liter in peripheral blood (left 
axis). , TPR-specific T cells; , NLV-specific T cells; , RPH-specific T cells. CMV DNA load ( ) is depicted as log 








Figure 3. CMV pp65 (NLV)-specific T cells in peripheral blood from patient 9 in relation to the CMV DNA load in 
peripheral blood. CMV-specific T cells ( , CD8+/NLV-tetramer+) are expressed as absolute numbers per liter in 
peripheral blood (left axis) and CMV DNA load ( ) is depicted as log CMV DNA load in peripheral blood (right axis). 
















In this study, a phase I/II clinical protocol for the adoptive transfer of donor- or patient-
derived CMV pp65-specific CD8+ T cell lines for patients with refractory CMV reactivation 
after alloSCT was conducted. No toxicity was observed after administration of the T cell 
lines and all patients who received a CMV-specific T cell line cleared CMV reactivation. A 
direct relation between administration of donor derived CMV pp65-specific T cell lines and 
clinical effect could be demonstrated.  
Both donor- and patient-derived CMV pp65-specific CD8+ T cell lines could be reproducible 
generated, even when precursor frequencies of CMV pp65-specific CD8+ T cells were very 
low (<0.01%). Directly after isolation the purity of the positive fraction (% CD8+/IFNγ+ 
T cells) appeared to be low for some isolations, which was also observed in other studies 
using the IFNγ based isolation method [18,23]. This can be due to nonspecific co-isolation of 
other cells and may also be due to the fact that the antibody on the microbeads used for 
isolation and the antibody used for analysis of the population recognize the same epitope. 
Preferential expansion of the CMV-specific CD8+ T cells during the subsequent culture 
period led to T cell lines with a high purity of CMV-specific CD8+ T cells, reducing the risk 
of the induction of GvHD after administration.  
In the current study five patients with refractory CMV reactivation received one or two 
donor-derived CMV-specific CD8+ T cell line(s). Administration was safe, no toxicity was 
observed after infusion, and all patients cleared CMV reactivation after treatment with the 
CMV-specific CD8+ T cell lines. In three patients, T cells with the same reactivity as the 
T cell line could already be detected in peripheral blood of the patients prior to 
administration of the T cell lines.  Although it is likely that the infused T cells contributed to 
the clearance of CMV reactivation in these patients, direct evidence for this can not be 
provided. However, in two of the five patients a direct correlation between the 
administration of donor derived CMV pp65-specific T cell lines, the appearance of CMV-
specific CD8+ T cells and clearance of CMV reactivation was demonstrated. No CMV-
specific T cells were present prior to the administration of the T cell lines, and within two 
weeks after administration of the T cell line increasing numbers of NLV- or TPR-specific 
CD8+ T cells could be detected in peripheral blood of the patients, illustrating persistence 
and in vivo proliferation of the infused T cells. The appearance of the CMV-specific CD8+ 
T cells co-incided with the clearance of CMV reactivation. Although CMV-specific CD8+ 
T cells have been detected in peripheral blood after the adoptive transfer of CD8+ T cell lines 
in previous studies, this study shows a direct correlation between the administration of a 













Two patients eligible for the study deceased due to CMV disease. CMV-specific T cell lines 
could be generated for these patients, however both patients deceased before the T cell line 
could be administered. Decreasing the time interval between the appearance of the clinical 
need and administration of the T cell product by direct administration of the isolated CMV 
pp65-specific T cells may improve the efficacy. Although in vivo proliferation is also likely 
to be necessary in these patients to allow a clinical effect, it has been shown that direct 
administration of CMV-specific T cells isolated based on their IFNγ production is effective 
and does not lead to GvHD induction [18]. 
In the current protocol T cell lines only could be generated for patients who were 
HLA-A*0201 and HLA-B*0702 positive. To increase the potential clinical use of CMV 
specific T cells a CMV pp65 whole protein overlapping 15 mer (11 mer overlapping) peptide 
pool may be used for the generation of CMV pp65-specific T cell lines. It has been shown by 
us and others that using this peptide pool CMV pp65-specific T cells can be isolated 
irrespective of HLA restriction of the donor and patient [24-26]. Furthermore, using these 
peptide pools also CMV-specific CD4+ T cells will be isolated and studies have indicated 
that adoptively transferred CMV-specific CD4+ T cells may promote development of a 
CMV-specific CD8+ T cell response in vivo and that adoptively transferred CMV-specific 
CD8+ T cells show better persistence in the presence of CMV-specific CD4+ T cells [10, 12, 
14-16, 26].  
In conclusion, we have shown that the clinical grade generation of donor and patient 
derived CMV pp65-specific CD8+ T cell lines is feasible, and that administration of CMV-
specific T cell lines to patients with refractory CMV reactivation after alloSCT was safe. A 
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In recipients of allogeneic stem cell transplantation (alloSCT), virus-specific T cells are 
eradicated or impaired by the conditioning regimen and immune suppression. Since 
reconstitution of antiviral immunity can be considerably delayed and is often incomplete, 
patients are exposed to a prolonged period of high risk of viral infections [1]. The major viral 
pathogens causing serious morbidity and mortality after alloSCT are the common viruses 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human adenovirus (HAdV) [2-6]. 
Since pharmacological treatment is limited by significant toxicity and is often not sufficient 
for long-term control of viral infections, other treatment options are needed [7-9]. It has been 
shown that reconstitution of T cells specific for CMV, EBV, and HAdV is essential for 
sustained protection from viral disease after alloSCT [10-17]. Therefore, the adoptive 
transfer of donor-derived virus-specific T cells to alloSCT recipients may be an effective 
strategy for prophylaxis or treatment of viral infections or reactivations. Since 
administration of donor T cells with unknown specificity increases the risk of development 
of graft-versus-host disease (GvHD), treatment with virus-specific T cells isolated from 
donor peripheral blood mononuclear cells (PBMC) is needed. In this thesis, methods were 
investigated for efficient activation of virus-specific CD8+ and CD4+ T cells in PBMC to 
allow detection and selection of the specific cells from PBMC. Using these methods, we 
studied the role of T cells in protection from HAdV disease after alloST, to support the 
rationale for HAdV-specific T cell therapy. Furthermore, strategies were developed for the 
efficient isolation of activated virus-specific T cells from PBMC. The clinical grade T cell 
lines with high specificity against multiple viral antigens, which can be generated using 
these strategies, may be used to establish the clinical benefit of adoptive immunotherapy for 
viral infections after alloSCT. 
 
In chapter 2, the IFNγ response of CMV-specific CD8+ T cells was studied to exploit the full 
potential of IFNγ-based isolation. Investigation of the kinetics of the T cell response after 
CMV peptide stimulation showed a rapid downregulation of the T cell receptor (TCR) 
which coincided with the induction of IFNγ production. The production of IFNγ was 
maximal after 4 hours of stimulation, and rapidly decreased thereafter, despite the 
continued presence of specific peptide. By varying the strength of stimulation, we observed 
that overstimulation can result in profound TCR downregulation, more rapid decline of 
IFNγ production, and reduced expansion of the specific cells. Based on these findings, we 
defined optimal conditions for IFNγ-based isolation of CMV-specific CD8+ T cells with 















was shown to be most efficient after 4 hours of stimulation with 10-7 M CMV peptide. The 
median frequency of CMV peptide-specific CD8+ T cells obtained in the T cell lines of the 
IFNγ-enriched fractions was 91% after 9-11 days of culture, while very low numbers of 
specific T cells were retained in the IFNγ-depleted fractions. The isolated CMV-specific 
CD8+ T cells produced both IFNγ and TNFα upon restimulation, and showed production of 
perforin and granzyme B, which was similar to the functional profile of CMV-specific CD8+ 
T cells in donor PBMC directly ex vivo. The data illustrated the importance of analyses of 
the kinetics of cytokine production for isolation of T cells specific for other infectious or 
malignant antigens to exploit the full potential of cytokine capture isolation of antigen-
specific T cells. 
 
The adoptive transfer of coordinated CD8+ and CD4+ T cell responses directed against 
multiple CMV epitopes may be more effective for protection from CMV disease after 
alloSCT, compared to CD8+ T cell lines specific for a single CMV epitope as described in 
chapter 2. In chapter 3, we showed that CD8+ and CD4+ T cells specific for CMV pp65 
epitopes were detected in all healthy CMV seropositive donors, while T cells specific for 
CMV IE1 epitopes were detected directly ex vivo in PBMC of 45% of healthy CMV 
seropositive donors. Subsequently, we developed a method for the simultaneous isolation of 
CMV pp65- and IE1-specific CD8+ and CD4+ T cells from PBMC of healthy CMV 
seropositive donors, irrespective of their HLA type. Stimulation of donor PBMC with a 
CMV pp65 protein-spanning pool of 15-mer peptides efficiently induced activation of CD8+ 
and CD4+ T cells specific for multiple CMV pp65 epitopes. In contrast, stimulation with the 
full-length CMV pp65 protein resulted in efficient activation of pp65-specific CD4+ T cells, 
but only part of the pp65-specific CD8+ T cells. The kinetics of IFNγ production by CMV-
specific CD8+ and CD4+ T cells after stimulation with 15-mer peptide pools was shown to be 
similar to IFNγ kinetics after stimulation with minimal MHC I or II binding peptides, with 
maximal IFNγ production after 4 hours of stimulation, which decreased thereafter. Based on 
these data, we developed a clinical grade protocol for generation of combined CD8+ and 
CD4+ T cell lines specific for CMV pp65 and IE1. Isolation of IFNγ-secreting cells was 
performed by IFNγ capture assay during the peak of IFNγ production after 4 hours of 
stimulation with CMV 15-mer peptide pools. Using this method, T cell lines containing a 
median of 91% of T cells specific for a broad repertoire of CMV CD8+ and CD4+ epitopes 
were reproducibly generated from all donors. The composition of the T cell lines correlated 
with the frequencies of pp65 and IE1-specific CD8+ and CD4+ T cells in donor PBMC, 
illustrating that the repertoire of CMV-specific T cells in donor PBMC was represented in 













was comparable to CMV-specific T cell lines in donor PBMC. This study provided a feasible 
strategy for the rapid generation of clinical grade CD8+ and CD4+ T cell lines with high 
specificity for multiple CMV pp65 and IE1 epitopes. 
 
Although the appearance of HAdV-specific T cells has been previously shown to confer 
protection from HAdV disease after alloSCT, the epitope specificity of these responses has 
not been characterized, and the relative contribution of CD8+ and CD4+ T cells in protection 
from HAdV was not clear. In chapter 4, we investigated the development of HAdV-specific 
T cell responses in peripheral blood from pediatric and adult alloSCT recipients who 
showed spontaneous resolution of disseminated HAdV disease. We demonstrated that 
clearance of HAdV viremia after alloSCT coincided with emergence of a coordinated CD8+ 
and CD4+ T cell response against HAdV hexon epitopes, providing a rationale for HAdV 
hexon-specific adoptive immunotherapy. Therefore, we developed a clinical grade method 
for rapid generation of T cell lines with high and defined specificity for HAdV hexon 
epitopes for adoptive transfer. Activation of HAdV hexon-specific CD8+ and CD4+ T cells in 
peripheral blood with a hexon protein-spanning pool of synthetic 15-mer peptides followed 
by IFNγ-based isolation allowed rapid expansion of highly specific T cell lines from healthy 
adults, including donors without detectable frequencies of HAdV hexon-specific T cells. 
HAdV-specific T cell lines recognized multiple MHC class I and II restricted epitopes, 
including known and novel epitopes, and efficiently lysed HAdV-infected target cells. This 
study provided a rationale and strategy for the adoptive transfer of donor-derived HAdV 
hexon-specific CD8+ and CD4+ T cells for treatment of disseminated HAdV infection after 
alloSCT. 
 
In chapter 5, we developed a single and feasible method for the simultaneous isolation of 
coordinated CD8+ and CD4+ T cell responses against epitopes from multiple viral proteins. 
To ensure that the method was applicable to a wide variety of virus-specific T cells that may 
differ in phenotypic and functional properties, we focused on T cells specific for the 
persistent viruses CMV and EBV, as well as T cells specific for HAdV and influenza (FLU), 
which are not repetitively activated in vivo after initial viral clearance. Although IFNγ-based 
isolation of antigen-specific T cells was shown to be feasible, it was unknown whether all 
virus-specific T cell populations showed similar kinetics of IFNγ production upon 
activation, which might allow simultaneous IFNγ-based isolation. Furthermore, the IFNγ-
based isolation procedure is technically demanding, which is a major drawback for wide 
clinical application. Therefore, we also explored the use of the activation-induced expression 















and TNFα, and expressed CD137, while the populations varied in production of IL-2, 
degranulation, and expression of phenotypic markers. Different kinetics of IFNγ production 
were observed between CMV/EBV-specific T cells and HAdV/FLU-specific T cells. 
However, after stimulation of donor peripheral blood with viral protein-spanning peptide 
pools, the activated virus-specific CD8+ and CD4+ T cells could be simultaneously isolated 
by either IFNγ-based or CD137-based enrichment. The simple CD137 labeling procedure is a 
major practical advantage over the laborious IFNγ labeling procedure, which may allow 
more feasible and cost-effective production of virus-specific T cell lines. However, only 
IFNγ-based isolation is currently available for the generation of clinical grade virus-specific 
T cell lines. This study provided an efficient and widely applicable method for the 
simultaneous isolation of both CD8+ and CD4+ T cells specific for a broad repertoire of 
antigens from multiple viral pathogens from donor peripheral blood. 
 
In chapter 3-5, in vitro stimulation of peripheral blood with pools of synthetic overlapping 
15-mer peptides spanning viral proteins was shown to efficiently induce activation of both 
CD8+ and CD4+ virus-specific T cells. Furthermore, synthetic long peptides that contain 
immunogenic T cell epitopes have been previously shown to efficiently activate antigen-
specific CD8+ T cells in vivo following peptide vaccination. However, the mechanisms and 
efficiency of presentation of exogenous long peptides in MHC class I are unknown. In 
chapter 6, we demonstrated that the efficiency of antigen-specific CD8+ T cell activation 
using extended peptide variants of common viral epitopes can be very variable. Although 
long peptides were shown to bind to the relevant MHC class I molecules, peptide trimming 
was likely to be required for MHC class I presentation and T cell activation. Since processing 
and MHC class I presentation of the long peptides was not dependent on the proteasome 
and TAP, it is very likely that peptide trimming was mediated by peptidases, which may be 
located either extracellularly, at the cell surface, or in endosomal compartments. 
Furthermore, the results suggested that processing of the correct minimal peptides was 
facilitated by binding in MHC class I molecules. The results illustrate the need of a more 
rational design and extensive evaluation of the proper dose of synthetic long peptides to 
optimize activation of CD8+ T cells in approaches of immune monitoring, adoptive transfer, 
and vaccination. 
 
In chapter 7, the clinical results were presented of a phase I/II study for treatment of 
refractory CMV reactivation after alloSCT by adoptive transfer of donor- or patient-derived 
CMV pp65-specific CD8+ T cells. Refractory CMV reactivation was defined by a high CMV 













viral relapse after antiviral pharmacotherapy. PBMC from CMV seropositive donors or 
patients were stimulated with HLA-A2/HLA-B7 restricted CMV pp65 peptides, followed by 
IFNγ-based enrichment. Eleven donor-derived CMV-specific T cell lines were generated of 
which 7 were administered to patients with refractory CMV reactivation. The T cell lines 
generated contained high frequencies of CMV-specific CD8+ T cells and showed CMV-
specific lysis of target cells. After administration no adverse events were observed, CMV 
peptide-specific CD8+ T cells could be detected, and CMV load decreased and remained 
undetectable. One pediatric patient, who remained lymphopenic for months after alloSCT 
and maintained a high CMV load under antiviral therapy during this period, received 2 
CMV-specific T cell lines. Within weeks after administration of the second CMV specific T 
cell line, CMV-specific T cells appeared and the CMV load turned negative. Patient-derived 
T cell lines were generated for 3 patients, but were not administered due to changes in 
patient status. This study demonstrated that administration of CMV-specific CD8+ T cell 
lines appears to be safe, feasible, and effective. 
 
In conclusion, the rationale for adoptive immunotherapy for viral disease after alloSCT was 
supported in this thesis. Furthermore, we developed efficient and feasible strategies for the 
rapid generation of clinical grade CD8+ and CD4+ T cell lines with high specificity for 
multiple viral antigens. These methods are widely applicable, and allow evaluation of the 
clinical benefit of adoptive immunotherapy for viral infections after alloSCT in future 
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Previously, several methods have been developed to isolate virus-specific T cells from 
PBMC to provide antiviral immune reconstitution after alloSCT, with a minimal risk of 
GvHD. However, these methods have only been performed in small exploratory clinical 
trials by a limited number of groups in the past decade. Some methods can not be 
implemented for clinical use, due to regulatory restrictions and the absence of clinical grade 
reagents. Other methods can be used for clinical treatment, but have not been optimized to 
consistently provide T cell lines with high specificity for viral antigens. In this thesis, we 
developed efficient and feasible strategies for the rapid generation of clinical grade CD8+ 
and CD4+ T cell lines with high specificity for viral antigens. Overlapping pools of 15-mer 
peptides spanning viral proteins were demonstrated to efficiently induce the simultaneous 
activation of virus-specific CD8+ and CD4+ T cells. Both IFNγ-based and CD137-based 
isolation were shown to result in efficient enrichment of CD8+ and CD4+ T cells specific for 
multiple viral epitopes from PBMC, but the simple CD137 labeling procedure has an 
advantage over the more laborious IFNγ labeling procedure. This method is widely 
applicable, and may be used in future clinical trials to establish the clinical benefit of 
adoptive immunotherapy for viral infections after alloSCT.  
In the clinical study presented in chapter 7, large scale IFNγ-based enrichment of CD8+ T 
cells specific for a single CMV pp65 peptide was shown to be feasible. The infusion of 7 
CMV pp65-specific CD8+ T cell lines without adverse events indicated that this treatment 
was safe. Furthermore, the adoptive transfer of CMV pp65-specific CD8+ T cells seemed to 
be effective, since the specific CD8+ T cells could be detected in vivo, and the CMV load 
decreased and remained undetectable. The potential effectiveness of this strategy was 
clearly illustrated in two patients with a high CMV DNA load, who rapidly cleared the 
CMV infection after appearance of CMV pp65-specific CD8+ T cells within weeks after 
adoptive transfer. However, in the other patients who received CMV-specific T cell 
infusions, low frequencies of CD8+ T cells recognizing the specific CMV pp65 epitope had 
already been detected in PBMC before infusion. It is possible that at least part of the specific 
CD8+ T cells detected after infusion was derived from the CD8+ T cells which had already 
been present, and that the CMV load would also have been cleared without adoptive 
transfer. Therefore, despite the promising results, non-controlled studies can not prove that 
adoptive transfer of virus-specific T cells is effective. 
In this same study, a total number of 14 clinical grade CMV-specific CD8+ T cell lines were 
generated, which all complied with the release criteria, but only 7 CMV-specific T cell lines 















load (4 T cell lines), which could either be spontaneous or due to standard antiviral 
pharmacotherapy, relapse of the malignancy (1 T cell line), or CMV-related death (2 T cell 
lines). From the moment of decision to generate a T cell line, on average 10 days were 
required to receive donor or patient cells, and 7 to 14 days were required to generate and 
expand the T cell line, perform quality controls, and release the product. This period of 2 to 
4 weeks can be too long for patients with rapid progression of viral disease and for patients 
developing complications which result in study exclusion. Direct infusion of isolated virus-
specific T cells would allow a more rapid treatment, and simplify the generation procedure. 
In addition, direct infusion may prevent the potentially negative effects of culture in vitro. 
Although direct infusion and in vitro expansion of isolated antigen-specific T cells have not 
been directly compared in animal models or clinical trials yet, the repetitive in vitro 
stimulation and culture of CMV-specific T cells has been shown to negatively affect their 
efficacy after adoptive transfer in mice [1]. Likewise, some human studies have 
demonstrated that in vitro expanded CMV-specific, but also HIV-specific and melanoma-
specific CD8+ T cells did not persist long-term in vivo [2-5]. In vivo efficacy and survival 
may be hampered by abrupt withdrawal from high concentrations of cytokines, or 
exhaustion, and functional changes developing during prolonged culture [6]. No functional 
alterations or decreased proliferative capacity were detected in the virus-specific T cell lines 
described in this thesis. In vitro, the virus-specific T cells kept proliferating in culture for 
many weeks in the presence of IL-2 and IL-15. However, the effect of in vitro expansion of 
the virus-specific T cells on their in vivo survival and efficacy remains uncertain. To allow a 
more rapid treatment, simplify the generation procedure, and exclude the effect of in vitro 
expansion, direct infusion of isolated virus-specific T cells is preferable. Since only limited 
information about product composition will be available before administration using this 
approach, the procedures of generation should be validated. Retrospective testing of an in 
vitro cultured fraction can provide additional information about the cellular product infused 
afterwards. For high risk patients, donor or patient cells should be stored as potential 
starting material before development of viral disease. Patient cells may be stored before 
transplantation for all patients transplanted from a CMV seronegative donor, and donor 
cells may be stored after transplantation when patients do not show spontaneous 
reconstitution of CMV-specific T cells. Subsequently, the procedure of thawing cells, viral 
peptide stimulation, and CD137 isolation can be rapidly performed, allowing direct infusion 
of virus-specific T cells within 24 hours. 
The strategy of activating virus-specific T cells by incubation of PBMC with synthetic 
peptides followed by CD137-based isolation permits a wide choice of viral peptides to be 













contributed to reconstitution of CMV-specific T cells and clearance of the CMV load, were 
specific for a single CMV pp65 epitope. Previous results of adoptive transfer of CMV-
specific CD8+ T cells directed against a single CMV epitope have also shown reconstitution 
and proliferation of the infused T cells in vivo, which was associated with clearance of CMV 
viremia [7]. Incubation with a single peptide allows a simple analysis of the specificity of the 
T cell lines generated and of the follow-up of the T cells after administration. However, both 
in healthy individuals and in immunocompromised patients, spontaneous antiviral 
immunity is mediated by polyclonal CD8+ and CD4+ T cell responses directed against a 
broad repertoire of epitopes derived from multiple viral proteins [8-13]. Although the 
incubation with pools of overlapping peptides spanning entire proteins can be performed to 
activate and isolate CD8+ and CD4+ T cells simultaneously, the analysis of specificity and 
follow-up in vivo will be more complicated. However, peptide pools can be used for all 
donors and patients irrespective of their HLA, and will result in the isolation of larger 
absolute numbers of both CD8+ and CD4+ T cells specific for a broad repertoire of viral 
epitopes. Therefore, the use of viral peptide pools for generation of T cell lines is not only 
more convenient, but also likely to result in more rapid and effective immune reconstitution. 
As shown in chapter 6, the efficiency of antigen-specific CD8+ T cell activation using long 
synthetic peptides can be very variable, and is significantly reduced compared with minimal 
peptides. The competition between endogenous peptides presented in MHC class I and 
exogenously added long peptides, which are likely to require peptide trimming by 
peptidase activity, may result in physiological levels of presentation of the exogenous 
peptides in MHC class I and proper CD8+ T cell activation. In contrast, when using minimal 
peptides for in vitro stimulation, the optimal dose of minimal peptide should be determined 
empirically to prevent high levels of peptide presented in MHC class I, which may result in 
overstimulation and activation-induced cell death. Due to the large variability in efficiency 
of CD8+ T cell activation using exogenous long peptides, protein-spanning overlapping 
peptide pools should be composed of many different overlapping peptide variants to 
increase the repertoire of specific CD8+ T cells that can be activated properly. 
As shown in chapter 3, the peripheral blood of all healthy CMV-seropositive adults tested 
contained high frequencies of CD8+ and CD4+ T cells specific for multiple epitopes derived 
from the immunodominant CMV pp65 protein. For treatment of CMV disease, it is therefore 
preferable to incubate PBMC with CMV pp65 peptide pool followed by CD137-based 
isolation, which is likely to allow generation of combined CD8+ and CD4+ T cell lines 
specific for multiple CMV pp65 epitopes from all healthy CMV seropositive donors. Since T 
cells specific for CMV pp65 only compose a small fraction of the complete CMV-specific T 















proteins, such as IE1, may be considered. The addition of other CMV peptide pools will 
further increase the absolute numbers of CMV-specific T cells isolated, and further extend 
the repertoire of epitopes recognized. However, it is likely that adoptive transfer of CD8+ 
and CD4+ T cells specific for CMV pp65 only will be sufficient for control of CMV disease.  
In chapter 4, as a rationale for adoptive immunotherapy for treatment of HAdV disease in 
patients after alloSCT, resolution of disseminated HAdV infection was shown to be 
associated with development of coordinated CD8+ and CD4+ T cell responses against HAdV 
hexon in alloSCT recipients. Furthermore, although previous studies had only shown very 
low frequencies of predominantly CD4+ T cells specific for HAdV in healthy individuals, we 
demonstrated that coordinated CD8+ and CD4+ HAdV hexon-specific T cell lines could be 
generated from all healthy adults. These data indicated that both CD8+ and CD4+ T cells 
specific for HAdV hexon contribute to control of HAdV infection, and persist as memory T 
cell afterwards, which is similar to T cell responses described against most other viral 
infection. Although the use of HAdV penton peptide pool and peptide pools derived from 
other HAdV proteins may be considered to activate and isolate additional HAdV-specific T 
cells, the adoptive transfer of HAdV hexon-specific T cells is likely to be effective for 
treatment of HAdV disease.  
The strategy of using specific viral peptide pools for stimulation of PBMC followed by 
CD137-based isolation and direct infusion of the virus-specific T cells can provide rapid and 
effective treatment of viral disease in alloSCT recipients. However, it will require significant 
expenses and efforts to maintain the appropriate facilities, reagents, personnel, and 
knowledge, for treatment of a limited number of patients. The availability of this treatment 
modality can also be exploited to isolate virus-specific T cells for a larger number of alloSCT 
recipients as prophylaxis of viral disease. Prophylactic administration of virus-specific T 
cells after alloSCT may be followed by in vivo activation of the virus-specific T cells during 
viral reactivations and de novo viral infections, resulting in adequate antiviral T cell 
responses preventing the development of viral disease. For this purpose, it would be 
preferable to stimulate PBMC with peptide pools derived from multiple viruses followed by 
CD137-based isolation. When performing T cell depleted alloSCT, the best moment to infuse 
the isolated virus-specific T cells will be soon after T cell depleting drugs have disappeared 
to provide most effective immune reconstitution due to homeostatic proliferation. The use of 
immune suppression as part of the alloSCT protocol or for treatment of GvHD may hamper 
T cell proliferation and function, but is not a contra-indication for adoptive transfer of virus-
specific T cells. Although expenses will be significant to apply this treatment 
prophylactically to large numbers of patients, the increased turnover will reduce the costs of 













will result in a reduction of total expenses for treatment of viral morbidity, and in 
improvement of the quality of life of alloSCT recipients. An additional advantage of 
prophylaxis would be that peptide pools derived from other pathogens that cause serious 
morbidity after alloSCT, such as varicella-zoster virus, human polyomaviruses, candida 
albicans, and aspergillus, may be included at low costs in the same prophylactic procedure. 
Due to the large number of eligible patients and predetermined moment of infusion, the 
safety and effectiveness of prophylactic administration of virus-specific T cells will be more 
feasible to assess in randomized clinical trials compared with therapeutic administration. 
In this thesis and previous studies, the development of adoptive immunotherapy using 
virus-specific T cells has focused on the generation of virus-specific T cell lines from healthy 
seropositive donors for adoptive transfer to their alloSCT recipients. However, virus-specific 
T cell lines can not be generated readily from seronegative alloSCT donors. Although no 
licensed CMV vaccine has become available yet, a recent case report suggested that current 
experimental CMV vaccines can be sufficient to generate CMV-specific memory T cells in 
CMV-seronegative donors that can be transferred adoptively [14]. An alternative approach 
for patients transplanted from a CMV-seronegative donor would be the generation of CMV-
specific T cell lines from PBMC that are harvested from the patient before transplantation, as 
has already been shown to be feasible in chapter 7. The risk of graft rejection by patient T 
cells and the risk of introducing malignant patient cells should be carefully weighed against 
the risk and severity of viral disease. The specific isolation of virus-specific T cells from 
PBMC will be even more important in this setting, to minimize the infusion of potentially 
donor-reactive patient T cells. An additional group of patients that could benefit from 
cellular immunotherapy for viral disease are solid organ transplant (SOT) recipients. A 
recent study has shown that CMV-specific T cell lines could be generated from patients after 
SOT who received immune suppression [15]. In this population, immunotherapy using 
expanded patient-derived virus-specific T cells can be considered for refractory viral 
disease. 
To ensure maximal safety, effectiveness, and feasibility of clinical application of virus-
specific T cell products, release criteria should be carefully defined. The release criteria as 
defined in the clinical study in chapter 7 are suitable, including DNA profiling of the 
starting material, absence of microbiological contamination, detection of a high frequency of 
virus-specific T cells, absence of significant numbers of B cells and non-virus-specific T cells, 
and functional responses against virus-loaded patient cells, but not unloaded patient cells. 
Direct infusion with limited pre-release quality control and retrospective testing of an in 
vitro cultured fraction afterwards can be warranted when using high quality reagents and 















the European Directive 2003/63/EC and the Advanced Therapy Medicinal Product (ATMP) 
regulation, the generation and infusion of virus-specific T cell lines should comply with all 
relevant regulations for investigational medicinal products for human use, including GMP 
and GCP guidelines. Although these regulations require a lot of effort in academic centers, 
they will contribute to increased quality of cellular products and are necessary to establish 
adoptive immunotherapy as standard clinical practice. To continue translation of promising 
cellular therapies towards clinical benefit, the cooperation between clinicians, researchers, 
pharmacists, and biotechnology companies will even become more crucial. 
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Cellulaire afweer tegen virussen 
 
In gezonde mensen worden virale infecties onder controle gehouden door virus-specifieke 
antilichamen en virus-specifieke T cellen. Virus-specifieke antilichamen binden aan 
virusdeeltjes die in het lichaam circuleren, en voorkomen dat deze virusdeeltjes gezonde 
cellen kunnen infecteren. Indien antilichamen de infectie van cellen niet volledig kunnen 
voorkomen, kunnen virusdeeltjes na infectie van cellen zich in die cellen gaan 
vermenigvuldigen, waardoor nieuwe virusdeeltjes gevormd worden en de cel kapot gaat. 
Dit proces kan zich uiten in ziekteverschijnselen die karakteristiek zijn voor het betreffende 
virus. De tweede vorm van specifieke afweer tegen virale infecties zijn virus-specifieke T 
cellen, een type witte bloedcellen, die viraal geïnfecteerde cellen kunnen herkennen en 
vernietigen. De T cellen herkennen door middel van hun T cel receptor een specifiek stukje 
van het virus, een viraal peptide van ongeveer 9 tot 15 aminozuren, dat wordt 
gepresenteerd door major histocompatibiliteit complex (MHC) moleculen op het oppervlak 
van de geïnfecteerde cellen. Over het algemeen is de T cel receptor van een enkele T cel 
specifiek voor een bepaalde combinatie van een viraal peptide en een MHC molecuul. Er 
wordt onderscheid gemaakt tussen CD8+ T cellen die peptiden herkennen in MHC klasse I 
moleculen, en CD4+ T cellen die peptiden herkennen in MHC klasse II moleculen. Tijdens 
een eerste virale infectie worden naïeve virus-specifieke T cellen geactiveerd. Deze 
ontwikkelen zich tot functionele effector T cellen, die zich kunnen vermenigvuldigen en de 
virale infectie onder controle kunnen brengen. Vervolgens gaat een groot gedeelte virus-
specifieke effector T cellen dood, en zullen een aantal effector T cellen differentiëren naar 
memory T cellen, die in kleine aantallen langdurig aanwezig blijven om bescherming te 
bieden tegen volgende infecties met hetzelfde virus. Na herkenning van viraal antigeen 
kunnen virus-specifieke memory T cellen snel een immuunrespons veroorzaken door 
vermenigvuldiging, productie van ontstekingsmediatoren of cytokines, zoals interferon-
gamma (IFNg), tumor-necrosis factor alpha (TNFa) and interleukin-2 (IL-2), en directe 
vernietiging van de geïnfecteerde cellen. CD8+ T cellen hebben vooral het vermogen om 
geïnfecteerde cellen te vernietigen en CD4+ T cellen hebben vooral een ondersteunende rol 
bij de ontwikkeling van specifieke CD8+ T cellen en antilichamen door productie van 













Niet alle virussen worden na een acute infectie volledig uit de patiënt verwijderd. Door 
evolutionaire interactie tussen virale pathogenese en humane cellulaire afweerreacties 
hebben sommige virussen eigenschappen ontwikkeld om te kunnen persisteren. Persistentie 
kan resulteren in chronische infecties, waarbij actieve virusdeeltjes voortdurend blijven 
delen in geïnfecteerde cellen, of in latente infecties, waarbij het virale genoom latent 
aanwezig blijft in cellen zonder zich te vermenigvuldigen. Vanuit deze latente vorm kan het 
virus reactiveren en opnieuw gaan delen. 
Cellulaire afweer tegen virussen kan verstoord zijn door genetische afwijkingen in het 
immuunsysteem. Daarnaast kan cellulaire afweer geremd worden door 
immuunsuppressieve geneesmiddelen, die nodig zijn ter voorkoming van afstoting in 
ontvangers van een getransplanteerd orgaan of stamcellen van een gezonde donor, of ter 
behandeling van auto-immuunziekten. In immuundeficiënte patiënten kan een gebrek aan 
antivirale cellulaire afweer leiden tot ernstige ziekte en mortaliteit door nieuwe virale 




Het transplanteren van stamcellen van een gezonde donor, allogene stamceltransplantatie 
(alloSCT), is een potentieel genezende behandeling van hematologische maligniteiten en 
aangeboren hematopoïetische ziekten.. Patiënten met hematologische maligniteiten die in 
aanmerking komen voor alloSCT worden voor transplantatie geconditioneerd met hoge 
dosis chemotherapie, bestraling, en immuunsuppressie om de overgebleven maligne cellen 
te vernietigen, en om het hematopoïetische systeem van de patiënt te vernietigen en te 
onderdrukken en zo plaats te maken voor het hematopoïetische systeem van de gezonde 
donor . Traditioneel werden sterke myelo-ablatieve conditioneringen toegepast die gepaard 
gingen met forse toxiciteit, waardoor de behandeling alleen bij jongere patiënten toegepast 
kon worden. Inmiddels zijn conditioneringen met gereduceerde intensiteit ontwikkeld om 
alloSCT voor oudere patiënten of patiënten met bijkomende ziekten mogelijk te maken. 
Vervolgens worden donor hematopoïetische stamcellen toegediend, die zich kunnen 
vermenigvuldigen en ontwikkelen tot rijpe bloedcellen en het hematopoïetische systeem 
van de patiënt kunnen vullen met donor bloedcellen. De hematopoïetische stamcellen 
kunnen direct uit het beenmerg van de donor geoogst worden, maar worden tegenwoordig 
meestal uit het perifere bloed geoogst na mobilisatie vanuit het beenmerg door toediening 
van granulocyte colony stimulating factor (G-CSF). 
Indien in het stamceltransplantaat naast stamcellen ook donor T cellen aanwezig zijn, 













specifieke donor T cellen kunnen direct bescherming bieden tegen virale infecties. Hoewel 
patiënt en donor gematched worden voor MHC moleculen, kan donor afweer ook gericht zijn 
tegen patiënt cellen. Genetische verschillen in eiwitten tussen patiënt en donor kunnen 
leiden tot herkenning van patiënt antigenen door donor T cellen. Herkenning van 
overgebleven maligne patiënt cellen door donor T cellen kan leiden tot een langdurige 
afweerreactie tegen de maligne cellen, het zogenaamde graft-versus-leukemia effect, en 
daardoor genezing van de ziekte. Herkenning van gezonde patiënt cellen door donor T 
cellen kan echter leiden tot ernstige schade aan met name huid, darmen, en lever, en wordt 
graft-versus-host ziekte genoemd. Om de frequentie en ernst van graft-versus-host ziekte te 
verminderen kunnen donor T cellen uit het transplantaat verwijderd worden. Echter, de 
afwezigheid van virus-specifieke donor T cellen vergroot de kans op virale complicaties, en 
de vermindering van het graft-versus-leukemia effect vergroot de kans op persistentie van 
maligne cellen. Het toedienen van donor T cellen kan daarom worden overwogen om virale 
infecties of terugkeer van de maligniteit te voorkomen of te behandelen. 
 
Virale infecties na allogene stamceltransplantatie 
 
Het langzame herstel van virus-specifieke T cellen na alloSCT gaat gepaard met een lange 
periode waarin ernstige virale infecties kunnen optreden. De belangrijkste virale 
pathogenen die ernstige ziekte en mortaliteit veroorzaken na alloSCT zijn de veel 
voorkomende virussen cytomegalovirus, Epstein-Barr virus, en humaan adenovirus. 
Daarnaast kan varicella-zoster virus reactiveren in alloSCT ontvangers wat kan leiden tot 
herpes zoster, met gelokaliseerde plekken op de huid en zenuwpijn. Ook andere 
herpesvirussen en humaan polyomavirus kunnen reactiveren vanuit latente infectie en 
leiden tot ernstige ziekte. In dit proefschrift is de aandacht gericht op cytomegalovirus, 
Epstein-Barr virus, en humaan adenovirus, omdat deze virussen een duidelijke invloed 
hebben op de mortaliteit na alloSCT. 
Cytomegalovirus (CMV) kan na een eerste infectie persisteren in latente vorm in 
endotheelcellen en myeloïde cellen. Afhankelijk van het geografische gebied is 40-90% van 
de bevolking CMV seropositief. In gezonde personen wordt vermenigvuldiging van CMV 
voorkomen door CD8+ en CD4+ memory T cellen, die antigene peptiden herkennen van vele 
CMV eiwitten, waaronder de eiwitten CMV pp65 en CMV IE1. In alloSCT ontvangers kan 
de verstoorde controle door CMV-specifieke T cellen leiden tot CMV reactivering en ziekte, 
die zich vooral uit in de longen en darmen, en ook in de lever, ogen en hersenen. In 
afwezigheid van adequate cellulaire CMV-specifieke afweer kan CMV reactivering zich 












geneesmiddelen als ganciclovir en foscarnet kan effectief zijn, maar gaat gepaard met 
hematologische en renale toxiciteit, en is vaak onvoldoende voor langdurige controle van 
CMV. Herstel van CMV-specifieke T cellen kan wel langdurige bescherming tegen CMV 
ziekte geven na alloSCT. 
Epstein-Barr virus (EBV) is latent aanwezig bij meer dan 90% van de bevolking, en wordt in 
gezonde personen onder controle gehouden door EBV-specifieke CD8+ en CD4+ T cellen. 
EBV-specifieke T cellen herkennen virale peptiden, zowel afkomstig van eiwitten die tot 
expressie komen tijdens de latente fase als van eiwitten die tot expressie komen tijdens 
vermenigvuldiging van het virus. In geïnfecteerde B cellen kan EBV de regulatie van 
celdeling beïnvloeden, wat uiteindelijk kan leiden tot de ontwikkeling van kanker. Door 
gebrek aan controle van EBV door EBV-specifieke T cellen in patiënten na alloSCT kan EBV 
reactivering leiden tot maligne ontaarding van geïnfecteerde B cellen. Deze EBV-
geassocieerde maligniteiten kunnen vervolgens leiden tot ernstige ziekte en mortaliteit. 
EBV-geassocieerde maligniteiten kunnen behandeld worden met antilichamen tegen CD20, 
dat op het oppervlak van maligne B cellen zit. Deze behandeling is echter niet altijd effectief. 
Humaan adenovirus (HAdV), waarvan 51 verschillende types bekend zijn, veroorzaakt 
vooral infecties in kinderen tussen 6 maanden en 5 jaar, met symptomen van de luchtwegen, 
darmen en huid. Het is niet helemaal duidelijk of HAdV latent aanwezig blijft in de 
luchtwegen en darmen, of dat de ziekte altijd veroorzaakt wordt door een nieuwe infectie. 
In gezonde personen zijn lage frequenties van vooral CD4+ T cellen gemeten, die specifiek 
waren voor met name het HAdV hexon eiwit. Vooral bij kinderen kan HAdV infectie na 
alloSCT leiden tot ernstige ziekte en mortaliteit. De effectiviteit van antivirale 
geneesmiddelen zoals ribavirine en cidofovir voor HAdV infectie is niet aangetoond. 
Herstel van HAdV-specifieke T cellen kan wel zorgen voor langdurige controle van HAdV 
infectie. Het is nog niet bekend welke eiwitten herkend kunnen worden door deze HAdV-
specifieke T cellen. Daarnaast is het onduidelijk of zowel CD8+ als CD4+ T cellen belangrijk 
zijn voor de bescherming tegen HAdV ziekte na alloSCT. 
 
Behandeling van virale infecties met cellulaire immuuntherapie 
 
Omdat het herstel van virus-specifieke T cellen gepaard gaat met langdurige bescherming 
tegen virale ziekte na alloSCT, is het overbrengen van virus-specifieke donor T cellen naar 
de ontvanger een aantrekkelijke strategie ter voorkoming of ter behandeling van virale 
ziekten. Bij toediening van niet-geselecteerde donor T cellen kunnen ook T cellen worden 
overgebracht die gezond weefsel herkennen en daardoor graft-versus-host ziekte 













op graft-versus-host ziekte zijn technieken ontwikkeld om virus-specifieke T cellen uit donor 
perifeer bloed te selecteren. 
De selectie van virus-specifieke T cellen is mogelijk na stimulatie van perifeer bloed met 
virale antigenen, waardoor de geactiveerde virus-specifieke T cellen cytokines uitscheiden 
en moleculen op het oppervlak van de cel tot expressie brengen. Om gelijktijdig CD8+ en 
CD4+ T cellen te activeren die specifiek zijn voor verschillende virale peptiden, kunnen 
virale eiwitten gebruikt worden om cellen in perifeer bloed te stimuleren. Er zijn 
aanwijzingen dat het toevoegen van volledige virale eiwitten vooral leidt tot presentatie van 
virale peptiden in MHC klasse II en activering van virus-specifieke CD4+ T cellen, en 
minder van CD8+ T cellen. Echter, als meerdere synthetische lange peptiden die elkaar 
gedeeltelijk overlappen en zo de hele sequentie van het virale eiwit omvatten gebruikt 
worden kan dat leiden tot presentatie van virale peptiden in zowel MHC klasse I en II en 
activering van virus-specifieke CD8+ en CD4+ T cellen. Het is nog niet duidelijk op welke 
manier deze lange peptiden uiteindelijk in de MHC klasse I moleculen gepresenteerd 
worden. 
Na activering kunnen virus-specifieke T cellen geïsoleerd worden op basis van IFNg 
productie. Het uitgescheiden IFNg wordt hierbij door een antilichaam aan het celmembraan 
gebonden, en vervolgens wordt een tweede IFNg-specifiek antilichaam met een magnetisch 
deeltje gebruikt om de aldus gelabelde cellen met behulp van een magneet te isoleren. Deze 
techniek is succesvol toegepast voor isolatie van T cellen specifiek voor CMV, EBV, en 
HAdV. De kinetiek van IFNg productie na activering van virus-specifieke T cellen is echter 
nog niet onderzocht, en het is onduidelijk of alle virus-specifieke T cellen op hetzelfde 
moment na activering IFNg produceren en dus ook gelijktijdig op basis van IFNg geïsoleerd 
kunnen worden.  
Omdat isolatie op basis van IFNg technisch lastig uitvoerbaar is, is men gaan onderzoeken 
of het ook mogelijk is T cellen te isoleren op basis van moleculen die na activering op het 
oppervlak van virus-specifieke T cellen verschijnen. Het molecuul CD137 speelt een rol bij 
de stimulatie van T cellen en verschijnt ongeveer 24 uur na activatie op het oppervlak van 
CD8+ T cellen specifiek voor CMV en EBV. Op vergelijkbare wijze als bij isolatie op basis 
van IFNg productie kon een magnetisch gelabeld CD137-specifiek antilichaam worden 
gebruikt om virus-specifieke T cellen te isoleren. Echter, het is nog onduidelijk of CD137 op 
CD8+ T cellen specifiek voor andere virussen en op virus-specifieke CD4+ T cellen ook tot 
expressie komt, en hoe de kinetiek van CD137 expressie precies verloopt. 
Inmiddels is een aantal exploratieve klinische studies uitgevoerd waarin patiënten met 
virale infecties na alloSCT zijn behandeld met virus-specifieke donor T cellen. In deze 












ontwikkeling van graft-versus-host ziekte. Daarnaast werden na toediening toegenomen 
frequenties virus-specifieke T cellen in perifeer bloed waargenomen, die zich vervolgens 
ook in het lichaam konden vermenigvuldigen en langdurig aanwezig bleven. Omdat de 
studies niet gerandomiseerd waren is het lastig om conclusies te trekken over de effectiviteit 
van de behandelingen. In de meeste studies werd wel een associatie gezien tussen het 
toedienen van virus-specifieke T cellen en een afname van virusdeeltjes in bloed of 
langdurige controle van de virale infecties. Op basis hiervan lijkt antivirale cellulaire 
immuuntherapie effectief te zijn. De methoden in deze studies waren erg verschillend wat 
betreft de virale antigenen die gebruikt werden, de isolatietechniek, de kweekperiode, en 
het aantal virus-specifieke T cellen dat werd toegediend. Daarnaast waren de patiënten erg 
verschillend wat betreft hun conditionering, transplantieprotocol, virale infecties, en het 
moment van toediening van virus-specifieke T cellen. Sommige methoden die ontwikkeld 
zijn om virus-specifieke T cellen te isoleren kunnen klinisch (nog) niet toegepast worden 
vanwege de huidige regelgeving of de afwezigheid van de juiste kwaliteit van de reagentia. 
Andere methoden kunnen wel klinisch toegepast worden, maar zijn nog niet 
geoptimaliseerd om consistente productie van T cel lijnen met hoge specificiteit voor virale 
antigenen mogelijk te maken. De optimale strategie voor cellulaire immuuntherapie voor 

















In dit proefschrift zijn methoden onderzocht om op een efficiënte wijze virus-specifieke 
CD8+ en CD4+ T cellen in perifeer bloed te activeren om detectie en isolatie van deze 
specifieke cellen mogelijk te maken. Gebruik makende van deze methoden, is de rol van 
HAdV-specifieke T cellen onderzocht in de bescherming tegen HAdV ziekte na alloSCT, om 
op basis hiervan een HAdV-specifieke cellulaire immuuntherapie te ontwikkelen. Daarnaast 
zijn methoden ontwikkeld voor efficiënte isolatie van geactiveerde virus-specifieke T cellen 
uit perifeer bloed. De klinisch toepasbare T cel lijnen met hoge specificiteit tegen meerdere 
virale antigenen, die met deze methoden geproduceerd kunnen worden, kunnen gebruikt 
worden om de klinische waarde van cellulaire immuuntherapie voor virale infecties na 
alloSCT vast te stellen. 
 
Cytomegalovirus-specifieke T cellen als cellulaire immuuntherapie 
 
In hoofdstuk 2 is de IFNg respons van CMV-specifieke CD8+ T cellen onderzocht om deze 
cellen op het juiste moment te kunnen isoleren op basis van IFNg productie. De productie 
van IFNg was maximaal na 4 uur stimulatie en nam daarna snel af, ondanks de 
voortdurende aanwezigheid van het specifieke CMV peptide. Door de sterkte van stimulatie 
te variëren werd duidelijk dat een te sterke stimulatie kan leiden tot een nog snellere afname 
van de IFNg productie en een verminderde vermenigvuldiging. Op basis van deze gegevens 
werd een optimaal schema voor isolatie van CMV-specifieke CD8+ T cellen gekozen. Met 
deze methode konden T cel lijnen geproduceerd worden met een mediaan van 91% CMV-
specifieke T cellen na 9-11 dagen, en nauwelijks specifieke cellen in de achtergebleven 
fracties. De functionaliteit van de CMV-specifieke T cellen was na kweken in vitro 
vergelijkbaar met die van de CMV-specifieke T cellen in het uitgangsmateriaal. 
Het toedienen van zowel CD8+ als CD4+ T cellen specifiek voor meerdere CMV peptiden is 
waarschijnlijk effectiever voor bescherming tegen CMV ziekte na alloSCT. In hoofdstuk 3 is 
beschreven dat in alle gezonde volwassenen zowel CD8+ als CD4+ T cellen specifiek voor 
het CMV pp65 eiwit aangetoond konden worden, terwijl T cellen specifiek voor het CMV 
IE1 eiwit in slechts 45% van de gezonde personen gedetecteerd konden worden. Vervolgens 
werden twee verschillende CMV antigenen getest om gelijktijdig zowel CD8+ als CD4+ 
CMV-specifieke T cellen te activeren en te isoleren. Stimulatie met pools van overlappende 
peptiden van 15 aminozuren in lengte resulteerde in efficiënte activering van zowel CD8+ 
als CD4+ specifieke T cellen, terwijl stimulatie met een volledig eiwit resulteerde in 












CD8+ T cellen. De kinetiek van IFNg productie na stimulatie met de peptide pools was 
vergelijkbaar met die na stimulatie met de losse peptiden, en hetzelfde voor CD8+ als CD4+ 
T cellen. Op basis van deze gegevens konden T cel lijnen geproduceerd worden met hoge 
frequenties CD8+ en CD4+ T cellen specifiek voor meerdere CMV peptiden, die gebruikt 
kunnen worden voor behandeling van CMV ziekte na alloSCT. 
 
Humaan adenovirus-specifieke T cellen als cellulaire immuuntherapie 
 
Hoewel al eerder was aangetoond dat de ontwikkeling van HAdV-specifieke T cellen 
geassocieerd was met bescherming tegen HAdV ziekte na alloSCT, was het niet duidelijk 
welke HAdV eiwitten hierbij herkend werden, en of zowel CD8+ als CD4+ T cellen hierbij 
belangrijk waren. In hoofdstuk 4 is daarom de ontwikkeling van HAdV-specifieke T cellen 
bestudeerd in perifeer bloed van kinderen en volwassenen na alloSCT die spontaan 
herstelden van gedissemineerde HAdV ziekte. Klaring van HAdV na alloSCT bleek gepaard 
te gaan met het verschijnen van zowel CD8+ als CD4+ T cellen specifiek voor HAdV hexon 
peptiden. Daarom werd een methode ontwikkeld om T cel lijnen te produceren met hoge 
specificiteit tegen deze peptiden. Stimulatie van perifeer bloed van gezonde volwassenen 
met HAdV hexon peptide pool gevolgd door IFNg isolatie resulteerde in gecombineerde 
CD8+ en CD4+ HAdV hexon-specifieke T cel lijnen. Deze HAdV-specifieke T cel lijnen 
herkenden meerdere HAdV hexon peptiden, waaronder zowel bekende als nieuwe antigene 
peptiden, en herkenden ook HAdV geïnfecteerde cellen. Deze gegevens bieden een 
onderbouwing en strategie voor de behandeling van HAdV ziekte na alloSCT met HAdV 
hexon-specifieke donor T cellen. 
 
Gelijktijdige isolatie van T cellen specifiek voor meerdere virussen 
 
In hoofdstuk 5 werd een methode ontwikkeld om CD8+ en CD4+ T cellen specifiek voor 
meerdere virussen tegelijk te kunnen isoleren. Om ervoor te zorgen dat de methode 
bruikbaar was voor verschillende virussen had het onderzoek betrekking op T cellen 
specifiek voor CMV, EBV, HAdV en influenza. Daarnaast werd zowel isolatie op basis van 
IFNg productie als isolatie op basis van CD137 expressie onderzocht. Na activering 
produceerden de virus-specifieke T cellen IFNg en TNFa, en brachten ze gelijktijdig CD137 
tot expressie op het oppervlak, terwijl slechts een gedeelte van de cellen IL-2 produceerde. 
Ondanks verschillen in kinetiek van IFNg productie tussen de virus-specifieke T cel 
populaties konden de geactiveerde CD8+ en CD4+ virus-specifieke T cellen gelijktijdig 













expressie is eenvoudiger uitvoerbaar dan isolatie op basis van IFNg productie. Echter, op dit 
moment is alleen de IFNg isolatie methode beschikbaar voor klinische toepassing. De in 
deze studie ontwikkelde methode voor gelijktijdige isolatie van CD8+ en CD4+ T cellen 
specifiek voor meerdere peptiden van verschillende virussen bleek efficiënt en is breed 
toepasbaar.  
 
Gebruik van synthetische lange peptiden als viraal antigeen 
 
De gegevens uit hoofdstuk 3-5 laten zien dat in vitro stimulatie van perifeer bloed met 
synthetische lange peptiden resulteert in efficiënte activering van zowel CD8+ als CD4+ 
virus-specifieke T cellen. Daarnaast is eerder aangetoond dat wanneer synthetische lange 
peptiden gebruikt worden voor vaccinatie dit ook resulteert in een efficiënte activering van 
specifieke CD8+ T cellen in vivo. Echter, normaal gesproken binden kortere peptiden van 9-
11 aminozuren in MHC klasse I moleculen, en de mechanismen die leiden tot MHC klasse I 
presentatie van lange peptiden zijn onbekend. In hoofdstuk 6 werd aangetoond dat de 
efficiëntie van activering van specifieke CD8+ T cellen met lange peptiden erg variabel is. 
Het knippen van lange peptiden bleek niet te verlopen volgens de klassieke route van MHC 
klasse I presentatie. Hoewel lange peptiden wel direct konden binden in MHC klasse I 
moleculen, is het zeer waarschijnlijk dat ze geknipt moeten worden voor MHC klasse I 
presentatie en activering van CD8+ T cellen. Omdat de klassieke route niet nodig bleek, zijn 
waarschijnlijk peptidase enzymen nodig, die buiten de cel, op het oppervlak van de cel, of 
binnen de cel in endosomen aanwezig kunnen zijn. Daarnaast leek het erop dat het knippen 
tot de juiste peptiden werd gefaciliteerd door de binding van de lange peptiden in MHC 
klasse I moleculen. Dit mechanisme kan belangrijk zijn voor het activeren van specifieke 
CD8+ T cellen met synthetische lange peptiden bij cellulaire immuuntherapie of bij 
vaccinatie. 
 
Klinische resultaten van adoptieve immuuntherapie voor cytomegalovirus ziekte 
 
In hoofdstuk 7 werden de resultaten gepresenteerd van een klinische studie voor de 
behandeling van CMV ziekte na alloSCT door middel van cellulaire immuuntherapie met 
CMV-specifieke CD8+ T cellen. De geïncludeerde patiënten reageerden onvoldoende op de 
standaard behandeling met antivirale geneesmiddelen. CMV-specifieke CD8+ T cellen 
werden geïsoleerd uit perifeer bloed op basis van IFNg productie na stimulatie met één of 
twee MHC klasse I gerestricteerde CMV pp65 peptide(n). Er werden 14 T cel lijnen 












toegediend aan 5 patiënten. Na toediening werden geen bijwerkingen waargenomen, 
werden CMV-specifieke CD8+ T cellen gedetecteerd in perifeer bloed, en de CMV infecties 
kwamen onder controle. In 2 patiënten was er een duidelijke relatie tussen het moment van 
toedienen en de opkomst van CMV-specifieke CD8+ T cellen in perifeer bloed en controle 
van de infectie. Deze studie heeft laten zien dat het toedienen van CMV-specifieke CD8+ T 
cellen uitvoerbaar, veilig, en effectief kan zijn. 
 
De resultaten beschreven in dit proefschrift onderbouwen de rationale voor het toepassen 
van cellulaire immuuntherapie voor virale infecties na alloSCT. Daarnaast zijn efficiënte en 
bruikbare methoden ontwikkeld om gecombineerde CD8+ en CD4+ T cel lijnen te 
produceren met hoge specificiteit voor meerdere peptiden van verschillende virale eiwitten. 
Deze methoden zijn breed toepasbaar en maken het mogelijk om de klinische waarde van 
cellulaire immuuntherapie voor behandeling van virale infecties na alloSCT in klinische 
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List of abbreviations 
AlloSCT  Allogeneic stem cell transplantation 
APC  Antigen-presenting cell 
ATMP  Advanced Therapy Medicinal Product 
BFA   Brefeldin A 
CCR7  CC-chemokine receptor 7 
CD40L  CD40 ligand or CD154 
CD62L  CD62 ligand 
cDNA  Complementary deoxyribonucleic acid 
CDR3  Complementarity-determining region 3 
CFSE   Carboxyfluorescein diacetate succinimidyl ester 
CMV  Cytomegalovirus 
EBV  Epstein-Barr virus 
EBV-LCL Epstein-Barr virus-transformed B cell lines 
ELISA   Enzyme-linked immunosorbent assay 
ER  Endoplasmic reticulum 
FLU  Influenza virus 
GCP  Good clinical practice 
G-CSF  Granulocyte colony stimulating factor 
GCV   Ganciclovir 
GMP  Good manufacturing practice 
GvHD  Graft-versus-host disease 
HAdV  Human adenovirus 
HLA  Human leukocyte antigen 
IFNγ  Interferon-gamma 
IL-2  Interleukin-2 
IL-15  Interleukin-15 
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility complex 
PBMC   Peripheral blood mononuclear cells 
PTLD  Post-transplant lymphoproliferative disease 
TAP   Transporter associated with antigen processing 
TCR  T cell receptor 
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